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CHAPTER 1: RESEARCH OBJECTIVES 
1. Introduction 
The main objective of this project was to enhance peripheral nerve regeneration following 
peripheral nerve injury (PNI) using interdisciplinary approaches involving polymeric scaffolds, 
stem cell therapies, cellular & tissue engineering and drug delivery. Biocompatible and 
biodegradable polymeric materials such as poly (lactic acid) (PLA) were used for engineering 
conduits with micropatterns capable of providing mechanical support and orientation to the 
regenerating axons and polyanhydrides for fabricating nano/microparticles for localized delivery 
of neurotrophic growth factors (NTFs) and cytokines at the site of injury. Transdifferentiated 
bone marrow stromal cells or mesenchymal stem cells (MSCs) were used as cellular 
replacements for degenerating Schwann cells (SCs) at the injured nerve tissue. MSCs that have 
been transdifferentiated into a Schwann cell like phenotype (tMSCs) were tested as substitute for 
the myelinating SCs. To further enhance the regeneration, nerve growth factor (NGF) and 
interleukin-4 (IL4) releasing polyanhydrides nano/microparticles were fabricated and 
transplanted along with tMSCs seeded conduits. Synergistic use of these proposed techniques 
were used for testing and developing efficient treatments in a peripheral nerve injury model. 
When a peripheral nerve injury occurs, the nerve starts to degenerate; demyelination of the nerve 
occurs and causes a long-term loss of sensory and autonomic functions. Intervention in the form 
of treatment is required to help the nerve reestablish connections and to regain its normal 
function and avoid neurological deficits. Various types of treatments have been used in the past 
to treat nerve related injuries. All of them have certain advantages and disadvantages, and 
researchers are trying to improve upon or synergistically combine the existing methods to restore 
the normal function of damaged nerves. 
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Current medical treatments for peripheral nerve injury involve coaptation[1, 2], autologous nerve 
graft[3], allografts, and xenografts. Coaptation is a common surgical procedure in which the 
proximal and distal ends of a nerve are forcefully sutured with each other. Currently, autologous 
nerve graft is the customary and widely accepted clinical procedure for treatment for PNI. It is 
also considered as the Gold Standard [4-6] for regenerative processes as this is still the best 
treatment which is capable of improving the functional behavior more than any other clinical 
procedure. Autologous grafting is the technique in which part of a healthy nerve is obtained from 
the same person and is transplanted at the site of injury.  By transplanting the tissue from the 
same person, this technique avoids ethical issues and also reduces chances of tissue rejection. 
There are many disadvantages associated with this technique such as donor site morbidity and 
multiple surgeries. Xenografts[7](transplantation of tissue from a different species) and 
allografts[8, 9](transplantation of tissue from different individual but same species) have also 
shown promising results but widespread use of these procedures raises ethical questions. Also, 
during these grafting procedures, patients are subjected to immunosuppression in order to 
decrease the possibility of foreign tissue rejection. This immunosuppression increases the 
possibilities of infections in the subject’s body and is not considered the most optimal way of 
doing surgeries.  
A PNI usually divides a nerve into two segments. The part which is proximal is considered to be 
the one that remains directly attached to the cell bodies and continues to be healthy while the 
other part distal to the injury starts to degenerate, the myelin sheath surrounding the axons starts 
to degrade and macrophages with help of Schwann cells (SCs) starts to clean up the cellular 
debris [10, 11]. Figure 1 illustrates the various steps that a neuron undergoes after an injury. 
Schwann cells (SCs) in the PNS and oligodendrocytes in the CNS are responsible for formation 
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of the myelin sheath. While SCs help in the reinnervation of regenerating axons, 
oligodendrocytes do exactly opposite of that and inhibit the regrowth[12]. In CNS, 
demyelination can also occur because of diseases, infections or spinal cord injury and 
transplantation of SCs at the site of lesions has helped remyelination of the degenerating axons 
[13-15]. 
 
Figure 1. Schematic showing various steps that a neuron undergoes after a nerve injury. 
(Josh Rastatter, Biomaterials for nerve regeneration.         
http://chen2820.pbworks.com/w/page/11951452/Biomaterials%20for%20nerve%20regeneration, 
accessed on: Feb 15, 2016) 
Because of these advantages, Schwann cells [16, 17] are considered as an ideal candidate cell 
type as they help in reinnervation of the damaged nerve and myelination of regenerating axons. 
Myelination is important as it prevents the electric signals propagating inside axons from 
decaying down. Therefore, myelinating cells such as Schwann cells ensure the proper 
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physiological function after reinnervation of damaged nerves. However, the procedure of 
obtaining Schwann cells requires multiple surgeries and damage to a healthy nerve that can result 
in donor site morbidity. Extracting SCs is analogous to obtaining an autologous nerve graft for 
use in regeneration; a healthy nerve is sacrificed for filling in the gap created by nerve 
transection. Even after extraction, SCs are very difficult to harvest or grow for multiple passages 
and prolonged times. Because of such limitations, researchers are seeking alternative cells which 
can provide similar functionality as SCs and can be grown for long time periods in cell culture 
conditions. 
Our hypothesis is that mesenchymal stem cells (MSCs) can be used as an alternative for 
Schwann cells. Mesenchymal stem cells [18] are multipotent cells which are capable of 
differentiating into multiple cells lineages such as osteocytes, chondrocytes and adipocytes. 
MSCs can be obtained from multiple sources such as bone marrow, adipose tissue and umbilical 
cord. MSCs can be extracted from bone marrow with an easy and less invasive surgical 
procedure compared to an autologous nerve grafts. MSCs, because of their high proliferation 
rate, self-renewing ability and differentiation capabilities into several lineages, have been 
suggested as an attractive cell type to be used for neural regeneration purposes. MSCs have also 
been shown to transdifferentiate [19, 20] into Schwann cell-like phenotypic cells when exposed 
to certain chemicals and growth factors. These transdifferentiated MSCs are similar to SCs in 
terms of morphology and expression of glial proteins such as S100β (Calcium binding protein), 
p75NTR (p75 Neurotrophin receptor protein). 
The advantage of using MSCs is that the isolation procedure of MSCs from a patient’s bone 
marrow is a routine surgical procedure and also MSCs are much easier to cultivate in a cell 
culture environment as compared to Schwann cells. Once propagated in cell culture, even a very 
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small initial culture of MSCs is capable of yielding a large number of MSCs for transplantation. 
The idea is to collect, isolate and transdifferentiate MSCs obtained from the patient, into SC like-
cells and then transplant them at the site of injury. 
Another way in which MSCs can be used for transplantation is to genetically modify them to 
secrete neurotrophic factors such as BDNF (Brain derived neurotrophic factor), GDNF (Glial 
cell-derived neurotrophic factor), or both BDNF and GDNF and then seed them inside a conduit 
or at the site of damaged nerve. Neurotrophins are a family of proteins that induce the survival, 
development, and function of neurons. Neurotrophins GDNF [21, 22] and BDNF [23, 24] have 
been used in literature for promoting regeneration and provide neuroprotection against 
degenerative diseases. Before using these cells for in vivo studies they need to be characterized 
well to make sure that they are not very different from wild type MSCs. Enhanced neurotrophic 
factor secretion may result in faster myelination and recovery of injured nerves. 
Because autologous nerve transplants and other surgical procedures have many disadvantages, 
currently researchers have started to focus on Neural Tissue Engineering (NTE)[25] to develop 
strategies and medical procedures to counter with deficits that occur after a nerve injury. NTE is 
a combination of the use of biomaterials, engineering, sciences and medicine together to create 
drug delivery vehicles and to support and orient the regenerating tissues using scaffolding and 
conduits. Before designing a conduit for neural regeneration, various functionalities[26] such as 
cell adhesion, migrations, proliferation, biocompatibility, biodegradability, release of non-toxic 
substances, orientation/directionality, nutrient transfer, local release of drugs and surrounding 
capable of mimicking extra cellular matrix(ECM) should be taken into account. 
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Artificial nerve conduits can be synthesized using a variety of artificial and natural polymeric 
substances[27]. Figure 2 illustrates functions of various conduit types engineered in different 
ways. A conduit can be engineered using conducting polymers for electrical stimulation, can 
have microporous lumens or aligned nanofibres and also can chronically release neurotrophic 
factors such as GDNF and BDNF. Both natural and artificial biomaterials have been used for 
making nerve conduits. Natural biomaterials are generally ECM components such as collagen, 
fibronectin, laminin, gelatin, chitosan and compounds formed by living organisms such as silk 
fibrins. On the other hand, artificial biomaterials such as polymers can be engineered in ways 
that enhance neural regeneration. 
 
Figure 2. Schematic diagram demonstrates the properties of an ideal nerve guidance conduit. 
Various guidance cues can be incorporated into NGCs to mimic the ECM[28]. 
 
An important limitation with regenerating axons is their orientation. Regenerating axons are not 
able to grow in the correct direction, and instead of growing from the proximal to distal part of 
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the nerve injury site, after little regeneration, they start to form scars. Micropatterning [29, 30] is 
an effective way of increasing the directionality and orientation of growing axons and our 
rationale is that if we use micropatterning inside a conduit, it will help in improving the 
connections between segments of a severed nerve. Our focus is on using polymers approved by 
the Food and Drug Administration (FDA) for other applications for engineering the conduit. 
Properties such as biodegradability[31] will reduce the necessity of multiple surgeries while 
other physical properties such as porosity and micropatterning will help in transfer of the 
nutrients and gases from surrounding tissue and will give directionality to the growing axons. 
Polymers that we are focusing on are PLA (poly lactic acid) and polyanhydrides. 
Neurotrophins and cytokines can also be embedded inside the conduit material and as the conduit 
biodegrades, a continuous release of these factors will help in modulating the microenvironment 
at the site of injury and thus help in axons to grow more and reduce inflammation and swelling at 
the injury site.  
Researchers have also used nanotechnology [32, 33] for delivering these therapeutic proteins to 
the regenerating axons. Nanotubes (NTs) and Nanofibers (NFs) have been used inside nerve 
conduits to help align and support the growing axons. Nano/microparticles (NPs) have been used 
for localized delivery of neurotrophic growth factors such as nerve growth factor (NGF) [34]. In 
this research, we will be fabricating NGF and IL4 releasing polyanhydride nano/microparticles 
for sustained release of proteins and then test them in vivo in a rat sciatic nerve injury model. In 
the literature, nanomaterials have been shown to improve as well as to inhibit [35, 36] neural 
regeneration across various research settings. Scientists have not yet been able to assess the 
drawbacks of nanotechnology and it is important to overcome the drawbacks before 
implementing them in clinical settings. 
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2. Summary 
The main objectives of these research projects are: 
1. Fabrication of polymer micropatterned films and conduits. 
2. Transdifferentiation of MSCs in SC-like phenotypic cells on micropatterned polymeric 
substrates. 
3. Characterization of NTFs secreting MSCs on various ECM substrates for application in 
neuroprotection and neuroregeneration. 
4. Fabrication and testing of micro/nanoparticles to release neurotrophic factors. 
5. These studies will lead to the transplantation of transdifferentiated MSCs seeded conduits 
in vivo in a sciatic nerve transection model with immunomodulation of macrophage 
phenotypes using Interleukin-4 releasing micro/nanoparticles. 
 
3. Organization of thesis 
Chapter 2 shows the literature review related to neural tissue engineering. Chapter 3 is adapted 
from a manuscript where we have published results related to transdifferentiation of MSCs on 
micropatterned substrates. Chapter 4 is adapted from manuscript in which we published the 
results related to the characterization of genetically modified MSCs using high content screening 
methodology. Chapter 5 and Chapter 6 are two manuscripts in preparation where we are going to 
publish results related to neurotrophic factor releasing polyanhydride nano/microparticles and 
proteomic analysis of transdifferentiated MSCs respectively. In chapter 7, I have assembled all 
the recently done preliminary work related to in vivo transplantation and cytokine releasing 
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nano/microparticles. In Chapter 8, I am summarizing the most important results and important 
conclusion drawn from this dissertation. 
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CHAPTER 2: NEURAL TISSUE ENGINEERING: A REVIEW 
 
Nanomaterial section of this chapter is adapted from book chapter titled 
“Nanomaterials for Neural Tissue Engineering”.  In “Nanomaterials in Tissue Engineering: 
Characterization, Fabrication and Applications”, Gaharwar, Sant, Hancock and Harding (eds.). 
Harvard-MIT Division of Health Sciences, published by Woodhead Publishing-Cambridge. 
Mustafa E. Marti, Anup D. Sharma, Donald S. Sakaguchi, Surya K. Mallapragada 
 
1. Introduction 
Nerve regeneration is a complex biological process. Nerves are intrinsic parts of the nervous 
system and are responsible for maintaining communication between the brain and other parts of 
body and vice versa. Nerves are very fragile and can easily get damaged when exposed to any 
external force. Depending on the extent of the force, a nerve can suffer three different types of 
injuries classified by Sir Herbert Seddon[1] 
 Neuropraxia – This kind of injury is caused by mild compression of the nerve causing 
interruption in the flow of signals. Easily recoverable. 
 Axonotmesis – Synonymous to crushing injury. Damages to axon occur but the myelin 
covering around the nerve fiber remains intact. This causes paralysis and loss of sensory 
neuron function. Recovery is possible to some extent. 
 Neurotmesis – Not only the nerve but the encapsulating tissue also undergoes damages. 
The nerve gets transected. There is complete loss of motor function and also there is very 
little chance of recovery. 
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When any of the aforementioned injuries occur, a cascade of cellular and molecular events 
occurs to overcome the effects of degeneration. After injuries, the nerve starts to degenerate; 
demyelination of the nerve occurs which causes a long term loss of sensory and motor functions. 
Degeneration mostly occurs in the distal part of the nerve stump while the proximal stump starts 
to grow and regenerate. Distal degeneration is also called Wallerian degeneration. The glial cells 
of the peripheral nervous system, Schwann cells (SCs), start to remove the cellular and myelin 
debris near the injured area along with macrophages which helps in process of phagocytosis 
(Figure 1). Though peripheral nerves have regeneration capabilities, regeneration is usually 
limited because of non-availability of mechanical support, orientation and absence of 
myelinating SCs. Depending on how big the nerve gap is after an injury, different treatment 
strategies are required to help the nerve regain its normal function and to avoid neurological 
deficits. Various types of treatments have been used in the past to treat nerve related injuries. All 
of them have certain advantages and disadvantages and there has not been a treatment so far 
which is capable of completely restoring the normal function of damaged nerve. 
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Figure 1. Process of nerve regeneration after an injury (adapted from Gaudet et. al, 2011 [2])  
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Various types of treatments that have been used for enhancing the nerve regeneration are 
described in the upcoming section of this chapter:  
2. Surgical treatments 
Current medical treatments for peripheral nerve injury involve coaptation[3, 4], autologous nerve 
grafts[5], allografts, xenografts. Coaptation is a common surgical procedure in which the 
proximal and distal end of a nerve is forcefully sutured with each other. But this type of 
treatment is effective only when the nerve gap is very small [6, 7]. Also, suturing should not 
enhance the nerve tension because that may result in inhibition of regeneration and increased 
nerve tension is one of the main reason why coaptation cannot be used as a treatment for 
addressing large nerve gaps. A nerve graft is mostly used in cases where injury creates a large 
gap in the peripheral nerves [8]. Currently, autologous nerve graft is the customary and widely 
accepted clinical procedure for treatment of PNI. It is also considered as the Gold Standard [9-
11] for regenerative processes as this is still the best treatment capable of improving functional 
behavior, more than any other clinical procedure. Autologous grafting is the technique in which 
part of a healthy nerve is obtained from the patient and is transplanted at the site of injury.  By 
transplanting the tissue from the same person, this technique avoids ethical issues and also 
reduces chances of tissue rejection. There are many disadvantages associated with this technique, 
such as donor site morbidity, limited length of graft material, multiple surgeries, and neuropathic 
pain [12, 13]. Also the success of autologous grafting always depends on the similarities between 
the organization of the donor and injured nerves[14]. Xenografts [15, 16](transplantation of 
tissue from a different species) and allografts [14, 17, 18](transplantation of tissue from different 
individuals from the same species) have also shown promising results, but widespread use of 
these procedures has given rise to ethical questions. Also, during these grafting procedures 
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patients are subjected to immunosuppression[19] in order to decrease the possibility of foreign 
tissue rejection. This immunosuppression increases the possibilities of infections in patient and 
can lead to other complications.  
3. Nerve regeneration conduits: Biomaterial approaches 
In order to avoid drawbacks associated with surgical treatments and to target even longer nerve 
gap injuries, researchers have come up with idea of polymeric scaffolds to facilitate and 
accelerate the tissue growth by mimicking the extra cellular environments around the injured 
area. These polymeric scaffold were fabricated in shape of conduits to connect the two severed 
ends of the nerve and thus they are also called nerve regeneration conduits (NRCs) (Figure 2). 
An ideal nerve regeneration conduit is expected to have various beneficial properties such as 
biodegradability, biocompatibility, non-immunogenicity, non-cytotoxicity, permeability, and be 
able to provide guidance cues, chemical cues, electrical cues, and trophic support to the 
regenerating axons and finally should be able to support the tissue growth for a sufficiently long 
period of time[20, 21]. Various types of natural and synthetic polymers have been used for 
fabrication of these NRCs. While natural polymers would be degradable and less cytotoxic, 
synthetic polymer properties can be altered to control the rate of degradation and release of 
trophic factors. It is of utmost importance to understand the intrinsic properties of these polymers 
and their compatibility with the biological materials before considering them for fabrication of 
scaffolds. NRCs have been modified internally to increase the surface area of interaction and 
also provide orientation/guidance to the regenerating axons. Various types of bio polymeric 
fillers have been used to provide additional support to the growing cells and tissues. 
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Figure 2. Schematic diagram demonstrates the properties of an ideal nerve guidance conduit. 
Various guidance cues can be incorporated into NGCs to mimic the ECM.[22] 
 
Various types of natural polymers that have been used for fabrication of NRCs are collagen, 
chitosan, gelatin, hyaluronic acid (HA), silk fibroin, laminin, fibronectin, chitin, alginate, 
agarose, fibrin, etc.[21, 23]. Major disadvantages associated with natural polymers is that they 
can be immunogenic and also the lot-to-lot variance during their production that affects their 
structure and possibly their function too[24]. While there are certain disadvantages associated 
with natural polymers, the main reasons why researchers are interested in pursuing the polymers 
is because of their biodegradability, biocompatibility, stability, non-reactiveness, similarity to 
materials found in vivo, lower toxicity and the presence of specific binding sites which may 
impact the tissue regeneration in a positive fashion[24].  
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Collagen is the main fibrous protein in connective tissues and also the most abundant protein of 
the animal kingdom. There are 16 different types of collagen but the body usually consists of 
type I, II or III. Various FDA approved conduits such as NeuraGenTM, NeuroflexTM, 
NeuroMatrixTM, NeuroMendTM, NeuroWrapTM etc. are fabricated using type I collagen[25]. 
A porous three-dimensional crosslinked structure was obtained when chitosan was added to 
collagen by chemical modifications using glutaraldehyde. Freeze-drying steam-extrusion method 
was used for preparation of the nerve conduit scaffold[26]. Magnetically aligned collagen type I 
gel and control collagen gel was filled inside collagen nerve guides and they were implanted into 
4 to 6mm nerve gaps in mice. It was shown that aligned collagen gel showed better regeneration 
as compared to the control collagen gel [27].  
 
Chitosan is widely used for biomedical applications for agricultural and horticultural purposes, 
drug and gene delivery, tissue engineering scaffolds. It is also used for fabrication of nerve 
regeneration conduits because of its biodegradability, biocompatibility and excellent mechanical 
properties[28]. Chitosan conduits seeded with bone marrow stromal cell (BMSC)-derived 
Schwann cells were transplanted in 12 mm sciatic nerve gaps in adult rats and were shown to 
improve mid-shank circumference, nerve conduction velocity, average regenerated myelin area, 
and myelinated axon count as compared to phosphate buffered saline (PBS) filled conduits[29]. 
Laminin (LN)-modified chitosan conduits filled with BMSCs were successfully used for treating 
a 10mm nerve gap in Sprague dawley rats in terms of nerve regrowth, muscle mass of 
gastrocnemius, functional recovery and tract tracing[30]. Xiao et. al, 2013 used a use a collagen–
chitosan (CCH) scaffold to mimic the bio-functional peripheral nerve and showed that it can 
support and guide the nerve regeneration after three months[31]. 
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Gelatin is a natural polymer derived from collagen which is biodegradable, in vivo resorbable, 
and easy to modulate physical and chemical properties, which makes it a widely used polymer 
for biomedical applications[32]. Biodegradable gelatin conduits were used for bridging a 7 mm 
sciatic nerve gap in mice and shown to direct and enhance nerve regeneration[33]. A 
chitosan/gelatin nerve regeneration conduit constructed with collagenous matrices was used as a 
vehicle for Schwann cells and transforming growth factor-β1 to bridge a 10-mm gap of the 
sciatic nerve in rats. These cell seeded conduits enhanced nerve conduction velocity, average 
regenerated myelin area, and myelinated axon count similar to an autograft but significantly 
higher transplanted chitosan/gelatin nerve graft alone[34]. Different types of photocured gelatin 
conduits were implanted in 10mm sciatic nerve gap in adult male lewis rats for upto one year and 
were evaluated for their impact on functional recovery, electrophysiological responses, and 
tissue morphological regeneration[35]. 
 
 
Hyaluronic acid (HA) or Hyaluronan is a non-branched polysaccharide that is biodegradable, 
biocompatible, water soluble, viscoelastic, non-immunogenic and has derivatizable groups along 
its backbone, which makes it a suitable candidate for development of tissue engineering scaffolds 
and drug delivery systems[36, 37]. HA film sheaths were shown to reduce the scar formation in 
sciatic nerve end to end neurorrhaphy in male Sprague Dawley rats[38]. Freeform fabrication to 
fabricate micro-length scale features was used to fabricate a variety of scaffolds which can 
possible be used for nerve tissue engineering using HA. These scaffolds were further 
functionalized covalently using laminin to further enhance cell adhesion[39]. HA-Collagen 
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conduits seeded with neural stem cells (NSCs) were shown to facilitate facial nerve regeneration 
in rabbit facial nerve injury model observed using electrophysiology and histological 
analysis[40]. 
 
Synthetic polymers have also been used for fabrication of NRCs. Some of the advantages 
associated with synthetic polymers is their tailorable properties such as degradation rate. Another 
important advantage is the unlimited supply of these polymers and less lot-to-lot variance 
compared to natural polymers. Other important properties that are taken into account while 
copolymerizing these synthetic polymers are material strength, wettability, elasticity and thermal 
properties[21]. Synthetic polymers are divided into two categories: non-biodegradable and 
biodegradable. Common non-biodegradable polymers include silicone rubber, 
polydimethylsiloxane (PDMS), polyamide (PA), acrylic, polyethylene (PE), polysulfone (PSU), 
poly (acrylonitrile-co-vinyl chloride) (PAN-PVC), poly (2-hydroxyethyl methacrylate-co-methyl 
methacrylate) (PHEMA-MMA), polypyrrole (PPy), porous stainless steel [21, 41-43]. Common 
biodegradable polymers include poly(l-lactic acid) (PLLA), poly(glycolic acid) 
(PGA), poly(lactic acid-ε-caprolactone), poly(l-lactide-co-glycolide), poly(1,3-
trimethylenecarbonate-ε-caprolactone) and poly(caprolactone) (PCL), poly(3-hydroxybutyrate) 
(PHB), polyphosphoester (PPE) , polytrimethylene carbonate-caprolactone (PTMC-CL), and 
polyurethane (PU) and other derivatives of these polymers[21]. 
 
Biodegradable synthetic polymers have been of most interest for researchers because of their 
unique property of biodegradation which can be further tailored by synthesizing derivatives of 
the polymers. Also because they biodegrade in vivo to release non-toxic by products, it 
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eliminates the need for a second surgery in order to remove the scaffold from the tissue. Because 
these polymers are usually elastic in nature, they also do not cause any additional stresses on the 
growing nervous tissue inside the conduit. Biodegradable polymers usually have ether, amide 
and ester groups on them and are usually synthesized by melt polycondensation reactions. 
Scaffolds made up of these polymers are designed in such a way that they do not lose their 
mechanical integrity till the end of the nerve regeneration process and support the regenerated 
tissue throughout the time period.  Biodegradable polymers usually degrade by mechanism of 
hydrolysis, bulk erosion and surface erosion[44]. Most important properties of biodegradable 
polymers are their non-immunogenicity, accepted shelf life, degradation rate matching with 
regeneration process, appropriate mechanical strength to support the growing tissue, non-toxic 
by products, biocompatibility and permeability to biomolecules if needed[21, 45]. 
4. Cellular therapies 
Depending on how big the nerve gap is, additional support to the regenerating axons is required 
to help them grow over longer distances. One of the most important strategies for enhancing 
regeneration is to provide a cellular alternative to the lost cells during nerve degeneration. A 
variety of cell types have been used as a cellular alternative to the native Schwann cells which 
includes autologous Schwann cells (SCs), mesenchymal stem cells, embryonic stem cells, neural 
stem cells, olfactory ensheathing cells etc. 
 
Schwann cells (SCs) are the supporting cells of the peripheral nervous system and are 
responsible for performing a large variety of functions including ensheathing axons, providing 
trophic support and nutrition to the axonal tissue, production of myelin, removal of myelin debris 
in case of injury and extracellular matrix molecules production for the peripheral nerve 
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trunk[46]. Schwann cells isolated from a peripheral nerve can be expanded in cell culture with 
help of mitogens and then can be used for transplantation inside scaffolds at the site of 
injury[47]. Allogeneic SCs were proposed as an effective treatment as opposed to the time taken 
in expanding the autologous SCs [48]. Polyhydroxybutyrate conduits filled with alginate 
hydrogels and allogeneic or syngeneic genetically labeled SCs were used to treat a 10mm gap in 
rat sciatic nerve [48]. Both allogeneic and syngeneic SCs enhanced axonal regeneration but more 
axons were found in the case of transplanted syngeneic SCs. Allogeneic SCs were rejected after 
a period of 6 weeks. Autologous SCs (200,000 cells/µl) seeded in collagen conduit was 
transplanted at 13mm sciatic nerve gap in male fischer rats [49]. Number of myelinated axons at 
16 weeks was found to be significantly higher than the tubes filled with only serum. Rutkowski 
et. al. 2004 used a porous poly(D,L-lactic acid) (PDLLA) conduit with inner micropatterned 
lumen seeded with SCs and showed that sciatic nerve regeneration was enhanced on basis of 
improved sciatic functional index and time of recovery in a 1cm sciatic nerve transection model 
in rats[50]. Acellular nerve sheaths repopulated ex vivo with Schwann cells (SCs) modified to 
express brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), 
or neurotrophin-3 (NT3) were used to repair 1cm defects in rat peroneal nerves and showed that 
different expression of aforementioned neurotrophic factors by genetically modified SCs had 
differential effects on graft morphology, the number and type of regenerating axons, 
myelination, and locomotor function[51].  
 
Embryonic stem (ES) cells are pluripotent in nature which means they can differentiate into any 
other cell of the body including neural and glial lineages. Another important property of ES cells 
is to self-renew which helps in growing ES cells in culture for prolonged times and passages. As 
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a result ES cell transplantation is used as a therapy for curing nervous system disorders as well as 
nervous tissue repair[52]. Lee et. al. 2012 developed a strategy where they differentiated human 
ES cells into mesenchymal stem cells spheres (hESC-MSC) and then used these spheres for 
transplantation in a 2mm sciatic nerve gap in athymic nude mice. Nerve conduction tests in these 
mice showed that hESC-MSC sphere transplantation repaired the nerve significantly better than 
when the hESC-MSC were transplanted in the form of cell suspensions[53]. In another study, 
embryonic stem (ES) cell-derived neural progenitor cells (ES-NPCs) were implanted in a 1cm rat 
sciatic nerve transection model[54]. Transplantation enhanced the axonal regeneration and tissue 
repair compared to the culture medium controls. 
 
Olfactory ensheathing cells (OECs) are the glial cells which ensheath the axons of the olfactory 
receptor neurons[55]. OECs are capable of supporting regeneration not only in olfactory system 
but in central nervous system (CNS) as well. Also, they are capable of changing their states from 
non-myelinating to myelinating cells in vitro and have also intrigued researchers in doing further 
testing and using these cells for neural repair[56]. Purified olfactory ensheathing cells seeded 
inside silicone tube filled with laminin gel was found to be successful in regeneration of 15mm 
sciatic nerve gap in 50% of the animals[57]. The percentage of animals where regeneration 
occurred successfully was found to be even higher in case of 12mm gap. OECs were transplanted 
after rat sciatic nerve was cut using microsurgical procedure and was compared to the injection 
of control media[58]. eGFP expression showed that OECs survived and got incorporated inside 
the regenerated axons. Axons were also found to be myelinated by OECs and improvement in 
the conduction velocity in the transplanted group showed the effectiveness of OECs in treatment 
of peripheral nerve injuries. In another study, OECs were injected after section and resection of 
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2cm of sciatic nerve and was found to restore the contractile properties of the gastrocnemius 
muscle and complete repair of the SN[59]. Also RT-PCR showed that there was an increase in 
the presence of neurotrophic factors. 
 
Neural stem cells (NSCs) or neural progenitor cells are also of great interest as a cellular 
replacement of SCs for treatment of PNIs. NSCs can be derived from ESCs and are also present 
in developing mammalian nervous system as well as the adult nervous system[60]. Because 
NSCs self-renew and are capable of differentiating into neurons and glial cells such as 
oligodendrocytes and astrocytes, they hold great promise in treating nervous system 
disorders[61]. Another advantage of using NSCs is that it is easier to manipulate the fate of 
differentiation of NSCs just by adding different type of trophic factors in vitro and in vivo [61]. 
Xu et. al. 2012 showed that silicone conduit seeded with brain derived neural stem cells when 
transplanted at a 10mm sciatic nerve gap, was able to enhance the peripheral nerve regeneration 
by measurement of sciatic functional index and sciatic nerve conduction velocity as compared to 
normal saline silicone conduits[62]. Co-transplantation of NSCs was done along with SCs in a 
hemisected adult rat spinal cord and it was shown that NSCs survive better when transplanted 
with SCs as compared to when NSCs are transplanted alone and also improves regeneration by 
measuring average number of myelinated axons in both treatment groups[63]. Fibroblast growth 
factor 1 (FGF1) immobilized microporous/micropatterned poly (D, L-lactic acid) 
(PLA) nerve conduits were seeded with neural stem cells and transplanted at 15mm sciatic nerve 
gap injury models in rat. Histology, walking track analysis and electrophysiology was used for 
testing the nerve regeneration and results showed that conduits seeded with NSCs enhanced the 
nerve regeneration equivalent to the autograft group[64]. Heine et. al 2004 transplanted GDNF 
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expressing NSCs in chronically denervated distal tibial nerve segments and by performing assays 
such as counting the number of axons and emergence of compound motor action potentials found 
that regeneration was better in animals transplanted with NSCs[65]. 
 
Mesenchymal stem cells (MSCs)[66] are multipotent cells which are capable of differentiating in 
multiple cells lineages such as osteocytes, chondrocytes and adipocytes. MSCs can be obtained 
from multiple sources such as bone marrow (BM), adipose tissue (AD) and umbilical cord (UC). 
MSCs can be extracted from bone marrow with quite an ease and less evasive surgical procedure 
as compared to autologous nerve graft. MSCs because of their high proliferation rate, self-
renewing ability and differentiation capabilities in several lineages, have been suggested as an 
attractive cell type to be used for neural regeneration purposes. MSCs have also been shown to 
transdifferentiate [67, 68] into Schwann cell like phenotypic cells when exposed to certain 
chemicals and growth factors. An acellular nerve graft was affixed with BM-MSCs using fibrin 
glue and was used to bridge a 15mm sciatic nerve defect in Sprague dawley rats[69]. MSCs 
embedded in fibrin glue survived and were capable of producing neurotrophic growth factors and 
supported the nerve regeneration and functional recovery as measured using histological and 
functional testing of the rats transplanted with grafts. Costa et. al. 2013 compared 
undifferentiated BM-MSCs or Schwann-like cells that had differentiated from BM-MSCs 
transplanted at a rat facial nerve injury model using a polyglycolic acid tube. Both cell-
containing groups had higher compound muscle action potential (CMAP) as compared to the 
control groups and the facial nerve with SC-like cell implantation had the highest mean axonal 
diameter[70]. Studies showed that both cell types enhanced nerve regeneration and the SC-like 
cells had superior effects. Allogeneic rat adipose derived stem cells (ADSCs) were transplanted 
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for evaluation in 15mm sciatic nerve gap by using a acellular nerve graft which helped in 
improving the walking behavior measured with footprint analysis, increased mass muscle ratio of 
gastrocnemius muscle, increased nerve conduction velocity and myelinated fibers within the 
graft[71]. A polycaprolactone tube filled with BM-MSCs was shown to improve nerve 
regeneration and motor neuron survival in 3mm sciatic nerve cut model in C57BL/6 mice by 
testing the animals for sciatic functional index, number of neurons in dorsal root ganglion and 
measuring weight and creatine phosphokinase enzyme activity in gastrocnemius muscle[72]. 
5. Regenerative cues 
5.1. Topographical cues 
Various types of guidance cues have been used in nerve regeneration conduits to orient the 
transplanted cells and regenerating axons which indirectly makes the nerve tissue to regrow for 
longer distances. Some of these topographical cues involve micropatterns/microgrooves, 
microporous luminal structures, aligned nanofibers and a gradient of ECM proteins in some 
cases [73]. Biodegradable PDLLA conduits with micropatterned inner lumen preseeded with 
Schwann cells was shown to enhance time of recovery and sciatic functional index in 1 cm 
sciatic nerve transection model in rats[50]. In another study, phase transition and micro printing 
was used to create a conduit with micropatterned inner lumen and also asymmetric pores through 
its wall using poly (D, L-lactide) (PLA) substrates [74]. After transplantation of the conduits in a 
10mm sciatic nerve transection model in rats, asymmetric conduits with surface microgrooves 
had thicker myelin sheaths, improved myelination and a better functional recovery as compared 
to the symmetric conduits with microgrooves at end of 6 weeks. Aligned nanofibers have also 
been used by various groups for fabrication of nerve guidance conduits. A modified one step 
electrospinning technique was used for 3D aligned nanofibrous nerve conduits made of 
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collagen/PLGA which was then used for transplantation at a 13mm sciatic nerve gap in rats[75]. 
Such 3D conduits were found to provide better recovery than randomly aligned nanofibers 
conduits after testing the animals for motor function, nerve conduction, axonal and Schwann cell 
morphology, and marker expression. Yao. et. al, 2010 studied the effect of channel number on 
axonal regeneration by fabricating collagen conduits with varied number of channels (1, 2, 4 and 
7) and found that 1-channel and 4-channel conduits showed better axonal regeneration in a 1cm 
sciatic nerve transection model[76]. Studies have shown that multiple channels inside conduit 
can limit the dispersion of axons without having any deleterious effects on nerve regeneration. 
5.2. Electrical cues 
Electrical stimulation has been shown to improve the nerve regeneration in various peripheral 
nerve injury models. There are various ways of providing electrical stimulations to the 
regenerating nerve such as Transcutaneous/percutaneous stimulation (TENS), Direct, brief, low-
frequency electrical stimulation, Electrical stimulation via the synthetic nerve graft etc [77]. 
Electrical stimulation has been shown to affect the axonal regeneration, expression of 
neurotrophic factor and Schwann cell behavior[77]. Huang et. al 2013 investigated the effect of 
brief electrical stimulation (ES; 3 V, 20 Hz, 20 min) on delayed nerve injury repair. Sciatic nerve 
was transected and nerve repair was delayed for multiple time durations. Electrical stimulation 
(ES) increased the diameter and regeneration of regenerated axons, the thickness of myelin 
sheath, as well as the number of Fluoro-Gold retrograde-labeled motor neurons and sensory 
neurons showing that ES can be used as an effective way for treating delayed nerve injuries[78]. 
In another study, brief electrical stimulation increased the speed and accuracy of motor axonal 
regeneration. Brief ES reduced the period of staggered regeneration (from 10 to 3 weeks) and 
accelerated the preferential motor reinnervation [79]. Conductive polypyrrole/chitosan scaffold 
28 
 
 
and non-conductive chitosan scaffold were fabricated and was used to bridge a 15mm sciatic 
nerve gap in Sprague Dawley rats[80]. Intermittent ES (3 V, 20 Hz) was applied to the 
polypyrrole/chitosan to create an electrical environment at the site of nerve defect. In another 
study, various frequencies (1, 2, 20, or 200 Hz) of electrical stimulation was tested out to check 
frequency effect on nerve regeneration [81]. 10 mm sciatic nerve gap was created in sciatic nerve 
of rats and then proximal and distal end was sutured using a silicone rubber tube. Electrical 
stimulation at different frequencies was carried out every other day starting after first week of 
transplantation and up to 6 weeks. Histological testing and electrophysiology testing showed that 
higher frequency stimulation has less effect on regeneration as compared to lower frequency 
stimulation. 
5.3. Biomolecular cues 
Biomolecular cues refer to delivery of growth and trophic factors at the site of injury to promote 
the survival of degenerating cells and promote regeneration of growing axons. Neurotrophic 
factors are the ones which has interested the researchers the most. Neurotrophic factors (NTFs) 
are a family of proteins responsible for growth and survival of developing neurons. They also 
provide nutrition and trophic support to the mature neurons[82]. When tissues are healthy, neural 
tissues secrete these factors for a better viability of target cells. But post-injury, non-neuronal 
cells such as Schwann cells (SCs) secrete these factors to aid the outgrowth of regenerating 
axons. NTFs are divided into three major classes[82]: (1) Neurotrophins; (2) neurokines; and (3) 
the transforming growth factor beta (TGF)-β superfamily.  
Neurotrophins consist of Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
Neurotrophin 3 (NT-3), Neurotrophin 3/4 (NT-3/4), Neurotrophin 6(NT-6) while neurokines 
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comprise of Ciliary neurotrophic factors (CNTFs) and leukemia inhibitory factor (LIF). TGF- β 
superfamily consists of TGF- β1, TGF- β2, TGF- β3 and glial cell line-derived factor (GDNF). 
NRCs loaded with neurotrophic factor have been shown to enhance the axonal regeneration. 
Optimized dosage and a long term sustained delivery of the factors are two important parameters 
while fabricating such neuroregenerative conduits [83]. Usually, these growth factors are directly 
loaded into the lumen of the conduits. They fill the lumen, and are also bound to the inner 
circumference of the lumen using various biocompatible molecules called as matrix materials 
such as hydrogel-forming collagen, fibrin, laminin, alginate, heparin, and heparin sulfate[84]. 
Plasma treatment of the surface of the conduits can be used to attach larger quantities of protein, 
thereby, increasing bioactivity of the conduit. 
The following section describes how different types of NTFs were loaded into NRCs. 
5.3.1. Nerve growth factor (NGF) 
NGF is the most commonly used neurotrophic factor for sciatic nerve regeneration. Kim et. al. 
used NGF immobilized porous polycaprolactone (PCL)/Pluronic F127 as a biological stimulator 
for the growing axons[85]. They found that NGF loaded conduit had a positive effect on neural 
regeneration viz. thicker neural tissues than the control nerves). Wang et. al. immobilized NGF 
on a nerve conduit made of chitosan using genipin crosslinking and observed the conduit to have 
nerve function  comparable to that of an autologous nerve graft [86].  
5.3.2. Glial cell-derived neurotrophic factor (GDNF) 
GDNF has been shown to enhance the survival of both sensory and motor neurons. An affinity 
based delivery system[87] of GDNF using a fibrin matrix inside a silicone conduit improved the 
sciatic nerve regeneration in a 13mm rat sciatic nerve defect model [88]. A considerably high 
number of large diameter fibers showed the increase in the mature neural content using GDNF 
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based delivery system [88]. NRCs were also fabricated using collagen and silk fibrion to reduce 
the initial burst of GDNF and a long term(28 days) sustained delivery[89]. Moore et. al. showed 
that GDNF from a fibrin-based delivery system enhanced motor nerve regeneration at a level 
similar to an isograft in the femoral motor nerve model. This level was observed in terms of 
total nerve fibers, percentage of neural tissue, and nerve density [90]. 
5.3.3. Glial growth factor (GGF)/Neuregulin 
GGF-containing conduits have been shown to improve the sustained axonal regeneration and the 
muscle innervation when used with a poly-3-hydroxybutyrate (PHB) conduit [91]. PHB-GGF 
conduits were found to have much more myelinated fibers as compared to the control PHB 
conduits. Also, GGF has been shown to facilitate nerve regeneration by speeding up the 
migration rate of Schwann cells [92]. 
5.3.4. Fibroblast growth factor (FGFs) 
Use of immobilized FGF1 has been proposed as an effective way to increase the bioactivity of 
NRCs. This is believed to speed up the regeneration rate for severely damaged nerves [64]. 
bFGF (basic FGF) has also been shown to promote the extension of early regenerating axons by 
directly influencing them, via a mechanism that excludes Schwann cells or angiogenesis[93]. 
bFGF embedded in the inner layer of poly(D,L-Lactide) (PDLLA) conduits have been proven to 
significantly improve the regeneration and nerve function in a transected 15-mm sciatic nerve of 
Sprague Dawley rats[94]. bFGF released from such conduits also enhanced the sprouting of 
nerve fibers from dorsal root ganglia and the proliferation of Schwann cells. 
5.3.5. Ciliary neurotrophic factor (CNTF) 
CNTF is considered as one of the important neurotrophic factor which can stimulate neurite 
outgrowth in sensory and motor neurons [95, 96]. CNTF along with chitosan was coated on a 
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PLGA conduit after treatment with pulsed plasma. This was shown to promote nerve 
regeneration in 25mm long canine tibial nerve defect [97].  The PLGA/chitosan conduits-CNTF 
conduits group performed better than PLGA/chitosan conduits alone and were found to be 
similar to the autologous nerve grafts group. Cao et. al. used a different approach wherein they 
cross linked linear ordered collagen scaffold (LOCS) fibers with laminin followed by fusion of  
N-terminal of CNTF to the  laminin binding domain in  order to retain CNTF on the LOCS [98]. 
They found that functional biomaterial retained more CNTF and promoted the functional 
recovery and enhanced nerve regeneration. 
Another way of delivering neurotrophic factors is to encapsulate NTF secreting cells into 
microcapsules and transplant them at site of injury. Cell encapsulation technology is widely used 
for immobilizing cells inside a semi-permeable polymeric membrane which allows bidirectional 
flow of nutrients and therapeutic proteins. Oxygen and other essential nutrients diffuse from 
outside the capsule into the cells and therapeutic proteins released from the cells permeate 
outwards to support healing of targeted injured tissue[99]. Also cells inside the capsule remain 
protected from the immune response of the host as well as antibiotics [100, 101]. This has been 
attributed to the pore size of the capsule membrane being impermeable to host cells. Various 
types of biopolymers such as cellulose sulphate, collagen, chitosan, gelatin and agarose have 
been used for encapsulating cells. 
 
6. Nanomaterials 
 (Adopted from book chapter titled “Nanomaterials for Neural Tissue Engineering”.  In 
“Nanomaterials in Tissue Engineering: Characterization, Fabrication and Applications”, 
Gaharwar, Sant, Hancock and Harding (eds.). Harvard-MIT Division of Health Sciences, 
published by Woodhead Publishing-Cambridge.) 
32 
 
 
Nanotechnology is the use of engineered materials on a nanometer (nm) scale. The sizes of these 
materials are generally between 1- and ~100 nm, and they are compatible with biological 
systems including regenerative neural tissue therapy. Nano-engineered structures, especially 
nanotubes (NTs) and nanofibers (NFs) imitate the structure of the extracellular matrix (ECM) 
and can mimic the environment of the nervous system. Recent and remarkable improvements in 
nanotechnology offer promising alternatives for neural regeneration studies. Nanotechnology can 
be used to engineer scaffolds with oriented NFs, NTs and other materials that are functionalized 
to serve as cell-binding domains or for the release of trophic- or growth factors. These scaffolds 
also facilitate nutrient- and oxygen diffusion, and provide topographical cues. Recent advances 
in nanotechnology, biomaterials and tissue engineering have improved the effectiveness of 
NGCs and enabled their use with a control at nano-scale to obtain enhanced and oriented (Figure 
3) neuroregeneration [102].  
In the next few sections, the use of nanotechnology combined with other guidance cues (e.g., 
biomaterials, support cells, chemical factors, etc.) in neural tissue engineering strategies is 
reviewed. Nano-structure fabrication techniques and nano-materials in NTE are presented. 
Applications and recent advances in research are also discussed. 
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Figure 3 The schematic diagram shows growth and orientation of nerve cell fibers (A: Axons 
stained with anti-tau-protein, B: the nerve cell bodies stained with anti-MAP2 protein). Confocal 
microscope images of elongated axons (C: tubulin, D: phosphorylated neurofilament E: tau 
protein) (Reproduced with permission from [103] and [104]. 
 
6.1. Nano-scaffold design techniques 
The structure and geometry of the nano-structural scaffolds are very important to promote 
enhanced cell activity for neural regeneration. Thus, graft technology to produce these materials 
is critical to obtain optimum mechanical strength and surface properties for axon regeneration. 
Nano-structures made of several biomaterials have been shown to support axonal outgrowth. 
Several methods have been used to fabricate nano-structural scaffolds such as electrospinning, 
self-assembly and phase separation [105].      
6.1.1. Electrospinning 
Electrospinning is a technique for producing NFs in micro-/nano-scale from natural and synthetic 
polymers or polymer composites. A solution of the starting material in an appropriate solvent is 
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charged using a spinneret and a high voltage supply. This is done at a polymer concentration 
above the critical entanglement concentration, below which NFs are not produced. Under the 
influence of an electrical field, the surface tension of the polymer is overcome at the tip of the 
spinneret and the charged polymer jet is directed at a target, resulting in formation of a Taylor 
cone. Nanofibers emerging for spinneret are then collected in a parallel orientation using a 
rotating collector (Figure 4). The latter can be a drum or a disk as well as a plate. The use of a 
stationary collector may result in randomly oriented NFs. 
 
 
Figure 4. This schematic diagram illustrates the experimental set-up for the production of aligned 
nanofibers using electrospinning. Reproduced with permission from [106]. 
 
By electrospinning, fibers of nano- to micrometer size dimensions can be fabricated. Solution 
properties (i.e. concentration, conductivity, viscosity and elasticity) and process parameters (i.e. 
voltage, distance from target, needle identity, and temperature) can be altered to fabricate various 
types of fibers for various applications. The mechanical properties of the NFs (e.g., thickness, 
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composition, surface area and porosity) are adjusted by controlling the solution and process 
parameters to optimize the alignment, stability and morphology [105, 107]. For different 
applications, the collection schemes can be varied as single ground, rotating single ground, 
horizontal ring, and in vitro onto cells [108]. To overcome the disadvantages associated with the 
fiber thickness and random orientation, blends of different biomaterials can be used. Thus, 
various types of biological materials, synthetic biopolymers and composites have been used to 
manufacture NFs by electrospinning.  
For neural regeneration, the features of the scaffolds are extremely critical to mimic the ECM 
and achieve successful repair. For example, electric fields used during fabrication enhance 
control of fiber alignment, which is significant for neural regeneration. Electrospun NFs have 
been shown to enhance and accelerate cellular activities such as proliferation, axon regeneration, 
growth and migration [109, 110] and have been used for neural tissue engineering applications 
[106, 111]. Research to produce nano-structural scaffolds with desired mechanical- and surface 
properties for nerve conduits using electrospinning is continuing. 
6.1.2. Self-Assembly 
Self-assembly (SA) is the reversible and spontaneous formation of a stable organized/ordered 
structure, from disordered elements through various weak interactions, e.g. non-covalent bonds 
and hydrophobic interactions. SA can occur at the molecular level and in the nano- and micro-
scale. In nature, numerous types of SA processes are carried out. Amino acids, fatty acids, and 
other molecules come together to form self-assembled nano- or larger structures [112].  
The SA process has been shown to occur with polypeptide sequences, and di- and triblock 
peptide amphiphilic copolymers. Porous NFs of 5-10 nm diameter fabricated by self-assembly 
from various biodegradable/biocompatible materials have the potential to mimic the 3-D 
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microenvironment of the ECM and promote neural regeneration by enhancing cell attachment, 
proliferation, differentiation and migration. Amphiphilic oligopeptides composed of repeating 
units of hydrophilic and hydrophobic amino acids formed stable β-sheet structures in water and 
have been used to make scaffolds for neuronal regeneration [113]. Zhang et al. reported that with 
the addition of salts, these oligopeptides self-assembled into stable macroscopic structures of 
ordered filaments with porous enclosures, and supported cell attachment and synapse formation. 
Holmes et al. demonstrated the enhancement of neurite outgrowth with self-assembled peptide 
hydrogels [114]. Various macromolecules such as peptides have the ability to self-assemble and 
form ordered structures and nanomaterials due to several interactions between the components 
[115]. Sur et al. designed a hybrid matrix consisting of collagen type I and a peptide amphiphile 
(PA). They produced homogenous NFs of 20-30 nm in diameter having the structural properties 
of the former and epitope-presenting ability of the latter components by self-assembly [116]. The 
cellular density was shown to be manipulated by epitope concentration, which could be changed 
by PA concentration. Besides, controllable axon and dendrite growth were carried out as well as 
neuronal survival and maturation with epitope concentration adjustment. Furthermore, 
controllable axon and dendrite growth were carried out, as well as enhanced neuronal survival 
and maturation with epitope concentration adjustment. In another recent study, Angeloni et al. 
used biodegradable bundles of PA-NFs (Figure 4), which were fabricated by self-assembly and 
incorporated sonic hedgehog (SHH) protein molecules, for controlled delivery of the latter, 
which has an important role in cavernous nerve integrity [117].   
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Figure 5 Structure of peptide-amphiphile (PA) used to form mono-domain noodle gels (a), 
molecular model of the PA molecule (b), nanofiber formation through self-assembly (c), 
nanofiber bundles assembled in a longitudinal alignment after noodle formation. Reproduced 
with permission from [117].  
 
SA is viewed as an approach to change and control the functions of the scaffolds for neural 
repair [114, 118]. However, self-assembled nanomaterials have limited mechanical strength and 
unfavorable degradation rates. Moreover, fabrication of these structures using this technique for 
large neural gaps is not very practical [115].    
6.1.3. Phase Separation 
Another technique for NF production is phase separation (PS). The rationale for phase separation 
is the physical incompatibility or immiscibility of the polymer and the solvent. Initially, the 
polymer is dissolved in a solvent and the resulting solution is kept at the gelation temperature to 
promote gel formation of the polymer phase. After this, the solvent can be extracted from the gel 
and a porous nanofibrous skeleton is recovered. There are various types of PS methods for 
preparing NFs, such as nonsolvent-, chemically- and thermally-induced phase separation (TIPS). 
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In TIPS, polymer-rich and solvent-rich phases are produced by reducing the temperature of the 
polymer solution. The solvent-rich phase is removed from the solution by extraction or simple 
evaporation, leaving behind a solid, skeletal-like polymer matrix with pores. The morphology of 
the pores depends on various factors like concentration of the polymer solution, solvent 
properties, PS temperature and type of solvent removal techniques. TIPS is classified into 
different methods depending on solvent freezing- and phase separation temperatures. If the 
former is lower than the phase separation temperature, then PS occurs when the solution is 
cooled to between the lower- and upper critical solution temperatures i.e. in the unstable region 
of the binary phase diagram. At this temperature, a stable morphological pore network forms in 
the polymer foam. This is called the liquid-liquid phase separation (LLPS) process. Several 
synthetic biodegradable polymer scaffolds have been formed using this method in solvents like 
tetrahydrofuran and dioxane/water etc. [119-121]. 
In the solid-liquid phase separation (SLPS) process, the solvent freezing point is higher than the 
phase separation temperature of the solution, and the solvent freezes when temperature is 
reduced below this point. The polymer comes out of solution with a pore structure corresponding 
to the crystallization front of the solvent. Similar to LLPS, some of the synthetic biodegradable 
scaffolds have been produced using this method in solvent mixtures of dioxane and water [122]. 
Microporous membranes of polypropylene, polyethylene etc. have been prepared using TIPS and 
SLPS [123]. 
 
6.2. Nano-structures 
Nanomaterials of different morphologies, produced by electrospinning, phase separation and 
self-assembly, can enhance axonal outgrowth and facilitate neural regeneration. Most important 
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of these nanomaterials are nanogels (NGs), nanoparticles (NPs) and, in particular, nanotubes 
(NTs) and nanofibers (NFs), as these can mimic the tubular structures and within cells and 
tissues [124].  
6.2.1. Nanotubes 
Nanotubes are cylindrical structures with diameters of ~1-100 nm [125-128]. They are capable of 
simulating various intracellular structures such as microtubules and axons, etc. and also can 
penetrate cell membranes. They have a very high tensile strength (i.e. high strength to volume 
ratio) [129, 130]. With respect to neural regeneration, NGCs with bundles of NTs may provide 
higher surface area compared to that of conduits alone [131]. Moreover, elongation in 1-D can 
provide a better support and orientation to axon regeneration [132, 133]. Carbon NTs (CNTs) 
were tested and recommended for use as NGCs because of their favorable mechanical, elastic, 
electrical and rheological properties [134-136]. Graphene, the main constituent of CNTs, has 
been shown to promote neurite sprouting and outgrowth compared to tissue culture polystyrene 
substrates [137]. Various functional groups (e.g., carboxylic acid, ethylenediamine etc.) can be 
attached to CNTs to modify their chemical and electrical properties to promote controlled 
neuronal regeneration [138]. It was reported that human embryonic stem cells differentiated into 
neural lineages more efficiently on silk-CNT scaffolds with higher expression levels of β-III 
tubulin and nestin [139]. CNTs were also shown to promote formation of synaptic contacts and 
modulation of the cells’ plasticity [140].  
 
6.2.2. Nanofibers 
Nanofibers or nanowires are similar to NTs in structure and functionality. They are porous 
cylinders oriented in 1-D with a high interconnectivity and high specific surface area. They can 
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mimic the tubular structure associated with ECM like NTs. Various biomaterials have been used 
to make NFs using electrospinning [109, 141, 142]. NFs made of polyhydroxyalkanoate (PHA) 
were observed to promote neural stem cell attachment, synapse formations (synaptogenesis) and 
central nervous system regeneration [16]. Chitosan NF mesh tubes immobilized with electrically-
charged β-tricalcium phosphate (β-TCP) particles improved nerve regeneration by increasing 
axon density and area [143]. Mammadov et al. used a synthetic peptide nanofiber to mimic the 
activity of laminin and heparan sulfate proteoglycans to enhance axonal growth and induce 
neuritogenesis, respectively. These self-assembled NF scaffolds were shown to be effective for 
neurite outgrowth as well as surmounting the inhibitory effect of chondroitin sulfate 
proteoglycans [144]. Electrospun-collagen NFs impregnated with neurotrophin-3 (NT-3) and 
chondroitinase ABC (ChABC) supported neuronal culture and neurite outgrowth for a longer 
period than bolus delivery of NT-3. These hold promise for nerve regeneration following spinal 
cord related injuries, as they provide topographical and biochemical cues and suppress the 
inhibitory activity during axonal regrowth in the CNS [110]. 
 
6.2.3. Nanoparticles  
Nanoparticles are tiny particles having at least one of dimension under 100 nm. NPs with lower 
melting points [145], higher solar absorption capabilities [146], and super paramagnetism [147] 
etc., are typically different from bulk materials. Due to this, NPs have been used in various 
industrial applications, e.g., electronics, biomedical engineering, optics etc. NPs have very high 
surface area-to-volume ratios resulting in high diffusion gradients [148] and enhanced released 
of substances such as drugs, proteins, peptides etc., from NPs to the surrounding environments.  
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Chitosan-heparin NPs impregnated with nerve growth factors were shown to improve nerve 
regeneration in mice and to function as a robust NP drug delivery system to the sciatic nerve 
[149]. Super-paramagnetic NPs functionalized with TrkB receptor antibodies were shown to be 
endocytosed into signaling endosomes by neurons which in turn promoted neurite outgrowth and 
activated TrkB dependent signaling [150]. Nano-silver embedded into collagen scaffolds coated 
with laminin and fibronectin were shown to increase axonal regeneration and number of the 
recovered nerves were comparable to an autologous nerve graft [151]. Nerve regeneration was 
improved using microstructured polymer filaments in the form of nerve implants containing 
chitosan/siRNA NPs. These stable were rapidly internalized by cells and did not affect cell 
viability [152]. A nanostructured 2-D substrate comprising gold NPs attached to the surface of a 
cover glass via an adsorption system has been shown to improve neurite outgrowth of PC12 cells 
in the presence of electrical stimuli [153]. Such gold NPs can be used as suitable tools for nerve 
regeneration from neuronal cells. 
6.2.4. Nanogels  
Nanogels are among the more recent products to be used in nanotechnology. They are nano-scale 
hydrophilic cross-linked networks of biocompatible polymers and are mostly used for 
encapsulating drugs and as efficient drug delivery vehicles [154, 155]. Nanogels are prepared 
using polymerization techniques such as free radical crosslinking [156], free radical precipitation 
[157], nano-emulsion polymerization [158], etc. Porous scaffolds have been prepared from 
protein NGs [159] which may be useful for NTE purposes as well. These gels have also been 
suggested as a promising system for delivering of drugs like oligonucleotides to the brain [160]. 
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7. Conclusions and future directions 
The cellular and chemical mechanisms essential for functionality of the nervous system are 
extremely complex and still not entirely understood. This in itself presents formidable challenges 
to neural tissue engineering efforts.  Research to discover and implement neural regeneration 
strategies have been underway for several decades. Substantial improvements in 
neuroregeneration with functional recovery have been obtained using NRC implantation. 
However, technology for NRCs has not sufficiently advanced to allow them to completely 
replace grafts for their effectiveness, especially in cases of severe injuries and longer gaps.  
Advances in nanotechnology along with other neural tissue engineering strategies have provided 
alternatives and implementation of guidance cues to facilitate healing of neural lesions.  
 
Several scaffold types have been used to make nano-NRCs from blends of natural or synthetic 
materials with the desired physical and chemical properties compatible with extracellular 
matrices. Their use has improved cell survival, adhesion, growth, proliferation, orientation and 
differentiation. Composites fabricated using the latest techniques in entubulization and 
bioengineering have produced encouraging results. Guidance cues are also critical to success, 
among them the use of specific cell types to maximize reinnervation and promote axonal growth 
to bridge nerve gaps. Growth factors have been combined with other guidance cues to facilitate 
nerve regeneration. Recent advances in tissue engineering have enabled the use of cells 
genetically modified to secrete specific growth factors. Thus, NRCs’ function is not only as 
guidance cues, but also as platforms for controlled release of therapeutic agents such as trophic 
factors and cellular constituents such as ECM molecules. Incorporation of these guidance cues 
may mimic the molecular and cellular components of the microenvironment. 
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The use of nanotechnology offers many significant and attractive advantages; however, at the 
molecular level, it poses a number of challenges. Nano-engineered structures can be 
functionalized for specific use in neural regeneration and other applications. For example, 
nanoparticles are used in designing devices for the controlled release of medicines, while NFs 
and NTs can mimic the tubular structures of the ECM, a desirable feature in designing NRCs for 
the repair of neural lesions. However, improvements in specificity are still needed to enhance 
and expand their therapeutic potential for clinical treatments [161]. In the case of NRCs, the use 
of nano-structures for improved control of guidance cues offers potential for successful 
neuroregeneration therapies.  
Neurotrophic factor releasing systems are also expected to play a pivotal role in the design 
NRCs. Current limitations of such devices are lower encapsulation efficiency, degradation 
products, sustained release, faster fabrication procedures and cost effectiveness. Combining 
variety of NTFs in required amounts in one single device is anticipated to be one of the 
challenges for developing such optimized systems. Another challenge is the time dependent 
release of proteins corresponding to the various stages of the neural regeneration. Additionally, 
reducing the cytotoxicity caused by these devices and reduction of negative impact on tissue 
sections other than the targeted areas should also be considered.      
In spite of the progress made to date, more research on scaffold design and evaluation in vivo is 
still needed. Using single regenerative cue at a time has shown to improve the nerve regeneration 
but still there are various limitations associated with them such as incomplete recovery and no 
functional benefits. Autologous nerve graft, also considered as the gold standard of nerve repair 
strategies comes with many drawbacks such as donor site morbidity, multiple surgeries and 
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cannot be used for larger nerve injuries. In our approach, we are trying a combinatorial approach 
to combat such limitations. We are combining various regenerative cues together to enhance the 
peripheral nerve regeneration. Topographical cues in form of micropatterned conduit can help 
the axons to grow larger distances. Biological cues by using transdifferentiated patient specific 
bone marrow derived MSCs may help in replacing the native Schwann cells of the peripheral 
nervous system. Chemical cues in form of NGF releasing nano/microparticles will provide the 
additional growth and trophic factors to the growing axons. In turn, combining these 
topographical, biological and chemical cues may result in an important strategy to overcome the 
limitations and to further enhance the peripheral nerve regeneration. Neural tissue engineering is 
a challenging undertaking, especially given the complexities of the nervous system.  The ability 
to duplicate the microenvironment of the ECM with guidance cues must be evaluated in models 
that mimic the human body. Trials with animals larger than rodents will provide a better 
understanding of how regenerative therapies will perform in humans. The contributions of 
nanotechnology should be used for NRCs after overcoming the drawbacks and possible health 
risks. In spite of the complex challenges, nanotechnology, along with improved biomaterials, 
drug delivery capability and tissue engineering will provide alternative therapies with successful 
clinical applications.  
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CHAPTER 3: ORIENTED GROWTH AND TRANSDIFFERENTIATION OF 
MESENCHYMAL STEM CELLS TOWARDS A SCHWANN CELL FATE ON 
MICROPATTERNED SUBSTRATES 
 
Adapted from manuscript: 
Sharma AD, Zbarska S, Petersen EM, Marti ME, Mallapragada SK, Sakaguchi DS. Oriented 
growth and transdifferentiation of mesenchymal stem cells towards a Schwann cell fate on 
micropatterned substrates. Journal of Bioscience and Bioengineering. 2016;121(3):325-35. Epub 
2015/09/16. 
 
1. Abstract 
While Schwann cells (SCs) have a significant role in peripheral nerve regeneration, their use in 
treatments has been limited because of lack of a readily available source. To address this issue, 
this study focused on the effect of guidance cues by employing micropatterned polymeric films 
to influence the alignment, morphology and transdifferentiation of bone marrow-derived 
rat mesenchymal stem cells (MSCs) towards a Schwann cell (SC) - like fate. Two different types 
of polymers, biocompatible polystyrene (PS) and biodegradable poly (lactic acid) (PLA) were 
used to fabricate patterned films. Percentages of transdifferentiated MSCs (tMSCs) 
immunolabeled with SC markers (α-S100β and α-p75NTR) were found to be similar on 
patterned versus smooth PS and PLA substrates. However, patterning had a significant effect on 
the alignment and elongation of the tMSCs. More than 80% of the tMSCs were oriented in the 
direction of microgrooves (0o-20o), while cells on the smooth substrates were randomly 
oriented. The aspect ratio (AR) of the tMSCs on patterned substrates had a value of 
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approximately five, as compared to cells on smooth substrates where the AR was one. 
Understanding responses to these cues in vitro helps us in understanding the behavior and 
interaction of the cells with the 3D environment of the scaffolds, facilitating the application of 
these concepts to designing effective nerve guidance conduits for peripheral nerve regeneration.  
 
2. Keywords 
 Micropatterning, Polymeric films, Mesenchymal stem cells, Transdifferentiation, Schwann cells. 
 
3. Introduction 
Schwann cells are peripheral glia that form myelin sheaths, and are known to play significant 
roles during peripheral nerve regeneration[1]. Nerve injury in the peripheral nervous system 
(PNS) is followed by Wallerian degeneration, which continues at the distal stump. Schwann cells 
clear the myelin debris while proliferating and forming bands of Büngner that promote axonal 
regeneration through the distal nerve stump. In addition, SCs secrete trophic and growth factors 
such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial-derived 
neurotrophic factor (GDNF), all of which promote neural regeneration [2, 3]. It has been shown 
that implantation of SCs supports axonal elongation and regeneration in vitro and in vivo [4, 5]. 
Furthermore, SCs were also reported to overcome the inhibitory effect of central nervous system 
(CNS) components following injury [6]. These properties enable SCs to be one of the most 
attractive cell based therapies for PNS and CNS regeneration. 
However, despite their enormous potential, harvesting SCs requires multiple surgeries and 
sacrifice of a donor nerve that may result in donor site morbidity. These drawbacks have led to 
alternative approaches, such as transdifferentiation of more readily available cells into SC-like 
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phenotypes. Multipotent MSCs are emerging as an important and versatile cell source for neural 
repair strategies. It has been shown that upon proper treatment, MSCs can be transdifferentiated 
into SC-like phenotypes [7]. These cells resemble typical SCs morphologically and molecularly 
[5]. Due to self-renewal ability, high proliferation rate, and multi-lineage differentiation abilities, 
MSCs are an attractive cell type to be used in neuroregenerative strategies [8]. MSCs can be 
harvested from several sources, i.e. bone marrow, adipose tissue, and umbilical cord and can 
differentiate into multiple mesodermal cell lineages (chondrocytes, osteocytes, and 
adipocytes)[9]; and several neuronal and glial phenotypes [10, 11] under certain conditions and 
stimulations.  
The morphological and phenotypic changes in the transdifferentiated MSCs (tMSCs) were 
demonstrated using SC markers by immunocytochemistry (ICC), enzyme-linked immunosorbent 
assay (ELISA) and Western blotting analyses [5, 7, 12]. These phenotypes were shown to 
enhance axonal growth [13] and remyelination [14] as well as promote functional outcomes [7, 
14-16].         
Enhanced neuronal regeneration should be supported with directionality. An oriented axonal 
regrowth or cell alignment will be superior compared to randomized cellular therapies for nerve 
regeneration.  Specific microarchitectures and topographical cues such as grooves, pores etc., 
have been shown to promote axonal growth and direct cellular orientation [17, 18]. 
Micropatterned biodegradable substrates in porous conduits, and pre-seeded with SCs have been 
shown to promote neurite outgrowth, axonal regrowth and nerve regeneration [19-21]. 
Micropatterning of the polymer scaffold enables building of specific biomaterial architectures 
and can also influence stem cell differentiation. Previously our lab has reported enhancement in 
neuronal differentiation and 75% alignment along micropatterned substrates for adult rat 
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hippocampal progenitor cells (AHPCs) [22]. In another study, the synergistic effects of 
micropatterned substrates, astrocyte-derived soluble factors and co-culturing with astrocytes, 
resulted in enhanced neuronal differentiation of AHPCs [23]. Qi et.al [24] demonstrated that the 
processes of neural stem cells (NSCs) were oriented parallel to the microgrooves, while those on 
the non-patterned surfaces were randomly positioned in vitro.  
Therefore, in the present study, the transdifferentiation of MSCs seeded on micropatterned 
substrates to SC-like phenotypes was investigated, due to the ease of harvesting bone marrow 
stem cells and for their potential use in conduits for nerve regeneration. Rat MSCs from bone 
marrows of Brown Norway rats were used. Several MSC types have been tested for their 
transdifferentiation ability; however, Brown Norway rat MSCs have not been tested yet, to our 
knowledge. They were favored due to the ease of harvesting bone marrow stem cells. 
Biocompatible polymers polystyrene (PS) and biodegradable poly (lactic acid) (PLA) were used 
for fabricating the micropatterned films to investigate the effect of topographical cues on 
transdifferentiation, alignment and morphology of the MSCs. In the present study, the 
transdifferentiation ability of Brown-Norway rat MSCs to a SC-like phenotype was tested 
quantitatively as well as qualitatively on smooth and micropatterned polymer substrates.  
4. Materials and methods 
4.1. Fabrication of micropatterned polymeric films 
Two different types of polymers were chosen for polymeric film fabrication – polystyrene (PS) 
(M.W. 125,000-250,000) (Cat #00575, Polysciences, Inc. Warrington, PA) and poly (lactic acid) 
(PLA). PS is a widely used biocompatible polymer in tissue culture applications, while PLA is a 
biodegradable polymer and is frequently used for making transplantable scaffolds for in vivo 
studies. Previously in our group, we have developed a method [22, 25] of producing 
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micropatterned PS and PLA films using micropatterned silicon wafers. Micropatterned silicon 
wafers were fabricated using conventional lithographic techniques and polymer films were 
fabricated using solvent casting [22] and detached from the wafers. These films have been shown 
to support growth of dorsal root ganglion cells, SCs, astrocytes and neural progenitor cells 
(NPCs) [20, 22, 25, 26]. 
For PS films, 6% PS solution in toluene was poured on the micropatterned silicon wafer and 
dried for approximately 4 hours. For PLA films, 10% PLA solution was poured onto a silicon 
wafer spinning at a speed of 75 rpm using a spin coater (Model PWM32-PS-R790, Headway 
Research, Inc. Garland, TX). The PLA solution on the wafer was left to dry for 10 minutes on 
the spin coater before transferring to a chemical hood for an additional 6 hours. Films were 
carefully peeled off using forceps after submerging the wafer and the dried films in deionized 
water. Dimensions of the micropatterns obtained on the polymeric films were measured using 
scanning electron microscopy (SEM, Quant FEG 250, Hillsboro, OR) and were found to be 11-
13 µm, 16-18 µm and 3.5-4.5 µm in groove, mesa and depth, respectively for both PS and PLA 
films. The dried square films were cut to the size of 0.71 cm2 with a razor blade, with half of the 
film being patterned and the other half smooth. Silastic medical adhesive (Dow Corning Corp., 
CITY, STATE) was used to attach the square film with a side length of 8.4 mm to a detergent-
cleaned 12 mm glass coverslip. The glass coverslips with attached films were sterilized with 
70% ethanol and UV light, and coated with poly-L-lysine (PLL, Sigma Aldrich, St. Louis, MO) 
at a dilution of 1:10 before cell plating. 
4.2. Isolation of Brown Norway rat MSCs 
All animals were acquired and cared for in accordance with the guidelines published in the NIH 
Guide for the Care and Use of Laboratory Animals and all procedures adhered to the principles 
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presented in the "Guidelines for the Use of Animals in Neuroscience Research" by the Society 
for Neuroscience and had the approval of the Iowa State University Institutional Animal Care 
and Use Committee, and were performed in accordance with committee guidelines. Brown 
Norway rats were obtained from Charles River Labs, and at 6 weeks of age were used for the 
isolation of bone marrow. The animals were kept in a constant environment (temperature: 22°C; 
humidity: 20 %; 14/10-hour light-dark cycle) with food and water provided ad libitum until the 
bone marrow was isolated. The rats were allowed to acclimate after arrival for at least 7 days 
before harvesting bone marrow. 
The rats were euthanized with isoflurane before the dissection of the femora and tibiae. The 
bones were placed in 50 mL conical tubes with ice-cold maintenance media (MM) composed of 
alpha minimum essential media (αMEM, Gibco BRL, Gaithersburg, MD), supplemented with 
20% fetal bovine serum (FBS, Atlanta Biologicals, Atlanta, GA), 4 mM L-glutamine (Gibco 
BRL, Gaithersburg, MD), and antibiotic-antimycotic (Invitrogen, Carlsbad, CA). Using a syringe 
and a 23-gauge needle filled with 3 mL MM, the marrow was forced from the Epiphysis of each 
bone, into a culture dish. The marrow suspension was dispersed through a 70 µm nylon cell 
strainer (BD Falcon, Bedford MA), dampened with MM and transferred into a T75 flask with 20 
mL MM. The cell suspension was maintained in a culture incubator (37°C, 5% CO2/95% 
humidified air atmosphere). After 48 hours, post-harvest, spindle-shaped cells adhered to the 
bottom of the flask. The cells were washed with phosphate buffered saline (PBS; Gibco BRL, 
Gaithersburg, MD) and the media was replaced with fresh MM (Ye et al. 2014, in preparation). 
4.3. Culturing of Brown Norway rat MSCs 
Brown Norway rat MSCs were plated in T75 flasks in MM, consisting of  minimum essential 
medium (αMEM, Gibco BRL, Gaithersburg, MD), 20% fetal bovine serum (FBS; Atlanta Bio.), 
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4 mM L-glutamine (Gibco), and antibiotic-antimycotic (Invitrogen, Carlsbad, CA) and incubated 
at 37°C/ 5% CO2/ 95% humidified air atm. Adherence to the flask was observed from flat 
fibroblast-like cells. When the MSCs were ~80% confluent, media was aspirated and cells were 
washed with PBS to remove serum before trypsinizing the cells. Cells were collected transferred 
into 15 ml conical tubes and centrifuged at 500 rpm for 5 minutes. Following centrifugation, the 
cell pellets were resuspended in MM and the cell suspensions plated out onto various polymeric 
films following Trypan blue viable cell counts. 
4.4. In vitro transdifferentiation of rat MSCs into SC-like phenotypes 
In vitro chemical induction of the rat MSCs into SC-like phenotypes was performed in three 
steps following the protocol established by Dezawa and coworkers [7]. Rat MSCs were kept in 
MM for 1-2 days in T75 flasks at 37°C/ 5% CO2. After reaching 30-40% confluence, the MM 
media was replaced with the transdifferentiation media-1 (TDM-1) containing αMEM 
supplemented with 1 mM β-mercaptoethanol (BME; Sigma-Aldrich, St. Louis, MO) and 
incubated for one day. After a PBS wash, TDM-1 was replaced with the TDM-2 containing 
αMEM, 10% fetal bovine serum (FBS) and 35 ng/ml all-trans-retinoic acid (ATRA; Sigma, St. 
Louis, MO). The cells were incubated in TDM-2 for the following 3 days at 37°C/ 5% CO2. 
Finally, the cells were incubated in TDM-3 which contained αMEM, 10% FBS, 14 µL forskolin 
(FSK; EMD Millipore, Billerica, MA), 5 ng/mL platelet derived growth factor (PDGF; Sigma), 
10 ng/mL basic fibroblast growth factor (bFGF, Promega Corporation, Madison, WI) and 200 
ng/mL heregulin β1 (HRG; Calbiochem, EMD Millipore, Billerica, MA ) for 8 days in vitro 
(DIV). Prior to the media changes, cells were always washed with PBS. At the transition to 
TDM-3, the cells were plated onto glass coverslips or half patterned-half smooth polymeric 
substrates attached to glass coverslips. The polymer film substrates were coated with poly-L-
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lysine (PLL) and placed in a 35 mm petri dish etched into quadrants with a soldering iron. 
Control or undifferentiated MSCs (uMSCs; MSCs cultured in MM) were always grown in 
parallel to the MSCs undergoing transdifferentiation (tMSCs; SC like-cells). Undifferentiated 
and transdifferentiated MSCs grew at different rates in MM and different TDMs respectively. In 
order to obtain a comparable cell number after a period of 14 DIV, initial cell plating density was 
altered. Undifferentiated MSCs were plated at a density of 1000 cells/cm2 while tMSCs were 
plated at a density of 3000 cells/cm2.  MSCs from passages 4 to 7 were used for replicate studies 
of the transdifferentiation experiment. Immunocytochemical procedures were used to 
characterize the uMSCs and tMSCs (see below). The transdifferentiation and cell morphology on 
the patterned half of each substrate was compared with that of the smooth half on the same 
substrate.  
4.5. Immunocytochemistry (ICC) 
After 8 DIV, the cells in culture dishes were rinsed with 0.1 M PO4 buffer and fixed with 4% 
paraformaldehyde prepared in 0.1 M PO4 buffer. The cells were then rinsed with filtered 
phosphate buffered saline (PBS; Fisher-Scientific) for 3 times every 7 minutes and incubated in 
blocking solution of PBS supplemented with 5% normal donkey serum (NDS, Jackson 
ImmunoResearch, West Grove, PA), 0.4% bovine serum albumin (BSA; Sigma) and 0.2% Triton 
X-100 (Fisher Scientific). 
Several antibodies were used for ICC analysis for characterization of undifferentiated MSCs 
(uMSCs) (Table 1) and transdifferentiated MSCs (tMSCs) (Table 2). The primary antibodies 
were diluted with blocking solution. Samples were incubated with primary antibodies at 4°C 
overnight. On the following day, the cells were rinsed with PBS for 4 times every 8 minutes, and 
subsequently incubated in appropriate secondary antibodies diluted in blocking solution. The 
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following secondary antibodies were used:  Donkey-α-Mouse-Cy3 (1:500, Jackson 
ImmunoResearch, West Grove, PA), Donkey-α-Rabbit-Cy3 (1:500, Jackson ImmunoResearch, 
West Grove, PA). In addition, MSCs were stained with Alexa Fluor 488 Phalloidin (1:1000, 
Molecular Probes-Life Technologies, Carlsbad, CA), and DAPI (4',6-diamidino-2-phenylindole) 
(1:2000, Invitrogen, Carlsbad, CA), all diluted in the same blocking solution used for secondary 
antibody staining. The cells were incubated for 60-90 minutes in the dark at room temperature 
and then rinsed with PBS for 3 times every 7 minutes. Immunolabeling control samples were 
incubated without primary antibodies, and with secondary antibodies. The glass coverslips were 
mounted cell side down on microscope slides with Vectashield with DAPI (Vector Laboratories, 
Burlingame, CA) and clear nail polish was used for creating an air-tight seal. The sample was 
mounted with careful removal of the polymeric film from the cover slip with a forceps. The film 
was slid into the middle of a drop of Vectashield, cell side up, on a microscope slide. Cover glass 
was placed on top of the film and Vectashield and an air tight seal was formed with nail polish. 
Preparations were examined and images captured using an upright fluorescence microscope 
(Nikon Microphot FXA) equipped with a Retiga 2000R digital camera controlled by QCapture 
software (QImaging, Surrey, BC, Canada). For image analysis, a minimum of 8 microscope 
fields from each substrate were taken randomly using a 20X objective. Each field represents 0.17 
mm2 (476 µm x 357 µm). To calculate the percentage of immunoreactive cells on each substrate, 
the number of cells immunoreactive for each antibody was divided by the total number of cells 
(DAPI-stained nuclei). Images were uploaded to MetaXpress software (Molecular Devices, 
Sunnyvale, CA) and with help of multiwavelength cell scoring module; number of cells stained 
with different antibodies/wavelengths were obtained.  
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Table 1. Undifferentiated MSCs were characterized using various positive and negative MSC 
antibody markers.  
 
Table 2. Antibody markers used for immunostaining transdifferentiated MSCs. 
 
4.6. Treatment with bromodeoxyuridine (BrdU) 
MSCs were cultured for 3 DIV and 12 hours before fixation, the cells were incubated with MM 
supplemented with BrdU to a final concentration of 5 µM. After fixation, the cells were treated 
with 2N HCl at 37C for 15 minutes and then replaced with 0.1 M borate neutralization buffer 
Primary 
Antibody 
Dilution Specific Protein Protein expression  
Mouse  
CD54 
1:100 Intracellular adhesion molecules-1(ICAM 1) 
Proteins 
Positive 
Rabbit  
CD29 
1:1000 Integrin 1 Positive 
Rabbit  
Collagen 
1:200 Collagen Positive 
Rabbit  
Fibronectin 
1:1000 Fibronectin Positive 
Mouse  
CD14 
1:100 Hematopoietic cell surface markers - present 
on leukocytes 
Negative 
Mouse  
CD45 
1:200 Hematopoietic cell surface markers - present 
on monocytes and macrophages 
Negative 
Primary Antibody Dilution Specific Protein Positive Cell Type 
Mouse  S100ß 1:1000 Calcium Binding Protein Glial Cells 
Mouse  GFAP 1:1000 Glial Fibrillary Acidic Protein Glial Cells 
 
Rabbit  p75NTR 
1:1000 Neurotrophic Receptor Glial Cells 
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for 15 minutes. The neutralizer was removed and the cells were rinsed with PBS for 3 times 
every 7 minutes. The rest of the procedure was carried out in accordance with the ICC stated 
above, starting with the one hour incubation in blocking solution. Primary antibody used was Rat 
α BrdU (1:200, Abcam, Cambridge, MA). 
4.7. Data and statistical analysis  
Aspect ratio (AR) of an object is defined as the ratio of object’s width to its height, when the 
width of the object is longer than its height. Aspect ratio of MSCs have been shown to affect 
their lineage commitment [27]. Objects such as regular polygons or circular objects have AR 
equal to one, which means that there is no difference in height and width of the object. Images 
were binarized by determining minimum threshold intensity to differentiate between the 
background and cells stained with phalloidin. Integrated morphometric analysis module of 
MetaXpress software was used for measuring various morphological parameters such as width, 
height, cellular area and orientation of the cellular objects obtained after thresholding. 
Orientation of the cells was measured between -90 to +90 degrees from the horizontal where all 
the images captured had micropatterns parallel to the horizontal. Thirty cells per condition (PLA 
pattern, PLA smooth, PS pattern, PS smooth) per experiment were analyzed to obtain the data. 
Three independent experiments were analyzed, giving 90 cells per condition. GraphPad prism v6 
software (GraphPad Software, Inc., La Jolla, CA) was used for statistical analysis. One way 
ANOVA with Tukey post-hoc test was used to compare the means across the various conditions. 
A p-value ≤ 0.05 was considered significant during mean comparisons. Error bars in graphs 
represent standard error of the mean. 
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5. Results 
Patterned PS and PLA films were successfully fabricated by solvent casting using 
micropatterned silicon wafers. Immunocytochemistry and cell staining procedures were used to 
examine changes in MSCs’ transdifferentiation, morphology and alignment. We have 
demonstrated that MSCs align themselves along the direction of microgrooves when grown on 
micropatterned substrates. In contrast, MSCs growing on a smooth, non-patterned surface were 
randomly oriented. Patterning did not affect transdifferentiation of MSCs towards SC-like 
phenotypic cells as compared to smooth polymeric substrates. Results indicate that substrate 
topography strongly influences the morphology and growth of the MSCs.  
5.1. Characterization of uMSCs 
Undifferentiated MSCs isolated from bone marrows of Brown Norway rats were characterized 
by immunostaining for various positive and negative rat MSC markers. MSCs were found to be 
positively immunostained against Fibronectin, Collagen, CD54 (ICAM1, Intracellular adhesion 
molecule 1), and CD29 (Integrin β1). Negative rat MSC markers such as CD14 and CD45 did 
not stain any of these cells. Also MSCs were successfully differentiated to form osteoblasts and 
adipocytes showing that they are multipotent in nature (Ye et al. 2014, in preparation). 
5.2. Fabrication of Polystyrene and Poly (lactic acid) films 
PS and PLA films were successfully fabricated by solvent casting, and scanning electron 
microscopy (SEM) was used to measure the dimensions of micropatterns. Dimensions of the 
micropatterns obtained on the polymeric films were found to be 11-13 µm, 16-18 µm and 3.5-4.5 
µm in groove, mesa and depth, respectively for both PS and PLA films. PS films obtained were 
similar to the ones fabricated by Recknor et. al. [22, 25]. Figure 1 shows SEM images of 
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micropatterned PS and PLA films at different magnifications. PLA films were found to have a 
small taper at the side of mesas as compared to PS films. 
 
Figure 1. Scanning Electron Microscopy (SEM) images of micropatterned Polystyrene (PS) and 
poly (lactic acid) (PLA) films. Dimensions of the micropatterns obtained on the polymeric films 
were found to be 11-13 µm, 16-18 µm and 3.5-4.5 µm in groove, mesa and depth, respectively 
for both PS and PLA films. (A) PS film at 300X magnification. (B) PS film at 1500X 
magnification. (C) PLA film at 300X magnification. (D) PLA film at 3000X magnification. 
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5.3. Effect of guidance cues on alignment and morphology of MSCs 
Undifferentiated MSCs (uMSCs) were grown on poly-L-Lysine coated half patterned –half 
smooth polymeric substrates in their normal maintenance medium (MM) for 3DIV (days in 
vitro). While the cells on smooth substrates were found to be fibroblastic in morphology, cells on 
patterned substrates were found to be elongated and growing in parallel to the direction of the 
grooves. Cells were found to be growing both within the grooves as well as on the top of the 
mesas. In order to determine the orientation and morphological changes associated with guidance 
cues, cells were then stained with Alexa Fluor 488 Phalloidin and DAPI, which stains actin 
filaments and nuclei, respectively.  
 Angle of the longest chord through each cell relative to the horizontal axis (i.e. parallel with the 
direction of the micropatterns) was used for the orientation data and was compared to the cells 
grown on the smooth part of the substrate. Number of cells was grouped between 10o sectors 
between 0o to 90o. More than 80% of the cells were found to be oriented in the direction of 
micropatterns (0o to 20o) (Fig. 2A for PS substrates and 2B for PLA substrates). 
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Figure 2. The distribution of uMSCs alignment on micropatterned and smooth PS and PLA 
substrates. It was demonstrated that an oriented cell alignment was obtained with 
micropatterning for uMSCs.  The data was grouped in 10º sectors from 0º to 90º. Over 80% of 
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the cells were found to be in range of 0o-20o for patterned substrates while cells were found to 
be randomly oriented on smooth substrates. Thirty cells per experiment (Total 90 cells/condition) 
were analyzed. (A) uMSCs alignment on Polystyrene films. (B) uMSCs alignment on PLA films. 
N=3 independent experiments and error bars represents standard error of the mean 
 
 
Here, in this study we also determined the AR of the cells grown on patterned substrate and 
compared to the AR of the cells grown on smooth substrate. Figure 3A showed that cells on 
patterned substrates were elongated with an AR closer to 5, while cells on the smooth substrates 
had an AR close to 1, showing the inclination of the cells to have a circular shape in the absence 
of patterns. Cells grown on PS Pattern and PLA Pattern were found to have AR of 5.03±1.14 and 
4.99±1.72 respectively as compared to values of 1.08±0.06 and 1.28±0.19 for PS Smooth and 
PLA Smooth, respectively. Cellular area was also compared between the cells grown on smooth 
versus patterned substrates. While the uMSCs seem to be elongated on patterned substrates, the 
average area of the cells on pattern substrates was found to be less as compared to cells grown on 
smooth substrates (Fig. 3B). Cellular area for cells grown on Pattern PS, Pattern PLA, Smooth 
PS and Smooth PLA was found to be 821.10±194.02, 594.29±73.34, 1196.26±147.60 and 
957.43±67.56 µm2, respectively. 
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Figure 3. The comparison of aspect ratios and cellular areas of uMSCs grown on micropatterned 
vs. smooth PS and PLA substrates. (A) Aspect ratio of uMSCs on various substrates. Aspect 
ratio is ratio of width to the height of the cell. Aspect ratios greater than one implies elongation 
of the object in one particular direction. (B) Cellular area of uMSCs on various substrates. 
Aspect ratios were found to be significantly different while cellular areas were not. 
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Aspect ratio of the cells growing on patterned PS (PS Pa) and patterned PLA (PLA Pa) was 
found to be significantly higher than smooth polystyrene (PS Sm) and smooth PLA (PLA Sm) 
substrates at p ≤ 0.05. Cellular area was found to be greater for the cells growing on smooth 
substrates. However, no significant differences were observed between cellular areas of the cells 
growing on patterned and smooth parts of the same polymer film at p ≤ 0.05. 
 
5.4. Effect of guidance cues on proliferation of MSCs 
In addition to quantifying the morphological changes of the cells associated with 
micropatterning, we also investigated whether patterning affects the proliferation of uMSCs as 
compared to the smooth control part of the polymeric film. BrdU was added to the cells 12 hours 
prior (at 2.5DIV) to fixation of the cells (3DIV).  No significant differences were observed in the 
proliferation of uMSCs on the basis of BrdU immunostained cells at p ≤ 0.05 across all 4 
conditions (PS Pa, PS Sm, PLA Pa and PLA Sm). Percentage of BrdU-stained uMSCs grown on 
PS Pa, PS Sm, PLA Pa and PLA Sm was found to be 33.62±8.01, 39.24±8.62, 42.44±14.87 and 
36.53±10.24% respectively (Figure 4). Proliferation was found to be slightly higher on PLA 
substrates as compared to PS substrates, suggesting that the biodegradability of substrates may 
have some influence on proliferation of uMSCs. Proliferation was found to be least for glass 
substrates (data not shown). Glass substrates were used for initial characterization and were no 
longer used for comparison for their inability to support cellular proliferation. Culturing of the 
cells on micropatterned substrates seems to cause no obvious reduction in proliferation. 
Supplemental Figure 3 shows percentage BrdU immunostained uMSCs data for both smooth and 
pattern PS and PLA substrates. 
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Figure 4. Graph showing percentage of BrdU-labeled uMSCs for various polymeric substrate 
conditions. Error bar represents standard error of the mean. N=3 independent experiments. No 
significant differences were observed between any of the substrate types and patterning does not 
seem to influence proliferation of uMSCs. 
 
These results show that micropatterning of polymeric substrates can be used as a strong tool to 
influence the morphology and alignment of the cells without causing any unexpected or 
deleterious changes in the elementary natural characteristics of the MSCs. 
 
 
5.5. Effect of guidance cues on transdifferentiation of MSCs toward a SC-like phenotype. 
Identification of the transdifferentiated MSCs (tMSCs) was based upon immunolabeling with 
antibody markers used to identify SCs, anti-S100β and anti-p75NTR [28]. 
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The cells were plated on the polymeric films attached to a glass coverslip. MSCs subjected to 
transdifferentiation conditions grew at a slower rate compared to uMSCs. Based on an initial 
study, the control undifferentiated MSCs (uMSCs) were plated at 1000 cells/cm2 and the MSCs 
subjected to the transdifferentiation conditions at 3000 cells/cm2. The results, obtained by 
fluorescent microscopy, revealed that both anti-S100β (Fig. 5 and 6) and anti-p75NTR 
(Supplemental Fig. 1 and 2) antibodies immunolabeled very few uMSCs compared to tMSCs. 
While no anti-S100β immunostaining was detected for the uMSCs, anti-p75NTR sometimes 
stained the nuclei of the uMSCs. However, anti-p75NTR staining for tMSCs was found to be 
cytoplasmic as opposed to occasional nuclear staining of uMSCs. 
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Figure 5. Transdifferentiated MSCs (tMSCs) on micropatterned PLA and PS films have a higher 
percentage of cells labeling with anti-S100β antibody than uMSCs. A, A’ and A’’ represents the 
corresponding anti-S100B, actin filaments (phalloidin) staining and merged image of tMSCs on 
patterned PLA substrate. B, B’ and B’’ represents the corresponding anti-S100B, actin filaments 
(phalloidin) staining and merged image of uMSCs on patterned PLA substrate. C, C’ and C’’ 
represents the corresponding anti-S100B, actin filaments (phalloidin) staining and merged image 
of tMSCs on patterned PS substrate. D, D’ and D’’ represents the corresponding anti-S100B, 
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actin filaments (phalloidin) staining and merged image of uMSCs on patterned PS substrate. 
Abbreviations: uMSCs, undifferentiated mesenchymal stem cells; tMSCs, transdifferentiated 
mesenchymal stem cells; S100β, anti- S100β antibody; PLA, poly(lactic acid); PS, polystyrene; 
Merged, merged image of S100β, Alexa-488 Phalloidin, DAPI and DIC (Differential 
interference contrast). Scale bar = 100µm 
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Figure 6. Transdifferentiated MSCs (tMSCs) on non-patterned (smooth) PLA and PS films have 
a higher percentage of cells labeling with anti-S100β antibody than uMSCs. A, A’ and A’’ 
represents the corresponding anti-S100B, actin filaments (phalloidin) staining and merged image 
of tMSCs on smooth PLA substrate. B, B’ and B’’ represents the corresponding anti-S100B, 
actin filaments (phalloidin) staining and merged image of uMSCs on smooth PLA substrate. C, 
C’ and C’’ represents the corresponding anti-S100B, actin filaments (phalloidin) staining and 
merged image of tMSCs on smooth PS substrate. D, D’ and D’’ represents the corresponding 
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anti-S100B, actin filaments (phalloidin) staining and merged image of uMSCs on smooth PS 
substrate. Abbreviations: uMSCs, undifferentiated mesenchymal stem cells; tMSCs, 
transdifferentiated mesenchymal stem cells; S100β, anti- S100β antibody; PLA, poly(lactic 
acid); PS, polystyrene; Merged, merged image of S100β, Alexa-488 Phalloidin, DAPI and DIC 
(Differential interference contrast). Scale bar = 100µm 
 
 
During data quantification, tMSCs and uMSCs were counted only when cytoplasmic staining of 
anti-p75NTR was observed. Figures 7A and 7B graphically show the comparison of data across 
various substrate conditions for immunostaining of anti-S100β and anti-p75NTR, respectively 
for both tMSCs and uMSCs. These results demonstrated that a greater proportion of MSCs 
subjected to the transdifferentiation protocol were anti-S100β and anti-p75NTR immunoreactive 
in comparison to the MSCs cultured under control conditions (cultured in maintenance media 
(MM)). It was also observed that MSCs transdifferentiated on polymeric (PS and PLA) 
substrates have a higher percentage of cells immunoreactive for S100β and p75NTR compared to 
glass coverslips (data not shown). Neurotrophin receptor p75NTR immunostaining also followed 
a similar trend as S100β, where very few uMSCs were found to be immunolabeled for p75NTR 
as compared to tMSCs where more than 90% cells showed presence of p75NTR protein. For 
both PS and PLA patterned and smooth substrates, the percentage of S100β and p75NTR 
immunolabeled cells were found to be significantly higher in cells subjected to the 
transdifferentiation protocol (tMSCs) as compared to cells grown just in MM (control cells: 
uMSCs) at p ≤ 0.05.  
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Figure 7. Graphs showing percentage of S100β and p75NTR labeled cells for various polymeric 
substrate conditions. (A) S100β labeling of the tMSCs were found to significantly different (p ≤ 
0.05) than the uMSCs for all substrate types. (B) p75NTR labeling of the tMSCs was 
significantly greater (p ≤ 0.05) than the uMSCs for all substrate. Patterning caused no deleterious 
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effect on the transdifferentiation of MSCs into SC-like phenotypic cells. Both polymers were 
found to have more S100β immunostaining as compared to glass coverslips (data not shown). 
Error bar represents standard error of the mean. N=3 independent transdifferentiation 
experiments were carried out. *Significantly different from smooth substrates at p ≤ 0.05. 
 
 
As shown before for uMSCs, more than 80% of tMSCs were found to be oriented in the direction 
of the micropatterns for both PS (Figure 8A) and PLA (Figure 8B) substrates. These results 
illustrate that micropatterning did not cause any decrease in the level of transdifferentiation, and 
yet facilitated an oriented cell alignment, which is likely to be advantageous for enhanced neural 
regeneration.  Aspect ratio (Figure 9A) was found to be significantly higher on patterned 
polymeric substrates as compared to their smooth counterpart at p ≤ 0.05. Average cellular area 
(Figure 9B) was found to be greater on smooth substrates as compared to pattern substrates, but 
no significant differences were observed at p ≤ 0.05. 
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Figure 8. The distribution of tMSCs alignment on micropatterned and smooth PS and PLA 
substrates. It was demonstrated that an oriented cell alignment was obtained with 
micropatterning for tMSCs.  The data was grouped in 10º sectors from 0º to 90º. Over 80% of the 
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cells were found to be in range of 0o-20o for patterned substrates while cells were found to be 
randomly oriented on smooth substrates. Thirty cells per experiment (Total 90 cells) were 
analyzed. (A) tMSCs alignment on Polystyrene films. (B) tMSCs alignment on PLA films. N=3 
independent experiments and error bars represents standard error of the mean. 
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Figure 9. The comparison of aspect ratio and cellular area of tMSCs grown on micropatterned vs. 
smooth PS and PLA substrates. (A) Aspect ratio of tMSCs on various substrates. Aspect ratio is 
ratio of width to the height of the cell. Aspect ratio of more than one means elongation of the 
83 
 
 
object in one particular direction. (B) Cellular area of tMSCs on various substrates. Aspect ratios 
were found to be significantly different while cellular areas were not. 
Thirty cells per experiment (Total 90 cells) were analyzed. N=3 independent experiments and 
error bars represents standard error of the mean. Abbreviations: PS, polystyrene; PLA, poly 
(lactic acid), Pa, patterned substrate; Sm, smooth substrate. *Significantly different from smooth 
substrate at p ≤ 0.05. 
 
6. Discussion 
In this study, we have successfully shown that micropatterned polymeric substrates act as very 
useful tools in providing orientation to the growing uMSCs and tMSCs. Mesenchymal stem cells 
grown on patterned substrates grew in the direction of the microgrooves, were highly oriented 
and showed elongation along the grooves. More than 80% of the cells were oriented parallel with 
the grooves on both PS and PLA patterned substrates. Cells were profoundly elongated (AR > 4) 
in the direction of the patterned substrates compared to their smooth counterparts (AR ~ 1). On 
the other hand, cells on the smooth substrates were found to have higher average cellular areas 
than cells on micropatterned substrates, but no significant differences were observed. While we 
were able to control the morphological characteristics of the cells with the help of these guidance 
cues, we found no obvious deleterious effect of patterning on the proliferation and 
transdifferentiation of the cells. Biodegradable PLA substrates supported the growth and 
directionality of the cells in a similar fashion to control biocompatible PS substrates. 
Transdifferentiation seemed to occur more on polymeric substrates as opposed to glass 
coverslips. Transdifferentiation of MSCs towards a SC fate on the smooth substrates were found 
to have a variety of morphologies from flat, fibroblast to multipolar in nature as opposed to 
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mostly flat, fibroblast looking shape of undifferentiated control MSCs. The transdifferentiated 
cells also immunolabeled for SC-specific protein markers such as α-S100β and α-p75NTR. 
Micropatterned substrates did not affect transdifferentiation of cells in any way as compared to 
smooth substrates and tMSCs on patterned substrates were elongated, oriented along direction of 
microgrooves and expressed SC marker proteins. 
6.1. Transdifferentiation of MSCs 
Autologous nerve grafts are considered as gold standards for nerve regeneration. But because of 
various disadvantages associated with autografts such as donor site morbidity and limited length 
of graft tissue, researchers have refocused on neural regeneration conduits/scaffolds (NRCs). 
Along with NRCs, SCs have been the foremost choice for cellular transplantation at the site of 
nerve injuries. However, the only source of SCs is to sacrifice a healthy nerve (analogous to an 
autograft) and SCs do not seem to proliferate under cell culture environments [29, 30]. 
Researchers have started looking into alternative cell types that can replace SCs. A variety of cell 
types have been investigated as cellular replacements of SCs for nerve regeneration strategies 
such as olfactory ensheathing cells [31-34], neural stem cells [35-38] and MSCs derived from 
various sources (bone marrow [39, 40], adipose derived [39, 41], umbilical cord derived [42], 
dental pulp [43] etc.). Both bone marrow and adipose derived MSCs are of considerable interest 
since their potential to transdifferentiate into SC-like cells has been documented [5, 7, 8, 10, 13, 
16, 44]. In the present study, we have used bone marrow derived MSCs because, in a clinical 
setting, they can easily be isolated by performing a routine surgical procedure under general 
anesthesia. MSCs are multipotent cells capable of differentiating into multiple cell types such as 
adipocytes, osteoblasts and chondrocytes. MSCs grown in large numbers under cell culture 
conditions and then transdifferentiated into SC-like cells (tMSCs), can be used as a great 
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alternative source of SCs. These tMSCs were characterized and compared with undifferentiated 
MSCs (uMSCs) by immunostaining using glial markers such as α-S100β, α-p75NTR and α-
GFAP [13, 44, 45]. Ladak et.al.[31] and Zaminy et.al.[45] have reported the S100β and p75NTR 
expression in the tMSCs to be about 50% and 75% respectively. In our experiments, on 
polymeric substrates, we found that S100β expression was about 70-80% and p75NTR about 90-
95% in the transdifferentiated cells. Also, we did not see any expression of GFAP protein on 
tMSCs unlike some of the previous transdifferentiation studies. Possible reasons for this 
difference in percentages could be attributed to the fact that we used MSCs from a different 
rodent model (Brown Norway rat) and we performed transdifferentiation on biodegradable and 
biocompatible polymeric films unlike the previous studies conducted on glass coverslips. In the 
experiments where we transdifferentiated the cells on glass coverslips in parallel to polymeric 
films, the percentage of glial marker-stained cells was found to be lower on glass coverslips as 
compared to polymeric films (data not shown). One of the differences between the uMSCs and 
tMSCs is the change in the morphology of the cells. Transdifferentiated cells have been shown to 
express a bipolar, spindle shape [5, 7] while uMSCs showed a flat-fibroblast–like morphology. 
In our experiments, the tMSCs population was a heterogeneous one and consisted of multipolar, 
spindle as well as fibroblastic cells (on the smooth substrates) while uMSCs were found to be 
mostly flat-fibroblast like cells. Also, tMSCs were found to be proliferating more slowly than 
uMSCs. Different concentrations of FBS in transdifferentiation media (10%) and maintenance 
media (20%) may have produced the difference in proliferation rates. In order to ensure a similar 
number of cells at the end of experiment, we plated uMSCs (1000 cells/cm2) and tMSCs (3000 
cells/cm2) at different initial seeding densities. 
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6.2. Scaffolding and MSCs 
Controlling the behavior and morphology of the cells using biomaterial scaffolds has become an 
important area of research in the past 20 years for tissue regeneration purposes [46-48]. Both 
natural and synthetic biomaterials have been used for fabrication of these scaffolds. Here we 
have used two commonly used synthetic polymers – biocompatible polystyrene (PS) and 
biodegradable poly (lactic acid) (PLA) for fabrication of micropatterned films using solvent 
casting. Our group has previously produced patterned PS films combining novel patterning 
techniques via reactive ion etching and solvent casting to study the effect of physical guidance 
cues on alignment and differentiation of glial cells [20, 22, 23] and neural stem cells [25, 26]. 
These micropatterned films significantly enhanced the alignment of the cells in all the previous 
studies conducted using these polymeric films. We are able to achieve similar results while we 
grew bone marrow derived MSCs on these films. Both PS and PLA films supported the growth 
of MSCs on both smooth and patterned regions of the substrates. MSCs were successfully 
transdifferentiated on these films and no significant differences were observed by percentages of 
α-S100β and α-p75NTR immunostained tMSCs (>70%) between smooth and patterned 
substrates. Undifferentiated MSCs grown in parallel to tMSCs on these smooth and patterned 
substrates had a lower percentage of cells immunostained with the glial markers (<10%), 
showing that only transdifferentiation reagents were responsible for the transdifferentiation of 
the MSCs and patterning has no effect on transdifferentiation. Also no significant differences in 
the percentage of glial marker-immunolabeled cells between smooth and patterned substrates 
shows that patterning does not cause any deleterious effects on the differentiation potential of 
MSCs. Physical guidance provided by the microgrooves greatly increased the alignment of the 
cells in the direction of the patterns for both PS and PLA substrates. More than 80% of the 
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uMSCs as well as tMSCs were found to be aligned in the direction of the micropatterns (0o-20o) 
while the cells growing on smooth substrates were found to be randomly oriented. In order to 
quantify the morphological changes of uMSCs and tMSCs associated with micropatterns, we 
calculated the AR, a parameter which takes into account both the length (in direction of 
microgrooves) and breadth (in direction perpendicular to microgrooves) of the cells into account. 
Transdifferentiated MSCs and uMSCs growing on patterned PS and PLA substrates were found 
to have AR of about 5 showing that cells were highly elongated while growing on the patterned 
substrates. Both tMSCs and uMSCs had an AR of about 1 when they were grown on smooth 
polymeric films displaying that cells were, in general, circular in shape (same length and width) 
or they do not have inclination to elongate in one particular direction. Changes in AR of cells on 
patterned substrates were significantly different from the cells on smooth substrates at p≤0.05. 
Also when we compared the cellular areas of the tMSCs and uMSCs between the smooth and 
patterned substrate we found that cells growing on smooth substrates had a somewhat larger 
surface area than cells growing on patterned substrates but no significant differences were 
observed at p≤0.05. Differences in surface area of the cells may be due to the 3D nature of the 
patterned substrates, as the method we used for calculating the surface area gives us a 2D 
projection of the surface area and does not take into account the surface area of the part of the 
cells growing along the vertical walls of the grooves. In order to compare the biodegradable 
nature of the two polymers, we found that mesas of the micropatterns of PLA substrate were 
considerably degraded and was difficult to visualize under differential interface contrast (DIC) 
microscopy as compared to the mesas of the PS substrates which were visualized easily by DIC 
imaging. A somewhat higher number of cells immunolabeled with glial markers (S100β and 
p75NTR) on PLA substrate as compared to PS substrate points towards a possible effect of 
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degrading PLA on the differentiation of MSCs. Degradation of the mesas of PLA films was 
found to have no effect on alignment and elongation of both uMSCs and tMSCs as compared to 
the PS substrate. Thus, our results have shown that these patterned films can be used as a means 
to control the alignment and morphology of the cells without causing any negative effect on their 
differentiation potential.  
Our research group has previously shown that nerve regeneration conduits produced using these 
biodegradable patterned films after seeding with SCs significantly improves the sciatic nerve 
regeneration in a rodent model of peripheral nerve injury [21]. Our future studies will include use 
of these films and transdifferentiated MSCs to test the synergistic potential of physical and 
biological cues on peripheral nerve repair in a rodent model. 
7. Conclusions 
Microfabrication techniques developed in our lab were successfully used for production of 
patterned PS and PLA films. Both polymers supported the growth of MSCs. Transdifferentiation 
of MSCs was carried out on these polymeric films and was characterized by 
immunocytochemical labeling of various glial protein (α-S100β and α-p75NTR) markers. MSCs 
undergoing the transdifferentiation protocol were found to have much higher percentage of glial 
protein immunostained cells as compared to undifferentiated MSCs. No significant differences 
were observed in the percentage of S100β and p75NTR-immunolabeled cells across the smooth 
and patterned PS and PLA substrates. Significantly higher AR of the cells on the patterned 
substrate implies that cells change their morphology because of the physical barrier and 
elongated in the direction of micropatterns. Not only do they elongate, but they also align 
themselves in the direction of micropatterns as compared to randomly oriented cells growing on 
smooth substrates. Cellular area of the cells growing on smooth substrates was found to be 
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higher than patterned substrates. However, no significant differences observed between smooth 
and patterned substrates with respect to transdifferentiation points towards no exceptional 
changes in the growth of the cells in terms of cellular area on patterned versus smooth substrates. 
Our results show that, micropatterning can be used as an effective tool for controlling the 
alignment and morphology of the MSCs without causing any deleterious effect on their growth 
and differentiation potential into SC-like phenotypes. 
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9. Supplemental material 
 
 
Supplemental Figure 1. Transdifferentiated MSCs (tMSCs) on micropatterned PLA and PS films 
have a higher percentage of cells labeling with anti-p75NTR antibody than uMSCs. A nuclear 
staining of p75NTR was observed for uMSCs which was completely different as compared to 
strong cytoplasmic staining of tMSCs. A, A’ and A’’ represents the corresponding anti-p75NTR, 
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actin filaments (phalloidin) staining and merged image of tMSCs on patterned PLA substrate. B, 
B’ and B’’ represents the corresponding anti-p75NTR, actin filaments (phalloidin) staining and 
merged image of uMSCs on patterned PLA substrate. C, C’ and C’’ represents the corresponding 
anti-p75NTR, actin filaments (phalloidin) staining and merged image of tMSCs on patterned PS 
substrate. D, D’ and D’’ represents the corresponding anti-p75NTR, actin filaments (phalloidin) 
staining and merged image of uMSCs on patterned PS substrate. Abbreviations: uMSCs, 
undifferentiated mesenchymal stem cells; tMSCs, transdifferentiated mesenchymal stem cells; 
p75NTR, anti-p75NTR antibody; PLA, poly(lactic acid); PS, polystyrene; Merged, merged 
image of S100β, Alexa-488 Phalloidin, DAPI and DIC (Differential interference contrast). Scale 
bar = 100µm 
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Supplemental Figure 2. Transdifferentiated MSCs (tMSCs) on non-patterned (Smooth) PLA and 
PS films have a higher percentage of cells labeled with anti-p75NTR antibody than uMSCs. A 
nuclear staining of p75NTR was observed for uMSCs which was completely different as 
compared to strong cytoplasmic staining of tMSCs. A, A’ and A’’ represents the corresponding 
anti-p75NTR, actin filaments (phalloidin) staining and merged image of tMSCs on smooth PLA 
substrate. B, B’ and B’’ represents the corresponding anti-p75NTR, actin filaments (phalloidin) 
staining and merged image of uMSCs on smooth PLA substrate. C, C’ and C’’ represents the 
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corresponding anti-p75NTR, actin filaments (phalloidin) staining and merged image of tMSCs 
on smooth PS substrate. D, D’ and D’’ represents the corresponding anti-p75NTR, actin 
filaments (phalloidin) staining and merged image of uMSCs on smooth PS substrate. 
Abbreviations: uMSC, undifferentiated mesenchymal stem cells; tMSC, transdifferentiated 
mesenchymal stem cells; p75NTR, anti-p75NTR antibody; PLA, poly(lactic acid); PS, 
polystyrene; Merged, merged image of S100β, Alexa-488 Phalloidin, DAPI and DIC 
(Differential interference contrast). Scale bar = 100µm 
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Supplemental Figure 3. BrdU immunolabeling for uMSCs grown on PS and PLA smooth and 
patterned polymeric substrates. A, A’ and A’’ represents the corresponding anti-BrdU, nuclear 
(DAPI) staining and merged image of uMSCs on patterned PLA substrate. B, B’ and B’’ 
represents the corresponding anti-BrdU, nuclear (DAPI) staining and merged image of uMSCs 
on smooth PLA substrate. C, C’ and C’’ represents the corresponding anti-BrdU, nuclear (DAPI) 
staining and merged image of tMSCs on patterned PS substrate. D, D’ and D’’ represents the 
corresponding anti-BrdU, nuclear (DAPI) staining and merged image of uMSCs on smooth PS 
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substrate. PLA, poly (lactic acid); PS, polystyrene; Pattern, patterned substrate; Smooth, non-
patterned substrate, BrdU, anti-BrdU antibody; Merged, merged image of BrdU, DAPI and DIC 
(Differential interference contrast). Scale bar = 100µm 
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CHAPTER 4: HIGH THROUGHPUT CHARACTERIZATION OF ADULT STEM 
CELLS ENGINEERED FOR DELIVERY OF THERAPEUTIC FACTORS FOR 
NEUROPROTECTIVE STRATEGIES 
Adapted from manuscript:  
Sharma AD, Brodskiy PA, Petersen EM, Dagdeviren M, Ye EA, Mallapragada SK, et al. High 
throughput characterization of adult stem cells engineered for delivery of therapeutic factors for 
neuroprotective strategies. Journal of visualized experiments: JoVE. 2015(95):e52242. Epub 
2015/01/16. Hyperlink for the video. 
 
1. Keywords 
Mesenchymal stem cells, high throughput screening, genetic modification, cell tracking, 
neurotrophic factors, high content screening, HCS, neuroprotection 
2. Short abstract 
This study describes an experimental platform to rapidly characterize engineered stem cells and 
their behaviors before their application in long-term in vivo transplant studies for nervous system 
rescue and repair. 
 
 
3. Long abstract 
Mesenchymal stem cells (MSCs) derived from bone marrow are a powerful cellular resource and 
have been used in numerous studies as potential candidates to develop strategies for treating a 
variety of diseases. The purpose of this study was to develop and characterize MSCs as cellular 
vehicles engineered for delivery of therapeutic factors as part of a neuroprotective strategy for 
rescuing the damaged or diseased nervous system. In this study we used mouse MSCs that were 
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genetically modified using lentiviral vectors, which encoded brain-derived neurotrophic factor 
(BDNF) or glial cell-derived neurotrophic factor (GDNF), together with green fluorescent 
protein (GFP).  
Before proceeding with in vivo transplant studies it was important to characterize the engineered 
cells to determine whether or not the genetic modification altered aspects of normal cell 
behavior. Different culture substrates were examined for their ability to support cell adhesion, 
proliferation, survival, and cell migration of the four subpopulations of engineered MSCs. High 
content screening (HCS) was conducted and image analysis performed.  
Substrates examined included: poly-L-lysine, fibronectin, collagen type I, laminin, entactin-
collagen IV-laminin (ECL). Ki67 immunolabeling was used to investigate cell proliferation and 
Propidium Iodide staining was used to investigate cell viability.  Time-lapse imaging was 
conducted using a transmitted light/environmental chamber system on the high content screening 
system. 
Our results demonstrated that the different subpopulations of the genetically modified MSCs 
displayed similar behaviors that were in general comparable to that of the original, non-modified 
MSCs. The influence of different culture substrates on cell growth and cell migration was not 
dramatically different between groups comparing the different MSC subtypes, as well as culture 
substrates.  
This study provides an experimental strategy to rapidly characterize engineered stem cells and 
their behaviors before their application in long-term in vivo transplant studies for nervous system 
rescue and repair.  
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4. Introduction 
A major issue with implementing useful therapies for treatment of nervous system disorders is in 
developing effective methods that prevent further degeneration and also facilitate recovery of 
function. An innovative strategy is to genetically engineer stem cells ex vivo, for production of 
neuroprotective factors, prior to their transplantation. This combination of cell-based therapy, 
coupled with a type of gene therapy, provides a powerful method for the treatment of disease or 
injury-induced neuronal death in the nervous system.  
Neurotrophic factors are essential for growth and survival of developing neurons as well as 
maintenance and plasticity of mature neurons. A number of studies have demonstrated 
significant roles of neurotrophic factors in promoting initial growth and differentiation of 
neurons in the central and peripheral nervous system (CNS and PNS) and they can also stimulate 
regeneration in vitro and in animal models of neural injury [1]. Brain-derived neurotrophic factor 
(BDNF) is highly expressed in the CNS and plays important roles in regulating neural 
development, synaptic plasticity and repair [2]. Glial cell line-derived neurotrophic factor 
(GDNF) promotes survival of many types of neurons including dopaminergic and motorneurons 
[3]. Thus, an important strategy for neural repair is to provide exogenous sources of neurotrophic 
factors to the injured or diseased regions of the nervous system.  
Multipotent bone marrow-derived mesenchymal stem cells (MSCs) hold great potential for 
delivery of therapeutic proteins to treat the damaged or diseased nervous system.  
Transplantation of MSCs has attracted considerable attention in efforts to develop patient 
compatible cell-based therapies since they have a number of advantages including, 1) relative 
ease of isolation and maintenance, 2) multipotential capacity, 3) little ethical concerns, 4) ability 
to survive and migrate following transplantation and 5) potential for autologous transplantation 
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[4, 5]. Promising results have been reported with use of naïve and genetically engineered MSCs 
in animal models for a number of different neurodegenerative conditions, including spinal cord 
injury [6, 7], stroke [8, 9], myelin deficiency [10], and retinal degeneration [11-13]. Coupling 
cell transplantation with delivery of neurotrophic factors from genetically engineered stem cells 
is a novel and important neural repair strategy.  
An essential step in developing cell-based therapeutic factor delivery systems is to determine the 
normal health of the engineered cells. As such, the principal purpose of this study was to 
evaluate general growth parameters of genetically engineered adult stem cells. An important 
approach to rapidly assess multiple cell parameters is to employ cellular image-based high-
through screening (HTS), often referred to as high content screening (HCS) procedures[14]. This 
technology allows automated image acquisition and analysis and this approach is particularly 
well suited for stem cell research applications. In this project we developed a profiling platform 
that allows for the rapid characterization and optimization of cell substrate preferences and 
cellular functions with genetically engineered adult stem cells employing a HCS system. 
5. Protocol 
5.1. Substrate Preparation for 96-well Plates 
1.1) Create a map of the 96-well plate outlining the different substrates and cell-types to be 
examined (Figure 1). 
1.2) Obtain the stock solutions of different substrates [poly-L-lysine, fibronectin, collagen type I, 
laminin, and entactin-collagen IV-laminin (ECL)], a 96-Well Multiwell Plate and prepare a work 
station in a sterile cell culture hood. 
1.3) Prepare individual substrates by diluting stock in sterile phosphate buffered saline (PBS) to 
a final concentration of 5 µg/ml. This concentration was previously determined based on a 
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substrate concentration-dependent assay for growth and proliferation of cells. Mix using a vortex 
before pouring into a sterile reservoir.  
1.4) Add 100 µl of substrate solution into each well according to the 96-well map (Figure 1) (a 
12- or 8-channel micropipette is convenient for micropipetting into a 96-well plate). Seal the lid 
to the 96-well plate using a strip of Parafilm and store overnight at 4 oC. 
 
5.2. Cell Plating and Time-lapse Imaging 
Mouse MSCs were isolated from the bone marrow of adult C57BL/6 mice and maintained as an 
adherent cell line. MSCs were infected using lentiviral vectors to engineer them to secrete brain-
derived neurotrophic factor (BDNF; human cDNA) and glial cell-derived neurotrophic factor 
(GDNF; human cDNA) using lentiviral vector’s encoding BDNF (LV-BDNF; CMV-BDNF-
IRES-GFP), GDNF (LV-GDNF; CMV-GDNF-IRES-GFP), and green fluorescent protein (GFP, 
LV-GFP; CMV-GFP). 
Note: Culture media for mouse mesenchymal stem cells (MSCs) is Iscove's Modified Dulbecco's 
Medium containing 10% hybridoma-qualified fetal bovine serum, 10% equine serum, 2 mM L-
glutamine, and 10,000 U/ml penicillin, 10 mg/mL streptomycin. The five different types of 
mouse MSCs (MSCs, GFP-MSCs, BDNF-GFP-MSCs, GDNF-GFP-MSCs and BDNF/GDNF-
GFP-MSCs) were plated at about 30% confluence in T75 cell culture flasks. 
 
5.2.1. Cell Plating 
5.2.1.1) On the following day, remove the substrate solutions by aspiration and rinse each well 
with approximately 200 µl of sterile PBS, twice. Add cell culture media (200 µl/well) to each 
well after the final PBS rinse. Place the 96-well plate into a cell culture incubator set at 37 °C 
and 5% CO2 for equilibration. 
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5.2.1.2) While the 96-well plate is equilibrating in the incubator, harvest the cells (MSCs in T75 
flasks should be approximately 70% confluent at time of harvesting/plating) by collecting the 
growth media (referred to as conditioned media) from the T75 flask and storing in a 15 ml 
conical tube under sterile conditions (this conditioned media will be used in step 2.1.4 below). 
5.2.1.3) Add 8 ml of sterile PBS to the flask and gently swirl and then pipette off the PBS and 
add 1 ml of 0.05% trypsin and 0.01% EDTA solution to detach the cells from the culture surface 
of the T75 flask. Monitor cell detachment by viewing the flask using an inverted microscope 
equipped with phase contrast optics. 
5.2.1.4) When the cells have detached, immediately add 8 ml of the conditioned media (collected 
in step 2.1.2) to the flask. Collect the cell suspension and transfer to a 15 ml conical centrifuge 
tube and centrifuge for 4 min at 450 x g to pellet the cells.  
5.2.1.5) Remove the supernatant and resuspend the cell pellet in 200 µl of fresh and warmed (37 
oC) cell culture media. 
5.2.1.6) Determine the number of cells in the cell suspension by performing a trypan blue viable 
cell count using a hemocytometer. Plate the cells at a density of approximately 300 cells/well 
into the appropriate wells of the 96-well plate. 
5.2.1.7) Repeat these steps for each population of cells. 
 
5.2.2. Time-lapse Imaging 
5.2.2.1) Once all of the MSCs have been plated, place the 96-well plate into an incubator for 2 hr 
to allow the MSCs to attach to the substrate. 
5.2.2.2) Start the HCS system and wait for 2 hr for the system to equilibrate. Set the 
environmental controller to 37 oC and connect a mixed gas cylinder containing 5% CO2 in air to 
the HCS system environmental chamber supplying a constant air source. 
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5.2.2.3) Remove the 96-well plate from the incubator following the 2 hr equilibration period and 
place directly into the cell growth chamber of the HCS system. Allow 30 min for equilibration to 
account for any heat-related expansion of the plate and then start the image acquisition and 
analysis software to configure the plate settings. 
5.2.2.4) Select the 20X objective for imaging. Select two wells per condition [i.e., GFP-MSCs on 
Fibronectin etc. (6 substrates X 5 MSC subtypes for a total of 30 conditions X 2 replicates = 60 
wells in total)] for setting up time-lapse imaging. Choose two sites for imaging within each well.  
5.2.2.5) Choose the correct light wavelengths for imaging. Note: Two different wavelengths 
(Phase contrast and GFP fluorescence) were selected for time-lapse imaging. 
5.2.2.6) Focus on the well bottom using laser autofocus and take test images for multiple sites 
and multiple wells to find an optimized focal plane. 
5.2.2.7) Once the focus has been established, begin capturing images every 5 minutes for 48 
hours for all 60 wells (120 sites). 
5.2.2.8) Feed the cells every 24 hr by removing the 96-well plate from the HCS system. Remove 
75 µl of media from each well and add 100 µl of fresh media to each well (equilibrate this fresh 
media at 37 oC and 5% CO2). 
5.2.2.9) At the end of the time-lapse experiment, remove the 96-well plate from the HCS system. 
Under sterile conditions, collect the conditioned media samples from each well and transfer these 
samples to another 96-well plate. These samples can be used for further analysis by performing 
ELISA for neurotrophic factors. 
5.2.2.10) Prepare the 96-well plate with cultured MSCs for additional assays such as Ki67 cell 
proliferation assay or Propidium iodide live/dead staining assay (see details below). 
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5.2.2.11) Perform time-lapse imaging analysis for cell migration/cell tracking as described in 
section 5 below. 
 
5.3. Ki67 Cell Proliferation and Propidium Iodide Live/Dead Assay 
5.3.1. Ki67 Cell Proliferation Assay (Immunocytochemistry) 
5.3.1.1) Rinse the cell cultures with 0.1 M phosphate (P04) buffer for one minute two times. Fix 
the culture with 4% paraformaldehyde (PFA) for 20 min at room temperature. Remove the PFA 
and rinse the wells with PBS for seven minutes three times.  
5.3.1.2) After the final rinse, add 100 µl of blocker solution (phosphate buffer saline, 5% normal 
donkey serum, 0.4% bovine albumin serum, and 0.2% triton X-100) to each well and incubate at 
room temperature for one hour. Prepare the primary antibody, rabbit anti-Ki67, by diluting in 
blocker solution at a working ratio of 1:200. 
5.3.1.3) Remove the blocker solution and apply 100 µl of the primary antibody solution to each 
well. Cover the 96-well plate and incubate the samples at 4 °C overnight. 
5.3.1.4) On the following day, remove the antibody solution and rinse with PBS for seven min, 
three times.  
5.3.1.5) Prepare the secondary antibody, donkey anti-rabbit Cy3 in blocking solution at a 
working ratio of 1:500. Add DAPI nuclear stain to the secondary antibody solution at a dilution 
of 1:100. After the removal of the last PBS rinse, apply 100 µL of the secondary antibody/DAPI 
solution to each well. Incubate at room temperature in the dark for 90 min.   
5.3.1.6) Remove the secondary antibody/DAPI solution and rinse each well with PBS for seven 
min three times. Cover the 96-well plate and store at 4 °C until imaging.  
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5.3.2. Propidium Iodide Live/Dead Assay 
Measure cell death by propidium iodide (PI) exclusion assay as described below.  
5.3.2.1) Prepare the propidium iodide stain solution at a concentration of 1.5 µM in culture 
media. 
5.3.2.2) Add 100 µl of 70% ethanol to one-well of the MSCs for two minutes with the intention 
of killing those cells. This well serves as a positive control for the PI stain. The majority of the 
MSCs will be PI-stained indicating cell death. Remove the ethanol solution. 
5.3.2.3) Add 100 µl of propidium iodide stain solution to each well and incubate for 20 min at 37 
°C in a 5% CO2 incubator. 
5.3.2.4) Rinse the cells with 0.1 M phosphate buffer for one min, two times. Fix the cells with 
4% PFA in 0.1 M P04 buffer for 20 min at room temperature. Remove the PFA and rinse with 
PBS three times for seven minutes.  
5.3.2.5) Incubate with DAPI solution (1:50) diluted in blocker solution for one hr at room 
temperature.  Rinse all wells with PBS three times for seven minutes.  
5.3.2.6) Remove the DAPI solution and rinse each well with PBS for seven minutes, three times. 
Cover the 96-well plate and store at 4 °C until imaging. 
5.4. Automated Imaging and Multiwavelength Scoring Analysis 
5.4.1) Load a 96-well plate (previously processed for Ki67 immunolabeling or propidium iodide-
stained) into the HCS system and allow the plate to equilibrate for 20 min.  
Open the HCS system image acquisition and analysis software.  
5.4.2) Choose the acquisition settings for the 10X objective using camera binning at 1 and a gain 
setting of 2. Find the Z-plane in which the cells reside by utilizing the Auto Exposure function 
and calculate the offset for each wavelength of interest. For this analysis, capture images for 
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DAPI (W1), Cy3 (W2), and FITC (W3). Choose the maximum intensity level at which the 
negative control wells show no signal for image acquisition. Confirm this setting is appropriate 
for the positive wells.  
5.4.3) Acquire plate. Capture images and store them in the image acquisition and analysis 
software’s database.  
5.4.4) Once images have been acquired, open image acquisition and analysis offline software and 
review plate data from the images acquired above.  
5.4.5) Select the Multi-wavelength scoring analysis. Configure the minimum and maximum 
intensities for each wavelength. Note: DAPI detection should mark the staining around each 
visible nucleus. Cy3 should detect the positive cells with Ki67 immunoreactivity (IR) and should 
not detect IR under the negative controls. For Cy3 Ki67 IR, the approximate minimum width 
was 7 µm, approximate maximum width was 30 µm, the intensity above the local background 
was 150 gray levels, and the minimum stained area was 50 µm2.  
5.4.6) Run analysis for all positions. Export the data to view in spreadsheet.  
5.5. Cell Tracking 
5.5.1) Open image acquisition and analysis program and click on “Review Plate Data [DB]…”, 
selecting the plate of interest.   
5.5.2) View the data as “Time vs. Well”. 
5.5.3) Choose one of the sites from the “Sites” section by left clicking on the desired selection. 
Select “Transmitted…” under the “Wavelengths:”.  Right click on the target well in the 96-well 
plate template and click on “Load Images”. 
5.5.4) Track the cells by clicking on the “Apps” and then “Track Objects”. 
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5.5.5) Use “Dynamic Data Exchange (DDE)” to choose the format to export the data, e.g., 
Microsoft Excel.  
5.5.6) Choose the tracking data to export, e.g., elapsed time, object number, distance, time 
interval, velocity, absolute angle, distance to origin, delta x and delta y.  
5.5.7) Tag each cell of interest with “Ctrl key + left click” on target cells. 
5.5.8) Track cells. If necessary, stop/change improper tracking of cells with the “Esc” key and 
then adjust the settings.  
5.5.9) After cell tracking is complete, save data with “Log Data”.  
6. Representative results 
MSC growth parameters were examined by culturing the different populations of MSCs on 
different substrates. The five different populations of MSC subtypes (MSCs, GFP-MSCs, 
BDNF-GFP-MSCs, GDNF-GFP-MSCs, and BDNF/GDNF-GFP-MSCs) were plated into 96-
well tissue culture plates pre-coated with the different substrates as illustrated in Figure 1. After 
four days of culturing, the plates were fixed and immunolabeled and/or stained with the 
appropriate reagents and then examined using the HCS system and analyses conducted with the 
image acquisition and analysis software program.  
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Figure 1: 96-Well plate template for experimental design. 
96-well plates were coated with various substrates and wells were seeded with engineered stem 
cells as shown in the template. As an example, only wells in rows B-F were used in this 
experiment. Rows A, G and H were left empty. Abbreviations – MSCs: mesenchymal stem cells; 
GFP-MSCs: green fluorescent protein-expressing MSCs; BDNF-GFP-MSCs: brain derived 
neurotrophic factor-GFP-expressing MSCs; GDNF-GFP-MSCs; Glial cell-derived neurotrophic 
factor-GFP-expressing MSCs; BDNF/GDNF-GFP-MSCs; BDNF and GDNF- GFP-expressing 
MSCs; ECL: Entactin-Collagen IV-Laminin). 
 
 
Anti-Ki67 immunolabeling, followed by DAPI counterstaining, was used to evaluate whether the 
different substrates influenced proliferation of the different populations of engineered MSCs 
(Figure 2A). Expression of the Ki67 antigen occurs preferentially during late G1, S, G2 and M 
phases of the cell cycle, and is not detected in cells in the resting phase (G0), and therefore is 
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useful as a cellular marker for proliferation [15]. 4',6-Diamidino-2-Phenylindole (DAPI), is a 
commonly used nuclear and chromosome counterstain that emits blue fluorescence upon binding 
to AT regions of DNA [16]. The total number of cells in a field can be determined by counting 
the number of DAPI stained nuclei. As illustrated in Figure 2B, although there was variation in 
the percentages of proliferating MSCs, all substrates nevertheless supported considerable cell 
proliferation for each of the MSC subtypes.  
 
 
Figure 2: Ki67 cell proliferation assay.  
(A) Merged, double-fluorescent image of Ki67 immunolabeling (red) and DAPI (blue) nuclear 
staining. Many of the MSCs were immunolabeled with the Ki67 antibody (red). Scale bar = 50 
µm. (B) Bar graph illustrating the percentages of Ki67 immunolabeled MSC subtypes grown on 
polystyrene (PS), poly-L-lysine (PLL), fibronectin, collagen type I, laminin, or entactin-collagen 
IV-laminin (ECL) substrates for 5 days in vitro (DIV). N = one experiment. Each bar represents 
averaged pooled data from 8 imaged sites from 2 wells for each condition.  
 
 
Propidium iodide (PI) staining was used to evaluate whether different substrates influenced cell 
survival (Figure 3). Propidium iodide is a commonly used red-fluorescent nuclear and 
chromosome counterstain. Propidium iodide is membrane impermeant and generally excluded 
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from viable cells, and thus is useful to detect dead cells in a population. The proportion of dead 
cells within a given condition can be determined when combined with a general nuclear label 
such as DAPI to identify all cells within a field. The percentage of PI-positive cells was low on 
all substrates examined (Figure 3). As a positive control for the PI reagent, a few wells 
containing MSCs were incubated in 70% ethanol, a condition known to kill most cells, resulting 
in a high percentage of PI-labeled cells as illustrated in Figure 3B and 3C (Ethanol treated 
positive control).  
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Figure 3. Propidium iodide cell death assay.  
(A) Merged, double fluorescent image for propidium iodide (red) and DAPI (blue) staining. 
Although the nuclei of all of the viable cells were stained with DAPI (blue), no propidium iodide 
staining was detected in the MSCs.  (B) Virtually all MSCs were stained with propidium iodide 
following exposure to 70% ethanol. Scale bars in A and B = 100 µm. (C) Bar graph illustrating 
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the percentages of propidium iodide (PI) stained MSC subtypes grown on polystyrene (PS), 
poly-L-lysine (PLL), fibronectin, collagen type I, laminin, or entactin-collagen IV-laminin (ECL) 
substrates for 5 days in vitro (DIV). Ethanol Control: This condition served as a positive control 
for the PI staining reagent. Most cells subjected to PI stain following ethanol treatment are dead 
and thus positively stained for the PI reagent. N = one experiment. Each bar represents averaged 
pooled data from 8 imaged sites from 2 wells for each condition.  
 
 
To investigate the possible influence of different substrates on the behavior of engineered MSCs, 
cell migration was analyzed using time-lapse digital microscopy and the transmitted 
light/environmental chamber system on the HCS system (see Supplemental Video 1). Multiple 
sites/well were time-lapse imaged and used to calculate cell migration rates for the different 
subpopulations of MSCs growing on the different substrates using the image acquisition and 
analysis software program. In general, as shown in Figure 4C, all subtypes of MSCs showed the 
fastest migration rate on the extracellular matrix-coated surfaces (Fibronectin, Collagen, Laminin 
and ECL) and the slowest on non-coated polystyrene surfaces.  
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Figure 4. Cell tracking and migration. 
MSCs tracked with image acquisition and analysis software. Overlayed images of transmitted 
light and fluorescence   images from (A) the start of time-lapse imaging and (B) at 29 hr later at 
the end of the time-lapse imaging session (see Supplemental Video 1). Cell migration tracks are 
indicated by the colored lines. Scale bar: 50 µm. (C) Bar graph illustrating the average migration 
rates (expressed as µm/hr) for MSC subtypes grown on polystyrene (PS), poly-L-lysine (PLL), 
fibronectin, collagen type I, laminin, or entactin-collagen IV-laminin (ECL) substrates for 2 days 
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in vitro (DIV). N = one experiment. Each bar represents the average of at least 10 imaged cells 
from 2 wells for each condition.  
 
 
Taken together, these results provide preliminary evidence that these subpopulations of 
genetically engineered MSCs display similar growth properties. These results provide 
compelling evidence that the lentiviral mediated genetic modifications of these MSCs induced no 
dramatic detectable deleterious effects on the growth parameters investigated using this 
screening platform.  
 
Supplemental Video 1. 
Time-lapse digital video of MSC tracking using the image acquisition and analysis software 
program. The migration paths for two MSCs [indicated as 1 (green tracking line) and 2 (Blue 
tracking line)] are illustrated. Video captured during a 29 hr period. Images were captured every 
5 min. Fluorescence images of GFP-expressing MSCs was used for time-lapse imaging in 
preparing the video. Calibration bar = 50 µm. This type of analysis is useful for investigating cell 
behaviors, including cell migration and cell division.  
 
Table 1: Materials and chemicals used during experiments 
Name of 
Material/ 
Equipment 
Company Catalog Number Comments/Description 
 
Greiner Bio One 655090 96 well plates 
Bovine serum 
albumin (BSA) 
Sigma-Aldrich (St. 
Louis, MO) 
A9647 
 
Rabbit anti-Ki67 
antibody 
Abcam (Cambridge, 
MA) 
Ab16667 1:200 dilution 
Collagen type I 
Sigma-Aldrich (St. 
Louis, MO) 
C7661 Collagen from rat tail 
DAPI 
Invitrogen 
(Carlsbad, CA) 
 
D3571 
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Table 1 continued 
 
   
Donkey anti-
Rabbit Cy3 
Jackson Immuno 
Res Lab (West 
Grove, PA) 
711-165-152 1:500 dilution 
ECL(Entactin-
Collagen-
Laminin) 
Millipore/Chemicon 
(Temecula, CA) 
08-110 
 
Fetal bovine 
serum (FBS) 
Hyclone (Logan, 
UT) 
SH30071.03 
 
Equine serum 
Hyclone (Logan, 
UT) 
SH3007403 
 
Ethanol 
Chemistry Store 
(Ames, IA) 
12003510 100%, 200 proof 
Fibronectin 
Fisher Scientific 
(Hampton, NH) 
CB-40008 
 
Iscove’s Modified 
Dulbeccos 
Medium (IMDM) 
Hyclone (Logan, 
UT) 
SH30396.03 
 
KH2PO4 
Fisher Scientific 
(Hampton, NH) 
P285 For PO4 buffer 
K2HPO4 
Fisher Scientific 
(Hampton, NH) 
P288 For PO4 buffer 
L-Glutamine 
Gibco/Invitrogen 
(Grand Island, NY) 
25030-081 
 
Laminin (mouse) 
Trevigen 
(Gaithersburg, MD) 
3400-010-01 
 
Mouse MSCs of 
adult C57BL/6 
mice 
Tulane Cent for 
Gene Therapy (New 
Orleans, LA) 
 
Isolated from bone 
marrow 
Genetically 
modified MSCs 
(GFP, BDNF, 
GDNF, 
BDNF/GDNF) 
These cells were 
obtained from our 
previous study: Ye 
et. al. (in 
preparation) 
  
Normal donkey 
serum (NDS) 
Jackson Immuno 
Res Lab (West 
Grove, PA) 
017-000-121 
 
Paraformaldehyde 
(PFA) 
Fisher Scientific 
(Hampton, NH) 
O4042 
4% PFA in 0.1M PO4 
buffer 
Penicillin-
Streptomycin 
Sigma-Aldrich (St. 
Louis, MO) 
P0781 
 
Phosphate 
buffered saline 
(PBS) 
Sigma-Aldrich (St. 
Louis, MO) 
P4417 
 
Poly-L-lysine Sigma-Aldrich P4707 
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Table 1 continued 
 
   
Propidium iodide 
(PI) 
Invitrogen 
(Carlsbad, CA) 
P1304MP 
 
Triton X-100 
Sigma-Aldrich (St. 
Louis, MO) 
X100 
 
Trypsin 0.05% 
(EDTA 1X) 
Invitrogen 
(Carlsbad, CA) 
25300-054 
 
 
 
 
 
7. Discussion 
Adult mesenchymal stem cells (MSCs) are an attractive cell type for development of an 
experimental strategy combining a cellular and gene delivery based therapy. MSCs are 
multipotent, capable of differentiating into cells of mesodermal lineage, and display considerable 
plasticity, differentiating/transdifferentiating into neuronal and glial lineages with the appropriate 
induction paradigms [17, 18]. Furthermore, MSCs have been transplanted and proven effective 
in preclinical studies for a number of disorders, including neurodegenerative conditions[19]. The 
therapeutic efficacy of MSCs is well known due to their beneficial anti-proliferative, anti-
inflammatory and anti-apoptotic activities[20]. MSCs are also known to produce and secrete 
various neurotrophic and growth factors, which likely contributes to the neuroprotective qualities 
associated with naïve MSCs following transplantation at sites of injury or disease[21]. 
Importantly, MSCs can be genetically modified for sustained delivery of neurotrophic factors for 
combined cellular and gene therapy-based applications and have been used in a number of 
animal models of injury or disease to the CNS[11, 19, 22].  
 
In developing a combined cellular and gene therapy-based strategy, it is important that the health 
of the cells is carefully assessed prior to their extensive use for in vitro, and especially in vivo 
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applications. As a proof of concept, we investigated multiple populations of engineered and 
control MSC lines in order to study the consequences of the genetic modifications on cell health 
and fitness using a high content screening (HCS) approach. In general, HCS refers to cellular 
image-based high throughput screening[14]. This screening approach permits a quantitative 
assessment of cellular phenotypes at multiple levels of spatial (cell to subcellular) and temporal 
(milliseconds to days) resolution across various experimental conditions. Using this approach we 
accessed possible differences in substrate preference on the following parameters: cell 
proliferation, expression of green fluorescent protein (GFP), cell death, and cell 
motility/migration. Experiments were designed in 96-well cell culture plate format. Within a 
single plate we routinely investigated possible substrate-related differences with respect to each 
parameter for the different MSC populations of lentiviral-transduced cells and compared the 
engineered MSCs with the original, non-transduced MSCs. This provided a means to directly 
compare the results for the different MSC subtypes with a battery of in vitro assays such as cell 
proliferation using Ki67 immunolabeling, live/dead cell viability assay using propidium iodide 
staining, and cell behavior by performing time-lapse digital imaging. As an extension of this 
HCS one can also perform ELISAs on conditioned media samples collected from individual 
wells to quantitatively determine secretion of neurotrophic factors. Conditioned media from 
different MSC subtypes may also be used in in vitro bioassays to determine biological activity of 
secreted factors [11, 23].  This type of HCS platform may also be used for in vitro measurements 
of neurite outgrowth from primary neuronal cultures and neural stem cell lines [24]. Overall, our 
results demonstrated that the subpopulations of the genetically modified MSCs displayed similar 
behaviors in comparison to the non-modified MSCs. The influence of diverse culture substrates 
on cell growth and cell migration was not dramatically different between the MSC subtypes, as 
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well as culture substrates. As such, the extracellular matrix substrates tested did not appear to 
play a critical role in modulating these aspects of cell behavior for these different engineered 
MSCs. 
This study demonstrates the use of an HCS system for analyzing different aspects of cell 
behavior. However, it is not uncommon to encounter limitations associated with image analysis. 
On occasion, while analyzing the fluorescence images, it was somewhat difficult to determine 
the correct threshold value above which immunolabeled or stained cells would be counted as 
positively labeled/stained. Thus, to minimize subjective bias, the determination of threshold 
values was dependent upon a comparison with controls (negative controls for fluorescence 
imaging were carried out in parallel during all processing by the omission of the primary or 
secondary antibodies). Another limitation was encountered during the analysis of cell migration 
using time- lapse digital imaging. In some cases, the imaging software was not able to 
differentiate between random Brownian motion of a cell versus a cell actually migrating only a 
very short distance. Additional limitations were evident in situations where the analysis software 
was not able to distinguish the presence of multiple cells in very close proximity to one-another. 
To overcome this limitation required manual cell selection during the analysis rather than a fully 
automated analysis. Cell plating density can also result in skewing cell migration data between 
populations of cells that display greater preference to grow in clumps versus cells that grow in 
isolation from each other. These types of differences are in part likely a reflection of cell-
substrate versus cell-cell preferences. 
Using an HCS system to acquire images and perform data analysis provides an efficient and 
rapid means to assess multiple cell parameters. In addition, time-lapse digital videos for 30 
different conditions (6 substrates and 5 different MSC subtypes) were routinely acquired for 
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periods ranging from hours to days (48 hr) while using the environmental chamber. This data 
was subsequently used to calculate and determine differences in cell migration rates across 
various cell lines on different ECM molecules.  
 
In this report we have highlighted the implementation of a high content screening platform to 
assess cell health and function. This type of analysis is useful for developing rational strategies 
for designing cell-types, as well as polymer substrates to facilitate directed cell growth and 
neural regeneration. This is an essential step towards application of stem cell-based delivery of 
therapeutic factors prior to extensive in vivo preclinical studies using cell transplantation 
strategies.  
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1. Abstract 
Peripheral nerve injuries with large nerve gap defects present a challenging problem facing the 
field of neuroregeneration. A potential solution is the design of multifunctional nerve 
regeneration conduits offering combinations of guidance and trophic cues with controlled release 
of growth factors to enable guided and accelerated nerve growth and regeneration. In this study, 
multifunctional poly(lactic acid) (PLLA) porous films were designed and fabricated with 
longitudinal micropatterns, which could then be rolled into conduits with the patterns in the inner 
lumen. These films also sported a surface gradient of nerve growth factor (NGF), along with 
NGF-releasing, surface-eroding, biodegradable, and amphiphilic polyanhydride microparticles 
distributed into the film matrix, to address this challenging issue. PLLA films with micropatterns 
and a porous structure containing NGF encapsulated polyanhydride microparticles were 
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successfully obtained by dry phase inversion techniques. XPS analysis indicated the formation of 
a successful β-NGF surface gradient, enabling directional neurite outgrowth. The use of 
polyanhydride microparticles with different chemistries distributed throughout the scaffold 
matrix provided long-term controlled release profiles of NGF, while the surface attachment of 
NGF provided an initial burst release at the film surface. The experimental release kinetics 
profiles showed good fit with the theoretical mathematical models to yield estimates of diffusion 
coefficients. The diffusion coefficients for NGF transport through the conduit matrix varied 
between 6x10-14 and 7.5x10-10 cm2/min while diffusion coefficients for NGF transport at the 
surface varied between 1.21x10-4 and 1.11x10-3 cm2/min. These multifunctional films 
successfully provided tunable release of bioactive NGF that promoted guided neurite extension 
from PC12 cells. 
 
2. Keywords 
Nerve regeneration conduits, poly (lactic acid) (PLA), nerve growth factor (NGF), surface 
gradient, micropatterning, polyanhydride nanoparticles and microparticles, controlled release 
 
3. Introduction  
Severe damage to the peripheral nervous system (PNS) may cause malfunction of sensory and/or 
motor properties, leading to poor recovery of function and subsequent impaired quality of life for 
patients [1]. The PNS has the capacity for spontaneous nerve regeneration; however, it may not 
be successful in bridging peripheral nerve gaps larger than 10 mm.  The use of bioengineered 
artificial nerve conduits based on synthetic biodegradable functional polymeric biomaterials has 
been proposed as a promising strategy for the regeneration of damaged nerves, circumventing the 
125 
 
 
limitations of autologous nerve grafting such as biological complexity, donor site availability, 
morbidity and requirement of multiple surgeries [1-8].  
 
An ideal conduit should possess many features such as biodegradability, biocompatibility, 
mechanical properties, functional surface chemistry, and growth factor bearing capabilities [9-
12] to overcome the current limitations in enabling peripheral nerve regeneration [5, 6, 13]. In 
order to further improve the conduit properties and enhance nerve regeneration, researchers have 
developed porous matrices to provide vascularization [14, 15], enable high permeability of 
nutrients/oxygen [14, 16, 17], fast drainage of nerve wound exudates, [18, 19] or neural cell 
alignment [20, 21]. In addition to these, our work has demonstrated the importance of surface 
nano/micropatterning the inner lumen to provide topographic guidance cues and alignment to 
create regenerative platforms for cells [22-33]. It has also been shown that the presence of 
neurotrophic factors within the conduit structure promotes neurite extension and growth of axons 
[34-36]. Among many neurotrophic factors, NGF has been found to promote the growth and 
survival of axons and protect neurons from injury-induced death in lesioned sciatic nerves [37]. 
However, considering short half-life, spatial distribution and the long duration required for 
regeneration of large gaps, strategies for sustained/controlled NGF release are needed in conduits 
[4].  
 
Various loading and controlled release strategies exist for neurotrophic factors based on 
functional biodegradable synthetic polymeric biomaterials, including biodegradable micro/nano 
particles and nerve regeneration conduits [37-50]. Recently, the combined release and synergistic 
activity of multiple growth factors on axonal regeneration has also been applied as a strategy 
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[34-36]. Most of these studies used degradable polyesters as particles or conduits, such as 
poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) due to their low toxicity and 
rapid degradation into metabolites [51]. However, these polymers undergo bulk erosion [52, 53] 
causing burst and rapid drug release [54-56]. Although the erosion rate and, hence, the drug 
release can be controlled by backbone chemistry [54, 56], molecular weight [55, 56] and 
hydrophobic surface coatings [57], this brings about extra challenges in the preparation steps and 
leads to loss of growth factor activity and stability. Besides, none of these strategies considered 
the effect of directional guidance and distribution of multiple growth factors in a concentration 
gradient pattern enhancing the guidance of growth cones to their target tissues [58-63]. There are 
very few studies focusing on creating neurotropic factor concentration gradients on the conduit 
surface. Although these conduits possess porous structure and surface concentration gradients, 
they lacked surface nano/micropatterns facilitating the guidance and alignment [4, 64]. 
Furthermore, a significant drawback with these studies was that the concentration of growth 
factor loading was limited by the surface area and the conjugation/attachment efficiency. More 
importantly, the loading of the growth factors during conduit fabrication can lead to loss of 
control over conduit properties, including controlled release of growth factors, and potential 
denaturation and activity loss of the growth factors. As an alternative, the incorporation of 
micro/nanoparticles within a polymer scaffold matrix has been employed as a strategy allowing 
more controlled sustained release [65-68]. Despite efficient control over the release rates, these 
systems suffer from the lack of alignment and directed growth properties. Overall, the 
approaches mentioned above target only one or two specific challenges in nerve regeneration at a 
time. However, the development of an ideal conduit system for effective nerve regeneration 
requires a multifunctional combinatorial approach addressing several critical issues at once. To 
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the best of our knowledge, there is no other study combining all of the mentioned individual 
properties above into one single conduit.    
 
Considering this motive, in this study, the combination of several of these guidance and trophic 
cues that aid nerve regeneration have been incorporated into one single conduit to provide 
effective controlled release of growth factors and stimulate cellular attachment guided nerve 
growth. For this purpose, β-NGF surface gradients were created on PLLA conduit surfaces with 
longitudinal micropatterns to provide initial burst β-NGF release and guided nerve growth while 
β-NGF encapsulated polyanhydride (PA) microparticles were incorporated into the 
biodegradable PLLA porous conduit matrix to provide sustained β-NGF release. This approach 
was also aimed at increasing the growth factor loading and furthermore, may also be used as a 
combined release strategy. PLLA was selected as conduit material due to low toxicity, 
controllable degradation and functional end groups allowing surface β-NGF modification [51, 
54-56]. In contrast to other studies achieving porous structures mostly with the use of pore 
forming agents, in our work, the porous structure of the conduit was created through dry-phase 
inversion techniques, allowing not only β-NGF loaded microparticle distribution inside of the 
matrix but also efficient β-NGF surface concentration gradient modification leading to higher β-
NGF loadings. Moreover, in this study, we focused on using biocompatible and biodegradable 
polyanhydrides for fabrication of β-NGF loaded nano/microparticles due to their advantages of 
providing β-NGF stability, surface erosion to better control sustained release over their polyester 
counterparts, and less acidic degradation by products. Polyanhydride copolymers were used to 
fabricate micro/nanoparticles for controlled release of β-NGF to stimulate the growing axons 
either alone or in combination with PLLA film matrix for the first time. In vitro β-NGF release 
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profiles and neurite extension and outgrowth against PC12 cells were evaluated to gauge the 
efficacy of these multifunctional conduits.   
4. Materials and Methods 
4.1. Materials 
Poly-L-lactide (L-PL-ester terminated B6002-2) was obtained from Lactel Absorbable Polymers. 
Beta-nerve growth factor (β-NGF, 556-NG/CF) was provided from R&D Systems. Ovalbumin 
(OVA) was purchased from Invivogen. Methylene chloride and pentane were supplied from 
Fisher Scientific. β-NGF ELISA kit (ab100757) and OVA ELISA kit (EKU06441) was ordered 
from Abcam and Biomatik, respectively. RPMI-1640 cell culture media and supplies, fetal 
bovine serum (FBS) and heat inactivated horse serum (HS), and phosphate-buffered saline (PBS) 
were obtained from Invitrogen. Bovine serum albumin (BSA), paraformaldehyde (PFA) and 
triton-x100 were obtained from Fisher Scientific. Cultrex® Mouse Laminin I was purchased 
from Trevigen. Anti-βIII tubulin antibody conjugated with Cy3 (AB15708C3) was obtained 
from EMD Millipore while DAPI (4′,6-diamidino-2-phenylindole) dye was ordered from 
Invitrogen. All the other required buffers were prepared by using ultrapure water according to 
standard laboratory procedures. 
4.2. Synthesis of copolymers and fabrication of bare and β-NGF loaded nano/microparticles 
Random copolymers of CPH:SA and CPTEG:CPH (1, 6-bis (p-carboxyphenoxy) hexane (CPH), 
1, 8-bis (p-carboxyphenoxy)-3, 6-dioxaoctane (CPTEG) and sebacic acid (SA)) were synthesized 
from the corresponding monomers with different copolymer ratios via a melt polycondensation 
reaction as described previously [69, 70]. Nuclear magnetic resonance spectroscopy (NMR) was 
used for resolving the structure and determining the molecular weight of the copolymer. Bare 
polymeric nanoparticles were fabricated by Solid/Oil/Oil (S/O/O) emulsion method, where 
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copolymers (200 mg) were first dissolved in methylene chloride (20 mL) and then rapidly nano-
precipitated in anti-solvent pentane to obtain the nanoparticles. In order to obtain β-NGF 
encapsulated nanoparticles, polymer (200 mg) was dissolved in methylene chloride (20 mL) and 
different amounts of β-NGF were added. Then, the β-NGF-polymer mixture was precipitated in 
anti-solvent pentane.  The amount of β-NGF used for encapsulation was 0.1% of the polymer 
weight used for fabrication of nanoparticles. In addition, polymeric microparticles were also 
fabricated using a benchtop spray-dryer (Buechi, Switzerland) to increase the β-NGF 
encapsulation efficiency. The polymer-protein solution was fed to the spray-dryer through a 
nozzle with argon as the feed gas at the feed temperature of 24ºC, vacuum of -50bar. The 
particles formed were collected using a high efficiency cyclone. As a bigger batch is required for 
production of nanoparticles via spray drying, 0.05% loading was tested as opposed to 0.1% 
loading for S/O/O method. Scanning electron microscopy (SEM, Quant FEG 250) imaging was 
performed to determine the dimensions and structure of nanoparticles obtained.  
 
4.3. β-NGF release from nano/microparticles 
β-NGF loaded nano/microparticles (5 mg) and  200 µL PBS, supplemented with 0.5wt%  BSA as 
stabilizer, were placed in an Eppendorf tube and incubated at 37ºC with continuous shaking. 
Samples were collected on day 3, 6, 10, 14, 21, 28, 42, and 56. During the sample collection, the 
particles in the tube were precipitated via centrifugation (10 mins at 15000 rpm) and all 200 µL 
of the sample supernatant was collected and subsequently fresh 200 µL of 0.5w% BSA-PBS was 
added to the precipitated particles. The tube was vortexed and placed back to the incubator. The 
concentration of released β-NGF collected in the sample supernatant was analyzed using a β-
NGF ELISA kit following the manufacturer’s procedure. Multiple ELISAs were performed to 
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optimize the dilution of the samples to bring the absorbance reading in the range of the ELISA 
kit.   
 
4.4. Preparation and characterization of β-NGF/microparticle incorporated, porous and surface 
micro-patterned PLLA films  
In this study, dry phase inversion technique was used to prepare β-NGF/microparticle-
incorporated, porous and surface micro-patterned PLLA conduits. For this purpose, PLLA (1g) 
was dissolved in chloroform (10 mL) to create a 10 wt% polymer solution. At the same time, β-
NGF-encapsulated polyanhydride particles (20 mg) were dispersed in 400 µL pentane (volatile 
non-solvent), which was used as a precipitator in the S/O/O technique, to provide a protective 
layer around loaded particles preventing their dissolution in chloroform and allowing their 
distribution in the PLLA film matrix. Then, 1 mL of 10 wt% PLLA solution was added on top of 
particles in pentane and shortly vortexed. This 1.4 mL casting solution was poured on a silicon 
wafer with longitudinal micro-patterns (4x4 cm2 area) and spin for 10 min in a spin coater. Then 
the films were left to dry at room temperature for 6 h. During drying, the different evaporation 
rates of pentane (non-solvent) and chloroform (solvent) resulted in phase separation, and 
consequently, when the solvent and non-solvent were completely removed from the film, porous 
structure were obtained. The particles were also found to be uniformly distributed throughout the 
film. At the end of drying, the films were peeled off the wafer surface and rolled by using a 
carbon rod with diameter of 2 mm in such a way that the patterned surface remained in the inner 
lumen along the conduit. The structure of the films was characterized by SEM.  
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4.5. Formation of β-NGF concentration gradient on the film surface 
For the formation of β-NGF concentration gradient on the film surface, the method described 
elsewhere was applied with modifications [4]. The PLLA films prepared as described above with 
dimensions of 1x3 cm2 were placed upright in a tube as shown in Supplementary Information, 
Figure S.1. The β-NGF solution (10 µg/mL) was pumped into the tube at a velocity of 5 µL/min 
using a syringe pump in a cold room (at 4ºC). With this approach, differential β-NGF exposure 
along the length of the films parallel with the walls of the tube was obtained. This differential β-
NGF exposure created concentration gradients along the length of the film and also the surface 
micro-patterns (Supplementary Information, Figure S.1.). It was anticipated that the β-NGF 
molecules were attached to the film surface through the interaction between the ester ends of 
PLLA and amine groups of β-NGF [71]. Addition of β-NGF solution was stopped at the end of 
6h. The membranes were stored at 4ºC and rinsed with sterile PBS three times before use. The 
presence of a β-NGF concentration gradient on the film surface was determined by X-ray 
photoelectron spectroscopy (XPS) by checking for the presence of primary amine (–NH2) groups 
on the surface. Analyses were performed on the film surface starting from section-1 to section-3 
by taking at least 3 random measurements in each section (Supplementary Information, Figure 
S.1.). Throughout the analysis a monochromatic Al KX-ray source (1486.6 eV) with an Omni 
Focus III small area lens and multichannel detector was used.  Measurements were taken at an 
electron take-off angle 45º from a normal sampling surface depth of ∼50 Å.  Survey scans were 
collected from 10 eV to 1100 eV with a pass energy of 187.85 eV. All spectra were referenced 
by setting the C 1s peak to 285.0 eV to compensate for residual charging effects. 
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4.6. β-NGF and OVA release kinetics from PLLA films 
Throughout the release experiments, polyanhydride particles loaded with different amounts of 
model protein OVA (1, 3 and 5%) to distinguish between the protein released from the conduit 
surface and from the microparticles, were prepared by spray drying method. For the release 
kinetics experiments, PLLA films (1x3 cm2), containing OVA encapsulated particles in the film 
matrix and coupled with the β-NGF concentration gradient on the film surface, were cut into 3 
sections (1x1 cm2 each section) representing the higher, middle and lower β-NGF concentration 
gradient (Supplementary Information, Figure S.1.). Then, the sections were placed in 1 mL PBS 
buffer at pH 7.4 and 37 ºC. The simultaneous release of OVA from the PLLA film matrix and β-
NGF from the film surface were observed. The release samples were collected at predetermined 
times and stored at -20 ºC till the day of analysis. The released amounts of OVA and β-NGF 
were detected using respective ELISA kits following the manufacturer’s procedure. 
4.7. Determination of transport properties of PLLA films  
Following the experimental data obtained through the release kinetics tests, the diffusion 
coefficient of OVA, released from the microparticles distributed in PLLA matrix, and dissolution 
constant of β-NGF, released from the PLLA film surface, were calculated using related 
mathematical models. The release rate of OVA was assumed to be controlled only by its 
diffusion through the microparticles distributed in PLLA film matrix, where Fick’s second law 
was used as the main transport equation to describe the change in the concentration of OVA in 
the film with respect to time and position. It was assumed that there was no chemical reaction 
between OVA and the film, the mass transfer is by diffusion only, the diffusivity of OVA is 
constant, and the thickness of the film does not change due to desorption of OVA. According to 
a solution of Fick’s second law with one initial and two boundary conditions applied[72], the 
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total amount of active compound desorbed from the film at any time t, due to Fickian diffusion, 
Mt is given by the following expression. 
   (1) 
where M∞ is the amount of protein desorbed at equilibrium, and the qn’s are the non-zero 
positive roots of   
       (2) 
 
The partition coefficient, K, used in the definition of α was defined as the ratio of OVA 
concentration in the film to that in the solution at equilibrium and it was calculated from the 
difference in the equilibrium and the initial concentrations of OVA measured in the solution, 
assuming that OVA does not degrade during the test. 
Eq. (1) clearly indicates that in cases where the release is controlled only by Fickian diffusion, 
the diffusivity of OVA in the film is the main transport parameter and it was determined by 
minimizing the difference between the experimental data and the model predictions from Eq. (1). 
β-NGF directly released from the film surface is based on the dissolution as described in the 
following equation.   
     (3) 
MDissolution represent the released β-NGF amount at time, t, and M∞ is the amount of β-NGF 
released at equilibrium. ‘k’ is the dissolution constant.  
4.8. Cell Culture of PC12 cells 
PC12 cells (CRL-1721, ATCC), which are known to extend their neurites in the presence of β-
NGF, were grown in complete cell culture media contained 85% RPMI-1640 Medium (30-2001, 
ATCC) supplemented with 10% (v/v) heat-inactivated horse serum and 5% (v/v)  fetal bovine 
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serum at 37°C under a humidified atmosphere containing 5% CO2. Cells were subcultured 
approximately every 2–3 days. 
4.9. Bioactivity of β-NGF encapsulated microparticles on PC12 cells 
Neurite extension assay of PC12 cells to assess the bioactivity of β-NGF released from 50:50 
CPTEG:CPH microparticles were performed. Previously these microparticles were found to be 
nontoxic at a concentration of 125 µg/mL[73, 74]. Therefore, the bioactivity of released β-NGF 
were detected using the same non-cytotoxic concentration (125 µg/mL). Before the experiment, 
the 6 well plates were coated with mouse laminin (10 μg/cm2) and incubated at 37°C overnight 
to facilitate the attachment of PC12 cells. PC12 cells were then plated into the bottom of each 
well of the 6-well culture plates at a cell density of 2x105 cells per well in 3 mL of complete cell 
culture media. The β-NGF encapsulated particles were then placed onto the membranes of 
transwell permeable support (BD Falcon) to perform a non-contact coculture assay. β-NGF at a 
concentration of 100 ng/mL was used as positive control while bare microparticles (without β-
NGF encapsulated) and PC12 cells were used as negative control. After 2 days of incubation at 
37°C under a humidified atmosphere containing 5% CO2, cells were immunostained with anti-
βIII tubulin antibody conjugated with Cy3 and DAPI to visualize neurite extension and nuclei of 
PC12 cells, respectively. Imaging of the cells was conducted using an ImageXpress Micro high 
content imaging system (Molecular Devices) and length of neurites for various conditions was 
quantified using a neurite outgrowth module of MetaXpress software (Molecular Devices).  
4.10. Assessment of Bioactivity of β-NGF released from PLLA films using PC12 cells 
The bioactivity of the released β-NGF from the PLLA films was assessed using PC12 cells. For 
this purpose, the PLLA films, incorporated with 0.5% β-NGF encapsulated 50:50 CPTEG:CPH 
microparticles and possessing surface β-NGF gradient were prepared, sterilized and sectioned 
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before the experiment. The 6 well plates were coated with mouse laminin (10 μg/cm2) and 
incubated at 37°C overnight to facilitate the attachment of PC12 cells. PC12 cells with a cell 
density of 2x105 cells per well were plated at the bottom of a six well plate in 3 mL complete cell 
culture media while the sectioned PLLA films were placed on top of transwell permeable 
support. Following 2 days of incubation at 37°C under a humidified atmosphere containing 5% 
CO2, the cells were immunostained and imaged as described above. 
4.11. Neurite alignment of PC12 cells on β-NGF gradients and micropatterned PLLA films 
PLLA films (1x3 cm2), incorporated with 0.5% β-NGF encapsulated 50:50 CPTEG:CPH 
microparticles and possessing surface β-NGF gradient were prepared, glued on a glass coverslip 
(micropatterned surface is upward) and sterilized. Then, the micropatterned films were placed 
into a 6 well plate, coated with mouse laminin (10 μg/cm2) and incubated at 37°C for 6 h to 
facilitate the attachment of PC12 cells. PC12 cells (1x104 cell/cm2) were seeded on section-1 
(Supplementary Information, Figure S.1.), which contains the least β-NGF surface concentration, 
to observe both the effect of micropatterning and surface gradient on neurite alignment and 
extension. For this purpose, the cell suspension with a cell density of 1x104 was placed on 
section-1 with a small volume (~100 µL) and incubated for 2 h in order to let PC12 cells become 
attached to the film surface. Then, the well was filled with 2 mL of complete cell culture media. 
Following 2 days of incubation at 37°C under a humidified atmosphere containing 5% CO2, the 
cells on the films were immunostained and imaged as described above.    
4.12. Statistical Analysis  
Throughout this study, significant differences between groups were evaluated using ANOVA 
analysis by Tukey’s method with 95% confidence interval. The results are presented as average 
± standard deviation calculated from at least three independent experiments. 
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5. Results and Discussion 
5.1. Characterization of polymers, particles and films 
5.1.1. Polymer and Particle characterization 
The NMR characterization shown in Supplementary Information Figure S.2 indicated that 
polymer molecular weight, structure, and composition were as intended and in agreement with 
previous studies [75-77]. Structure and size of the particles were assessed by SEM analysis. 
Nanoparticles and microparticles obtained were found to be of spherical shape and polydisperse 
in nature. Figure 1 shows SEM images of different types of nano and microparticles with and 
without encapsulated β-NGF. Size of particles fabricated using S/O/O double emulsion method 
was found to range from few nanometers to a micron (Figure 1 A and B) while the particles 
obtained by spray drying (Figure 1 C-I) possessed sizes ranging from a few nanometers to ~4 
microns. Therefore, the method of particle fabrication significantly affected the size leading to 
the conclusion that spray drying resulted in larger sized particles. On the other hand, it was also 
observed that β-NGF or OVA encapsulation did not affect the particles in terms of shape, size 
and structure regardless the loaded amount (Figure 1 D-F and G-I). It was also noticed that the 
shape, size and structure of the particles were not altered by the type of protein loaded (β-NGF or 
OVA). 
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Figure 1. SEM images of different nano/microparticles. (A) 20:80 CPH: SA nanoparticles 
without β-NGF fabricated by S/O/O method (B) 20:80 CPH: SA nanoparticles with 0.1% β-NGF 
fabricated by S/O/O method. (C) 20:80 CPH: SA microparticles with 0.05% β-NGF fabricated 
by Spray drying. 20:80 CPTEG: CPH microparticles (D) blank (E) with 0.05% β-NGF loading 
and (F) with 0.1% β-NGF loading fabricated by spray drying method. 50:50 CPTEG: CPH 
microparticles (G) blank (H) with 1% OVA loading and (I) with 5% OVA loading fabricated by 
spray drying method.     
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5.1.2. Film characterization 
Porous PLLA films with longitudinal micropatterns, containing 50:50 and 20:80 CPTEG:CPH 
microparticles loaded with different amounts of OVA, were prepared by dry phase inversion 
method. In this method, the different evaporation rates of non-solvent (pentane) and solvent 
(chloroform) resulted in phase separation during drying, and consequently, when the solvent and 
non-solvent are completely removed from the film, a porous structure is obtained. The advantage 
of this technique was to avoid the use of pore forming agent, which forms pores upon leaching in 
coagulation bath, and allow uniform distribution of particles in film matrix while creating pores. 
In addition, pentane, which is the precipitation agent in S/O/O method, was used to prevent the 
dissolution and facilitate dispersion of the OVA loaded particles. The particles loaded by various 
amounts of OVA were intended to be used to determine the release characteristics of the PLLA 
films while the particles loaded by different amounts of β-NGF were applied to observe the 
bioactivity of the PLLA films. The type and compositions of the prepared films used throughout 
this study is shown in Table 1.   
 
Table 1. The type and composition of prepared PLLA films used in release tests.  
Film 
Type PLLA DCM Pentane Particle Type 
OVA 
Loading 
β-NGF 
Coating Pattern 
PLLA-1 10% 64% 25% 1% 50:50 CPTEG:CPH 1% + + 
PLLA-2 10% 64% 25% 1% 50:50 CPTEG:CPH 3% + + 
PLLA-3 10% 64% 25% 1% 50:50 CPTEG:CPH 5% + + 
PLLA-4 10% 64% 25% 1% 20:80 CPTEG:CPH 1% + + 
PLLA-5 10% 64% 25% 1% 20:80 CPTEG:CPH 3% + + 
PLLA-6 10% 64% 25% 1% 20:80 CPTEG:CPH 5% + + 
(+, represent the presence of β-NGF coating and micropattern) 
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The SEM images of the prepared film represented in Figure 2 A and B show the achieved 
micropatterns and surface porosity in both patterned and flat surfaces. Following the use of films 
for release experiments during 15 days, the pore size of the films in both sides increased 
indicating the degradation of PLLA (Figure 2 C and D). However, the pattern structure and 
shape maintained its solidity.   
 
 
Figure 2. SEM images of porous, OVA encapsulated 50-50:CPTEG-CPH particles incorporated 
PLLA films. (A) patterned (B) flat surfaces of unused films. (C) patterned (D) flat surfaces of 
used films. Films were maintained in PBS at 37°C for 15 days. Magnification: 2000x 
 
Upon the preparation of the films with protein-loaded polyanhydride particles, the film surfaces 
were modified by β-NGF by creating a surface gradient through ester amine interactions [71]. 
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The peaks at 288.8 and 288.1 eV of the high-resolution C1s spectra are attributed to N–O–C=O 
and N–C=O, respectively, which resulted from the ester end groups of PLLA (Supplementary 
Information Figure S.3.A) [71]. Similarly, the XPS spectra of N1s indicate distinguishable 
increases at 402 eV of N–O as the portion of primary amines in the structure of β-NGF attached 
on the film surface (Supplementary Information Figure S.3.B)[71]. These XPS results indicated 
that ester terminated PLLA has the capability of forming covalent bonds with amines in the 
structure of β-NGF. The presence of N1s band on the β-NGF modified film (Supplementary 
Information Figure S.3.D) as compared to the plain film (Supplementary Information Figure 
S.3.C) indicates the presence of β-NGF on the surface.  
 
The presence of a surface β-NGF gradient was also supported by XPS analysis as described in 
Section 2.5. Figure 3 indicates the changes in β-NGF concentration along the film sections on the 
surface. As the exposure time of β-NGF solution increases, the attached β-NGF amount increases 
along the sections (Sections-1: lowest, Section-3: highest) leading to the formation of 
concentration gradient as depicted in Figure 3.  
 
The β-NGF loading on PLLA films through surface concentration gradient and microparticle 
distribution in PLLA conduit matrix enhances the loading capacity and control over the sustained 
release properties of the developed conduit system over its counterparts.  
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Figure 3. XPS analysis indicating the intensity of surface β-NGF gradient along different 
sections of the PLLA film (Section-1: Lowest β-NGF concentration, Section-3: Highest β-NGF 
concentration). *p<0.05 represents statistically significant difference. 
 
5.2. β-NGF release from nano/microparticles   
Various blank and β-NGF encapsulated polyanhydride copolymers with different ratios and 
chemistries, including poly SA, poly CPH:SA and poly CPTEG:CPH, were successfully 
fabricated and their β-NGF release properties were tested. The preliminary β-NGF release data 
obtained from different particles indicated that nano/microparticles of all copolymers except poly 
CPTEG:CPH showed none to very small amount of β-NGF release in PBS (data not shown). 
Only 50:50 and 20:80 CPTEG:CPH copolymer chemistry showed reliable β-NGF release in 
pictogram levels in PBS. The released β-NGF amount was subsequently increased to nanogram 
levels by using 0.5w% BSA in PBS as stabilizer. Therefore, 50:50 and 20:80 CPTEG:CPH 
chemistries were used for the rest of the experiments. It was observed that the spray dried 50:50 
and 20:80 CPTEG:CPH particles were able to release β-NGF for up to 8 weeks with the highest 
release amounts. Figure 4 shows cumulative release curves for 50:50 and 20:80 CPTEG:CPH 
particles. A sustained release of β-NGF was observed for almost 2 months where different 
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CPTEG:CPH polymer chemistries affected the release profiles. While the 50:50 CPTEG:CPH 
showed a slight burst release with higher amounts of β-NGF released at the start, the 20:80 
CPTEG:CPH released lower amounts of β-NGF at the initial time points but the amount released 
at the later time points was found to be more than 50:50 CPTEG:CPH particles. This was mainly 
due to the increased hydrophobic CPH content (from 50 to 80) in the polymer chemistry leading 
to the slow surface erosion of the particles and thus, slow β-NGF release [78-82]. Blank control 
particles did not show any release. Overall, the particle chemistry has a major impact on surface 
erosion properties and, therefore, release characteristics. As opposed to the studies controlling 
the release through polyester based particles possessing bulk erosion or requiring excessive cross 
linking [37, 39], the polyanhydrides with surface erosion properties provided easy synthesis and 
better control over the protein release. In addition, the loading capacity of the synthesized 
polyanhydrides were significantly high.     
 
Figure 4. Cumulative β-NGF release from 50:50 and 20:80 CPTEG:CPH particles in PBS buffer 
containing 0.5%BSA. N=3 and error bar represent standard error of the mean. 
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5.3. β-NGF and OVA release from films 
The release characteristics of the films represented in Table 1 were also analyzed. OVA was used 
to observe the release characteristics of microparticles distributed in the PLLA film matrix, while 
β-NGF was released from the surface. Diffusion coefficients were calculated for each film and 
each protein (OVA and β-NGF) represented in Table 1 by using the equations mentioned in 
Section 2.7. The selected release plots, showing good fit of the experimental results with the 
theoretical calculations, are shown in Supplementary Information Figure S.4. This analysis was 
conducted for all of the cases and tabulated in Table 2. Most studies in the literature have not 
calculated the diffusion coefficients nor provided a detailed quantitative discussion about the 
release characteristics of the conduits. However, in this section, a detailed discussion regarding 
the release characteristics of the films for conduits is presented. 
Table 2. The calculated diffusion coefficients of OVA and β-NGF released from each film. 
 
 
Diffusion Coefficient of OVA 
(cm2/min) 
 
Diffusion Coefficient of β-
NGF (cm2/min) 
Film Type 
Section-
1 
Section-
2 
Section-
3 
Section-
1 
Section-
2 
Section-
3 
PLLA-1 
(50:50 CPTEG:CPH 1% 
OVA) 
3.19x10-
10 
2.57 
x10-10 
1.67 
x10-10 
3.00 
x10-4 
3.70 
x10-4 
5.31 
x10-4 
PLLA-2 
(50:50 CPTEG:CPH 3% 
OVA) 
3.57x10-
10 
2.76 
x10-10 
2.02 
x10-10 
4.01 
x10-4 
4.70 
x10-4 
7.04 
x10-4 
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The effect of the surface gradient, which was previously confirmed by XPS analysis (Figures S.3 
and 3), was further supported by the release curves of OVA and β-NGF (Figure 5). An initial β-
NGF burst release from the film surface was observed for all cases represented in Figure 5 and 
Table 2 due to the fact that the mass transfer resistance in the surface is low. It was noted that the 
released amount of β-NGF increased as the film sections changed from Section-1 (with the 
lowest β-NGF concentration) to Section-3 (with the highest β-NGF concentration) for both of the 
films PLLA-1 (Figure 5 A) and PLLA-4 (Figure 5 C) regardless of the type of the particles used, 
as expected. This was due to the increased β-NGF concentration going from Section-1 to 3. In a 
similar fashion, an increase in the diffusion coefficients calculated for β-NGF was observed for 
Table 2 continued       
PLLA-3 
(50:50 CPTEG:CPH 5% 
OVA) 
7.51 
x10-10 
6.51 
x10-10 
2.36 
x10-10 
1.11 
x10-3 
1.07 
x10-3 
1.05 
x10-3 
PLLA-4 
(20:80 CPTEG:CPH 1% 
OVA) 
6.00 
x10-14 
5.59 
x10-13 
2.89 
x10-13 
1.15 
x10-4 
2.30 
x10-4 
3.14 
x10-4 
PLLA-5 
(20:80 CPTEG:CPH 3% 
OVA) 
2.54 
x10-12 
2.00 
x10-12 
4.36 
x10-13 
1.39 
x10-4 
1.70 
x10-4 
2.31 
x10-4 
PLLA-6 
(20:80 CPTEG:CPH 5% 
OVA) 
6.70 
x10-10 
1.23 
x10-10 
9.70 
x10-11 
1.21 
x10-4 
2.63 
x10-4 
3.63 
x10-4 
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both types of the particles used (PLLA-1 to 3, 50:50 CPTEG:CPH and PLLA-4 to 6, 20:80 
CPTEG:CPH regardless the loading amounts) in Table 2, as the sections changed from 1 to 3 due 
to the increased surface β-NGF concentration. A consistent trend could not be established in 
Table 2 between the β-NGF diffusion coefficients and the type of the particles or their OVA 
loading contents. However, according to the release plots represented in Figures 5 A and C, 
although the presence of OVA loaded particles in the film matrix did not affect the creation of 
surface gradient on PLLA films and effective β-NGF release from the surface, the type of the 
microparticle did affect the β-NGF amount attached to and released from the film surface. For all 
of the sections, the released β-NGF amount from the surface were significantly lower in film 
PLLA-4, containing 20:80 CPTEG:CPH particles, than film PLLA-1, bearing 50:50 
CPTEG:CPH particles. This could be due to the increased CPH content of the particles 
conferring more hydrophobicity and reducing the β-NGF attachment.  
 
For all cases investigated, the release of OVA from the PLLA matrix was found to be slower 
than that of the release of β-NGF from the film surface due to the additional mass transfer 
resistance throughout the film matrix. Contrary to the case of β-NGF released from the surface, 
the amount of OVA released from the PLLA film matrix was highest at Section-1 (the lowest β-
NGF concentration) and lowest at Section-3 (the highest β-NGF concentration) as indicated in 
Figures 5 B and D. This contradictory observation was due to the fact that during the β-NGF 
surface modification, as the β-NGF concentration level increases, the bottom part of the film 
(Section-3) was exposed to β-NGF solution for longer times (6 h) than the upper parts (Section-2 
and 1), which resulted in loss of OVA, which was loaded into the particles and distributed across 
the PLLA matrix. This situation was true for all of the films regardless the type of the particle or 
146 
 
 
OVA loading percentage. Although the amount of OVA loss was small, the release curves in 
Figures 5 B and D indicated that it was enough to create another internal OVA concentration 
gradient through the film matrix. However, the formation of internal concentration gradients 
throughout the PLLA film matrix and loss of protein during the modification did not affect the 
overall β-NGF gradient of the films prepared by β-NGF loaded microparticles distributed in 
PLLA film matrix for bioactivity tests, due to the small losses (data not shown). The amount of 
OVA released from the film PLLA-4 was found to be lower than the film PLLA-1 for all 
sections. This could be due to the presence of 20:80 CPTEG:CPH particles with increased 
hydrophobic CPH polymer content in film PLLA-4 resulting in retarded surface erosion and 
therefore slow OVA release (Figures 5 B and D). The same situation is also valid for other cases 
shown in Figure 6. Similar trends can also be observed from the OVA diffusion coefficients 
presented in Table 2. The diffusion coefficients calculated for OVA release were significantly 
lower (varying between 1 to 4 order of magnitude) in films PLLA-4 to 6, with the 20:80 
CPTEG:CPH particles, than films PLLA-1 to 3, with the 50:50 CPTEG:CPH particles, for the 
same sections and same OVA loadings (Table 2 and Figure 6). In addition, the decrease in 
diffusion coefficients from Section-1 to 3 can also be seen in Table 2.   
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Figure 5. The release profiles of PLLA-1 films containing 1% OVA loaded 50:50 CPTEG:CPH 
particles (A) β-NGF release from film surface (B) OVA release from film matrix. The release 
profiles of PLLA-4 films containing 1% OVA loaded 20:80 CPTEG:CPH particles (C) β-NGF 
release from film surface (D) OVA release from film matrix.  
 
Besides the effect of different particles, the OVA loading also had a significant effect on the 
release kinetics and diffusion coefficients. As shown in Figure 6, the increase in OVA content 
from 1 to 5% resulted in higher amount of OVA release for all sections and particle types. 
Similarly, the increased OVA loading caused higher diffusion coefficient values due to the 
increased concentration difference promoting the faster release for all sections and particle types 
(Table 2). However, the OVA loading dependent increase in diffusion coefficients for 20:80 
CPTEG:CPH  particles were found to be more drastically changed (at least 2 orders of 
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magnitude change) than that of 50:50 CPTEG:CPH particles (remains in same order of 
magnitude) in Table 2 due to the slower release of 20:80 CPTEG:CPH  particles with increased 
hydrophobic CPH content.  
 
Figure 6. OVA release from Section-3 of films (A) PLLA-3, 5% OVA loaded 50:50 
CPTEG:CPH and PLLA-6, 5% OVA loaded 20:80 CPTEG:CPH  (B) PLLA-2, 3% OVA loaded 
50:50 CPTEG:CPH and PLLA-5, 3% OVA loaded 20:80 CPTEG:CPH  (C) PLLA-1, 3% OVA 
loaded 50:50 CPTEG:CPH and PLLA-4, 1% OVA loaded 20:80 CPTEG:CPH. 
 
The effect of successful surface concentration gradients was clearly observed from the presented 
data. The β-NGF release from the surface and OVA release from the particles in PLLA matrix 
improved the control over the release rates. As an alternative to the studies mentioning co-
delivery systems based on cross-linking and layering approaches [34-36], this strategy can also 
be used for simultaneous combined release of multiple growth factors providing different release 
rates for each individual growth factor to increase the flexibility.  
5.4. Bioactivity of β-NGF released from nano/microparticles  
The bioactivity of released β-NGF from spray dried 50:50 CPTEG:CPH particles was tested 
against PC12 cells. The differentiation of PC12 cells in the presence of β-NGF encapsulated 
microparticles was observed for 2 days in vitro. Since the released β-NGF amount from 20:80 
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CPTEG:CPH particles was low to trigger the differentiation of PC12 cells within 2 days of 
incubation (Figure 4), only 50:50 CPTEG:CPH spray dried particles, providing a burst release in 
2 days, were tested for this assay. A non-contact co-culture assay was performed where 
microparticles at non-cytotoxic concentration were placed on cell culture inserts to observe their 
influence on PC12 cells growing at the bottom of the wells. It was observed that both β-NGF 
released from microparticles and soluble β-NGF, directly added to PC12 cells in culture media, 
caused significant neurite extension in PC12 cells, whereas the PC12 cells growing in media 
alone and in contact with blank particles (without β-NGF) had little to no neurites (Figure 7 A-
C). Similarly, the quantitative measurement of neurite length per cell indicated that β-NGF 
released from microparticles caused ~6.5 µm long neurite extension per cell which was close to 
the effect of soluble β-NGF, directly added to PC12 cells in culture media (Figure 7 D).  This 
assay showed that β-NGF released from 50:50 CPTEG:CPH microparticles was indeed stable 
and bioactive and showed a neurite extension pattern similar to that of free recombinant β-NGF 
in PC12 cell culture media. Furthermore, the process of β-NGF loading and storage time (one to 
two weeks) did not cause a significant decrease in bioactivity. Not only that, β-NGF 
encapsulated 20:80 CPH:SA particles, which did not show any β-NGF release during the ELISA 
test, were still able to cause neurite extension in PC12 cells (data not shown). This shows that 
most of the β-NGF released from the particles degrades in discontinuous systems, like release 
kinetics assays, and the amount quantified using ELISA kits is actually just the minimum amount 
that can be detected while the actual cumulative amount released is way higher than the detected 
amount. However, in continuous systems, like the non-contact co-culture assay with PC12 cells, 
the released β-NGF likely to be taken up by the cells immediately and shows a bioactive effect 
where released β-NGF was actually not detectable with ELISA tests.  
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Figure 7. Bioactivity of β-NGF released from 50:50 CPTEG:CPH microparticles (125 µg/ml) on 
the neurite extension of PC12 cells. PC12 cells density: 2x105 cells per well. Incubation time: 2 
days.  Neurites of the cells in every condition were immunostained with βIII-tubulin along with 
Cy3 secondary (shown in red), DAPI for nuclei (shown in blue). (A) Differentiated PC12 cells 
by the influence of β-NGF released from microparticles. (B) soluble β-NGF, directly added to 
PC12 cells in culture media (100 ng/mL). (C) PC12 cells only. (D) Quantification of neurite 
extension using ImageXpress Micro high content screening system and MetaXpress software. 
(N=3 independent experiments and Scale bar = 100 µm) 
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5.5. Bioactivity of β-NGF released from films 
The bioactivity of released β-NGF from films containing 0.05% β-NGF loaded 50:50 
CPTEG:CPH particles and β-NGF surface concentration gradients was tested using PC12 cells. 
50:50 CPTEG:CPH microparticles were used for bioactivity tests considering their relatively 
faster β-NGF release than  the 20:80 CPTEG:CPH microparticles, thereby providing sufficient 
amounts of β-NGF to trigger neurite outgrowth in PC12 cells. The quantitative neurite extension 
analysis shown in Figure 8.A indicated that as the surface concentration of β-NGF along the film 
surface sections (Sections-1 to 3) increased, the neurite length per cell increased as expected. The 
film bearing only β-NGF loaded particles showed similar effect with the Sections-2 and 3 of the 
film possessing only β-NGF surface modification while causing larger neurite extension than the 
Section-1 of the film possessing only β-NGF surface modification. The films with both β-NGF 
surface modification and β-NGF loaded 50:50 CPTEG:CPH particles produced the highest 
neurite extension in PC12 cells. It may be noted that the presence of β-NGF loaded 50:50 
CPTEG:CPH particles in PLLA film matrix did not alter the overall β-NGF surface gradient. It 
can be anticipated that following the initial burst β-NGF release, the 50:50 CPTEG:CPH 
particles provided sustained β-NGF release, leading to higher and longer NGF activity. The 
images presented in Figure 8.B-G also showed neurite extensions upon exposure of released β-
NGF. Therefore, the β-NGF loaded in particles and PLLA film matrix retained its stability and 
activity during the production steps. 
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Figure 8. (A) Bioactivity of β-NGF released from PLLA films possessing β-NGF surface 
gradient alone, containing 0.05% β-NGF encapsulated 50:50 CPTEG:CPH microparticles alone 
and combination of the two, both containing 0.05% β-NGF loaded 50:50 CPTEG:CPH particles  
and possessing β-NGF  surface gradient, on the neurite extension of PC12 cells. PC12 cells 
density: 2x105 cells per well. Incubation time: 2 days. Same letters and * represents the 
statistically significant difference (p<0.05). Bioactivity of β-NGF released from PLLA films. 
PLLA films possessing β-NGF surface gradient alone (B) Section-1 (C) Section-2 (D) Section-3. 
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PLLA films possessing both 0.05% β-NGF encapsulated 50:50 CPTEG:CPH microparticles and 
β-NGF surface gradient (E) Section-1 (F) Section-2 (G) Section-3. PC12 cells density: 2x105 
cells per well. Incubation time: 2 days. 
  
The alignment of the neurite extension in one direction was also achieved by surface 
micropatterning. Figure S.5. in Supplementary Information clearly indicates the alignment of the 
extended neurites parallel to the direction of the micropattern. The additional effect of the 
surface gradient on the directional growth of the neurite extension was also explored; however, 
the fast β-NGF release likely resulted in the formation of homogeneous β-NGF concentration in 
the cell culture media preventing the observation of a surface gradient effect. 
 
6. Conclusions 
The overall results indicated that the multifunctional PLLA films possessing porous structure 
with longitudinal micropatterns as would be seen in the inner lumen of conduits, with β-NGF 
surface gradients and containing β-NGF-encapsulated surface eroding biodegradable and 
amphiphilic polyanhydride microparticles distributed into the film matrix were successfully 
produced. The change in particle type, protein loading amount and presence of β-NGF surface 
gradient succeeded in providing controlled release with several tunable parameters. It was shown 
that the NGF diffusion coefficient can be controlled over a wide range of values. The films and 
particles showed significant bioactivity with PC12 cells, causing effective neurite growth. Thus, 
these films bearing surface eroding polyanhydride particles are promising materials for 
peripheral nerve regeneration. The in vivo efficiencies of the designed conduits will further be 
investigated. 
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The schematic for NGF surface modification, NMR of synthesized polymers, XPS results for 
surface NGF coating, representative plots for the applied mathematical model, and effect of 
surface patterning in neurite alignment.  
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CHAPTER 6: PROTEOMIC ANALYSIS OF MESENCHYMAL STEM CELLS 
TRANSDIFFERENTIATED TOWARDS SCHWANN CELL-LIKE PHENOTYPIC 
CELLS 
(manuscript in preparation in collaboration with Dr. Howard Gendelman’s group at UNMC) 
 
1. Introduction 
Peripheral nerve injuries can result in complete disruption of neuronal signals from peripheral 
limbs to the central nervous system (CNS) and vice versa and may cause paralysis in extreme 
cases.  Anterograde (Wallerian) degeneration initiates a cascade of degenerative as well as 
regenerative events starting with infiltration of macrophages and Schwann cells (SCs) to help 
remove the debris created by degradation of axonal tissue, axonal fibers and myelin sheath of the 
distal end of the nerve segment. Schwann cells present in the distal end secrete neurotrophic 
factors that attract the axons regenerating from the proximal end. If sufficient support is provided 
to the growth cones they regenerate through the nerve gap and then grow into the remaining 
skeleton of the degenerated distal neural tissue. Various strategies are presented to provide 
support for regenerating neural tissue and commonly, a tube specifically called as a “nerve 
guidance conduit” is used for providing support for regenerating axons. Nerve guidance conduits 
filled with SCs have been shown to enhance regeneration significantly [1-3]. However, there is 
no good source of SCs, and usually, a healthy nerve is sacrificed to isolate SCs. Also, once 
isolated, isolation and enrichment of SCs is difficult process and can take weeks to months to 
obtain an enriched population of SCs devoid of other cell types such as fibroblasts and ultimately 
results in a limited number of SCs to transplant [4, 5]. To avoid such complications, various 
researchers have used other cell types such as mesenchymal stem cells [6-8], neural stem cells[9, 
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10], olfactory ensheathing cells [11, 12] and various other stem cell types [13, 14] to replace lost 
native SCs after nerve injury. Such cellular transplantation has also been shown to improve nerve 
regeneration significantly as well [2, 3]. One promising strategy that has been studied and shown 
to work effectively is the usage of mesenchymal stem cells (MSCs) as an alternative cellular 
source for transplantation at the site of nerve defect. Mesenchymal stem cells can be easily 
obtained from various sources[15] including bone marrow and adipose tissue using common 
surgical procedures. Mesenchymal stem cells provide benefits such as autologous 
transplantation, ability to continuously grow in cell culture environment, secretion of growth 
factors, and ability to transdifferentiate into SC-like phenotypic cells [16-18]. Transdifferentiated 
MSCs (tMSCs) used along with a nerve regeneration conduit resulted in enhanced nerve 
regeneration in a few studies [7, 8, 19]. After transdifferentiation, the MSCs show various 
morphological and molecular changes similar to native SCs and these changes are assessed using 
various experimental techniques such as immunocytochemistry, western blots, Enzyme-linked 
immunosorbent assays (ELISAs) and Reverse transcription-polymerase chain reaction (RT-
PCR). However, in previous transdifferentiation studies, there have been no detailed proteomic 
analysis to understand the differences in the proteome of transdifferentiated MSCs (tMSCs) vs. 
undifferentiated MSCs (uMSCs). This study will help us in understanding the proteins which get 
regulated during transdifferentiation process and how proteome of differentiated cells differs 
from control cells. In this study, we are performing a proteomics analysis to identify and quantify 
proteins that may be differentially expressed by tMSCs and uMSCs, and to assess further the 
regulation of various pathways associated with identified proteins. 
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2. Materials and Methods 
2.1. Culturing of bone marrow-derived mesenchymal stem cells 
Mesenchymal stem cells were isolated and cultured from Brown Norway rats using previously 
established procedures [17]. Cells isolated were propagated in maintenance media containing 
alpha minimum essential media (αMEM, Gibco BRL| Thermofisher Scientific, Waltham, MA, 
USA), supplemented with 20% fetal bovine serum (FBS, Atlanta Biologicals, Atlanta, GA, 
USA), 2% 200 mM solution GlutaMAX (Gibco BRL), and 1% antibiotic–antimycotic 
(Invitrogen| Thermofisher Scientific, Waltham, MA, USA) and maintained in incubators at 
37oC/5% CO2. Cells were harvested when they were approximately 80% confluent and Trypan 
Blue (T8154, Sigma–Aldrich, St. Louis, MO, USA) viable cell count performed using a 
hemocytometer prior cell platings. To harvest the cells, conditioned media was collected in a 15 
ml centrifuge tube and then washed with PBS (Gibco BRL) followed by trypsinization using 
0.05% trypsin-EDTA (catalog number 25300, Gibco BRL). After cell dissociation, conditioned 
media collected initially was used to neutralize the trypsin and collect the cells to transfer back to 
the centrifuge tube. The cell pellet was obtained by centrifuging the tube at 500 RPM. After 
centrifugation, the supernatant was aspirated, and cells were resuspended in the desired amount 
of fresh maintenance media. 
2.2. Transdifferentiation of mesenchymal stem cells into Schwann-like cells 
Protocol for in vitro transdifferentiation of MSCs into SC-like cells was obtained from Dezawa 
et al. [8]  and was previously used to successfully transdifferentiate MSCs into SC-like cells on 
micropatterned substrates in our research group [17]. To start transdifferentiation, MSCs were 
allowed to grow under normal growth conditions and grown till they reached a confluence of 
about 30-40% before being subjected to 1 mM β-mercaptoethanol (BME; Sigma–Aldrich, St. 
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Louis, MO, USA) in αMEM for a day. After incubation for a day in BME, media from the flask 
was removed and then cells were washed with PBS before subjecting them to media containing 
αMEM, 10% FBS and 35 ng/mL all-trans-retinoic acid (ATRA (R2625); Sigma) for three days. 
Finally, after three days of incubation in retinoic acid supplemented medium, cells were again 
washed with PBS and further subjected to media containing αMEM supplemented with 20% 
FBS, 14 μL forskolin (FSK; EMD Millipore, Billerica, MA, USA), 5 ng/mL platelet-derived 
growth factor (PDGF; Sigma), 10 ng/mL basic fibroblast growth factor (bFGF, Promega 
Corporation, Madison, WI, USA) and 200 ng/mL heregulin β1 (HRG; Calbiochem, EMD 
Millipore) for 8 days in vitro (DIV). 
2.3. Immunocytochemistry 
In order to quantify protein expression after immunostaining using a high throughput imaging 
system, transdifferentiated MSCs (tMSCs) and undifferentiated MSCs (uMSCs) were plated in 
96 well plates (655090, Greiner Bio-One, Monroe, NC, USA) at a density of 2000 cells per well 
at day 12 of transdifferentiation. Cells were first washed with 0.1M PO4 buffer twice and then 
fixed for 20 minutes in 4% paraformaldehyde in 0.1M PO4 buffer. After fixation, cells were 
washed with PBS three times every ten minutes and then blocked with a blocking solution 
prepared using PBS containing 5% normal donkey serum (NDS, Jackson ImmunoResearch, 
West Grove, PA, USA), 0.4% bovine serum albumin (BSA; Sigma) and 0.2% Triton X-100 
(Fisher Scientific) for one hour. Various antibodies specific to glial, neuronal and proliferation 
markers (Table 1) were diluted at desired concentration in blocking solution and then applied to 
the cells overnight at 4oC. On the following day, cells incubated with primary antibodies were 
again washed with PBS three times every ten minutes before applying secondary antibodies 
Donkey-α-Mouse-Cy3 (1:500, Jackson ImmunoResearch) or Donkey-α-Rabbit-Cy3 (1:500, 
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Jackson ImmunoResearch) along with DAPI (1:50) for 60-90 minutes in the dark. Finally, as the 
last step, cells were washed with PBS again three times every ten minutes to remove any non-
bound secondary antibody. 200 µl PBS was left in the wells to keep the immunostained cells 
hydrated for fluorescence imaging. Plates were imaged using an ImageXpress Micro high 
content screening system (Molecular Devices, Sunnyvale, CA, USA) and percent 
immunostaining for each antibody was quantified using multiwavelength cell scoring module of 
the MetaXpress software (Molecular Devices, Sunnyvale, CA, USA). 
Table 1. Antibodies used for characterization of transdifferentiated MSCs 
Primary antibody Dilution Specificity Vendor (catalog number) 
Rab-α-S100 1:500 Glial marker (SC marker) Sigma-Aldrich (S2644) 
Mo-α-S100β 1:1000 Glial marker (SC marker) Abcam (ab11178) 
Rab-α-p75NTR 1:1000 Glial marker (SC marker) Promega (G3231) 
Mo-α-TUJ1 (βIII tubulin) 1:200 Neuronal marker R&D systems (MAB1195) 
Rab-α-Ki67 1:200 Proliferation marker Abcam (ab16667) 
 
2.4. PC12-TrkB cell culture 
PC12-TrkB cells (obtained from…) were grown in maintenance medium containing RPMI-1640 
Medium (30-2001, ATCC, Manassas, VA, USA) supplemented with 10% heat-inactivated horse 
serum and 5% fetal bovine serum. PC12-TrkB cells were genetically modified to express the 
BDNF receptor, TrkB[20]. The PC12-TrkB cells are capable of differentiating in the presence of 
both nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF). Cells were 
grown in 37oC/5%CO2 incubators. For passaging, cells were transferred to 15 ml centrifuge 
tubes, and the cell pellet was obtained by centrifuging tubes at 800 RPM. The supernatant was 
164 
 
 
aspirated before suspending the cell pellet in fresh maintenance media to count the number of 
cells using a hemocytometer. For differentiation experiments, multi-well plates were coated with 
laminin (10 µg/ml) before plating the cells. 
2.5. PC12-TrkB and tMSCs/uMSCs non-contact co-cultures 
To test out the differentiation of PC12-TrkB cells in the presence of soluble factors secreted by 
tMSCs or uMSCs, we employed a non-contact co-culture system using cell culture inserts in six 
well plates. For non-contact cocultures, PC12-TrkB cells were plated on laminin coated six-well 
plates at a density of 100,000 cells per well. tMSCs and uMSCs were plated on top of cell culture 
inserts (CLS3450, Sigma) at a density of 125,000 cells per well. From a previous experiment 
(data not shown), we determined that a 70:30 ratio of PC12-TrkB maintenance media and 
uMSCs maintenance media supports growth of all three cell types. A control condition was also 
maintained where PC12-TrkB cells were grown in maintenance media alone. After two days of 
differentiation, PC12-TrkB cells were immunostained with βIII-tubulin antibody conjugated to 
Cy3 along with DAPI to stain the nuclei. Imaging was performed using the ImageXpress Micro 
high content screening system and average neurite extensions across each condition was 
quantified using the neurite outgrowth module of the MetaXpress software. 
 
2.6. Nerve growth factor-β enzyme-linked immunosorbent assay (ELISA) 
A nerve growth factor-β (NGFβ) ELISA Kit (ab100757, Abcam, Cambridge, MA, USA) was 
used for quantification of released NGFβ from tMSCs and uMSCs. Similarly, a BDNF Elisa kit 
(BDNF Emax® ImmunoAssay System, Promega, Madison, WI, USA) was used to quantify the 
BDNF release. ELISAs were performed based on the instructions provided by the kit 
manufacturer. Cells were plated in 6 well plates at an initial plating density of 30,000 cells/well 
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and then grown for two days. After two days, conditioned media samples were collected, cells 
were fixed and stained with DRAQ5 (nuclei stain) (ab108410, Abcam) to assess the number of 
cells present at the time of sample collection. 
 
3. Results 
3.1. Expression of Schwann cell and neuronal marker proteins 
Transdifferentiated MSCs (tMSCs) showed a higher expression of Schwann cell marker proteins 
such as S100, S100β and p75 as compared to undifferentiated MSCs (uMSCs) after performing 
immunocytochemical staining. tMSCs also showed higher expression of βIII-tubulin which is a 
neuronal marker. The presence of both glial and neuronal markers points out that after 
transdifferentiation MSCs appear to pass through a hybrid multipotential neuronal-glial fate. 
Despite higher expression of glial and neuronal markers, Ki67 immunostaining showed that 
tMSCs were proliferating at a much lesser rate compared to uMSCs. Figure 1 shows 
quantification of immunostaining for various marker proteins. S100 and TUJ1 were expressed 
significantly higher in tMSCs showing their neuronal-glial nature while Ki67 was expressed 
significantly higher in uMSCs showing that transdifferentiated cells proliferate slower than 
undifferentiated cells. S100β and p75NTR expression was found to be slightly higher in tMSCs 
but no significant differences were observed between tMSCs and uMSCs for these two markers. 
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Figure 1. Percentage immunostaining of S100, S100β, p75, TUJ1 and Ki67 for 
transdifferentiated MSCs (tMSCs) and undifferentiated MSCs (uMSCs). N=8 and error bars 
represent standard deviation. tMSCs showed significantly higher S100 and TUJ1 expression 
(p≤0.05) while uMSCs showed a significant higher expression of Ki67 (p≤0.05). S100β and 
p75NTR expression was slightly higher in tMSCs but no significant differences were observed. 
 
3.2. PC12-TrkB neurite outgrowth quantification 
PC12-TrkB cells (100,000 cells) cocultured with tMSCs/uMSCs (125,000 cells) under non-
contact coculture conditions resulted in longer neurite outgrowth. PC12-TrkB cells growing in 
tMSCs coculture condition had significantly longer neurites as compared to uMSCs coculture 
(p≤0.1) and the control media condition (Figure 2). From these experiments, we showed the 
functional benefits of using tMSCs for growth and differentiation of PC12-TrkB cells as 
compared to uMSCs by showing that PC12-TrkB cells growing in the presence of tMSCs 
displayed longer neurite outgrowth as compared to PC12-TrkB cells growing in the presence of 
uMSCs. 
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Figure 2. Effect of tMSCs and uMSCs on PC12-TrkB cells neurite extension using noncontact 
coculture (NCCC) system. After two days of coculture, tMSCs caused a higher neurite extension 
as compared to uMSCs and control media condition showing the functional benefits of using 
tMSCs for transplantation purposes. N=3 and error bar represent standard deviation. PC12-TrkB 
cells had significantly longer neurite growth in presence of tMSCs as compared to PC12-TrkB 
cells growing in presence of uMSCs (p≤0.1) after 2 days. 
 
3.3. Release of Nerve growth factor-β (NGFβ) and Brain derived neurotrophic factor (BDNF) 
In parallel to cocultures, tMSCs and uMSCs were also plated in 6 well plates at an initial plating 
density of 30,000 cells per well to measure the release of nerve growth factor. Cells were stained 
with DRAQ5 and quantified to compare relative cell numbers for tMSCs and uMSCs at the time 
of collection of conditioned media samples. Media was collected after two days of cell growth 
and then the amount of NGFβ released from tMSCs vs. uMSCs was quantified using the NGFβ 
ELISA kit. Figure 3 and 4 illustrates the relative amount of NGFβ and BDNF released, 
respectively from tMSCs and uMSCs. Both BDNF and NGFβ release from tMSCs was found to 
be significantly higher as compared to uMSCs at p≤0.05. 
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Figure 3. The amount of nerve growth factor-β (NGFβ) released from transdifferentiated MSCs 
(tMSCs) and undifferentiated MSCs (uMSCs) after two days of cell growth. N=3 and error bars 
represent standard deviation. NGFβ release was found to be significantly higher from tMSCs as 
compared to uMSCs (p≤0.05). 
 
Figure 4. The amount of brain derived neurotrophic factor (BDNF) released from 
transdifferentiated MSCs (tMSCs) and undifferentiated MSCs (uMSCs) after two days of cell 
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growth. N=3 and error bars represent standard deviation. BDNF release was found to be 
significantly higher from tMSCs as compared to uMSCs (p≤0.05). 
 
4. Discussion and conclusion 
Immunostaining of tMSCs using various SC marker proteins showed that tMSCs had a higher 
expression of SC marker proteins as compared to undifferentiated MSCs confirming that 
transdifferentiation of MSCs was successful. NGFβ ELISA showed that tMSCs released a 
significantly higher amount of neurotrophic factor NGFβ as compared to uMSCs pointing out 
another similarity of tMSCs with SCs. Finally, neurite outgrowth assay using PC12-TrkB 
confirmed that tMSCs provides a better functional benefit as compared to uMSCs and causes 
higher neurite extension in PC12-TrkB cells. A detailed proteomic analysis is currently in 
progress and will help to determine differences in regulation of proteins and pathways between 
tMSCs and uMSCs. Initial proteomics analysis has revealed 1025 proteins at the Global 1%FDR.  
Using PEAKView software, 808 proteins were included in the SWATH analysis and out of these 
808, 388 proteins were found to be significantly changed by performing a Ztest for comparing 
tMSCs with control uMSCs values. Also, protein list was uploaded to Ingenuity pathway 
analysis (IPA) program to identify the protein and pathways of interest. Table 2 shows the 
pathways and protein of interest after performing IPA analysis and detailed analysis will be 
conducted on these proteins. 
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Table 2. Proteins and pathways of interest after performing IPA analysis 
Pathways of interest Protein of interest 
NGF Signaling MAPK3 
Axonal Guidance Signaling RASA1 
Neuregulin Signaling RHOA 
PDGF Signaling RRAS 
GDNF Family Ligand-Receptor Interactions STAT3 
CNTF Signaling WNT5A 
Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency ITGB1 
Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency PDLIM7 
Mouse Embryonic Stem Cell Pluripotency ACTR2 
Neurotrophin/TRK Signaling ACTR3 
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CHAPTER 7: ONGOING AND FUTURE WORK 
(In vivo transplantation of conduit and behavioral test were performed by Dr. Svitlana Zbarska) 
 
The work described in the previous chapters is leading to the potential of transplantation of 
transdifferentiated MSCs seeded conduits in vivo in a sciatic nerve transection model with 
immunomodulation of macrophage phenotype using Interleukin-4 releasing micro/nanoparticles. 
This work is currently undergoing, and more studies will be conducted in the future. 
Section 7.1 and 7.2 describes some of the preliminary data generated while conducting these 
studies. 
 
7.1. In vivo experiments to test the therapeutic effect of transdifferentiated MSCs pre-seeded in 
micropatterned PLA conduits 
7.1.1. Conduit implantation  
Our initial pilot study to optimize the in vivo experiments was conducted on sixteen animals. The 
main goal of these experiments was to test and compare survival and possible therapeutic effects 
of tMSCs and uMSCs preseeded in the micropatterned biodegradable conduits for the sciatic 
nerve regeneration model. Young adult Brown Norway rats were used for these experiments. 
The right sciatic nerve of each animal was transected and a 10 mm segment of the nerve 
removed thus creating a gap that was bridged with micropatterned PLA conduits preseeded with 
either GFP-expressing tMSCs or uMSCs 24 hours before transplantation (20000 per conduit). 
The left sciatic nerve remained intact and used later as a control. Aseptic techniques were used 
during surgeries to ensure sterility. To eliminate bias, a double-blind study was performed. The 
conduits were prepared, preseeded with cells and given a number corresponding to the cell type. 
All procedures followed NIH guidelines for the care and use of laboratory animals and had the 
approval of the IACUC. The rats were tested weekly for functional recovery for 12 weeks after 
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conduit implantation. Shortly after surgery, one animal was excluded from the study and 
euthanized due to the right foot autotomy.    
  
7.1.2. Functional tests: walking track test.    
 
All animals were tested using the walking track test for footprint analysis to quantify possible 
functional recovery of the sciatic nerve. This non-invasive method has been shown to measure 
sensory and motor recovery. It can also be repeatedly used to detect the dynamics of functional 
recovery in an animal. For this analysis, we used video recordings using a mirror placed 45 
degrees beneath the rat runway (Fig.1).  
The video recording method used a Plexiglas runway running 100 cm long and 10 cm wide and 
was attached to a darkened cage at the end of the runway. The mirror underneath the runway 
reflects the image of the animal’s footprints. A running animal was video recorded using an 
HD Sony camcorder (Fig. 2, A) and then the video files were converted to images (30 frames 
per second). Afterward, the images were selected, and footprint analysis was performed using 
Avanti and VirtualDub software.  
 
 
Figure 1. Diagram of gait analysis system. Setting up a mirror at 45 degrees helped with two 
different orientations (Figure 2A and 2B) of rat walking on the system. 
 
 
 
 
45⁰ 
Mirror Camera  
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Figure 2. A: Image of running rat during the walking test. B: the image of a footprint with 
represented measurements: PL – print length; ITS – intermediate toe spread; OTS – outer toe 
spreading.  
The footprints were evaluated for three footprint parameters (Fig. 2, B):  the distance between 
the first and fifth to – outer toe spread (OTS), the distance between the second and fourth toes 
– intermediate toe spread (ITS), and the distance between the heel to the tip of the third toe – 
print length (PL). Six prints from each hind foot were measured and then averaged.  The ratio 
of (injured-uninjured)/uninjured hind feet parameters was calculated. Based on these 
parameters, the sciatic functional index (SFI) was calculated according to the following 
formula:  
SFI = -38.3*(EPL-NPL)/NPL + 109.5*(ETS-NTS)/NTS+13.3(EITS-NITS)/NITS-8.8 
Where: 
EPL – experimental print length, 
NPL – normal print length 
ETS – experimental toe spread,  
NTS – normal toe spread 
EITS – experimental intermediate toe spread 
NITS – normal intermediate toe spread.   
A B 
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The sciatic functional index is a common parameter that is calculated based on the empirically 
derived formula and is widely used for walking track analysis. The index score of 0 is defined 
as normal and an index score of -100 indicates total impairment. The measurements were taken 
weekly for two weeks before surgery and for 12 weeks after in order to observe functional 
recovery after sciatic nerve transection. For data analysis, data from all animals were pooled 
together due to the blind study requirements. On the group level, SFI dropped dramatically 
after surgery, and there was a little increase of SFI observed during the 12- week recovery 
period (Fig. 3).  
 
 
Figure 3. Changes of Sciatic Functional Index before and 12 weeks after sciatic nerve 
transection and PLA rolled conduit implantation (N=15).   
 
These data are similar to the SFI results of the previous group of animals that were implanted 
with empty conduits suggesting a limited therapeutic effect of preseeded cells. Following 
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histological analysis of extracted conduits revealed the absence of the GFP-expressing cells in 
the conduits 12 weeks after surgery. This might explain the low rate of recovery of motor 
function. 
7.1.3. Functional tests: reflex test 
All animals were tested using the hindlimb withdrawal reflex from a hot water bath. This water 
test is used to quantify sensory recovery of the sciatic nerve following injury. To conduct this 
test, the rat’s toes on the hind limbs were alternately dipped into water maintained at a 
temperature of 55°C and the time of the limb withdrawal reflex was measured using a video 
recording system. Withdrawal reflex time was defined as the period between the moment of 
crossing the water level and the first upper movement. To determine the average withdrawal 
reflex time, four trials were performed alternating between each limb with a minimum 30 sec 
time interval. Water temperature was constantly monitored. Our results indicated that the 
average time for normal withdrawal reflex of Brown Norway Rats is about 1-1.2 second (Fig. 
4). While withdrawal reflex time (WRT) for the affected limb increased up to 2.91±0.96 s after 
surgery (Fig. 4). WRT for the affected limb decreased up to 1.89±0.37 s at the end of the 12-
week period.  
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Figure 4. Time of hind limbs withdrawal reflex before and after conduit implantation for all 
animals implanted with conduits (N=15).  
 
 
 
Based on these pilot experiments, we have established sterile surgical procedures for sciatic 
nerve transaction and conduit implantation at the injury site. Two functional tests, the walking 
track analysis, and withdrawal reflex test, were used to measure the motor and sensory 
functions of the affected nerve. The video recording method was used to capture the footprints 
during walking track test. This method was chosen because of its high accuracy, visibility, and 
minimum stress for animals. At the end of the 12-week recovery period, all animals were 
perfused with 4% paraformaldehyde. Conduits and the unaffected sciatic nerve from the 
contralateral side were extracted, and histomorphological analysis is underway.  
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7.1.4. Morphological analysis of conduits. 
A morphological analysis of the conduit with regenerated nerve and surrounding tissue is being 
performed to evaluate the conduits and possible extent of regenerated nerve tissue. Conduits with 
proximal and distal nerves attached were removed, examined qualitatively (Fig.5, A), post-fixed, 
cut into four segments, and embedded in paraffin. Each segment of the conduit was given the 
name according to the position in the conduit (Fig 5, B): most proximal (MP), proximal (P), 
distal (D) and most distal (MD). 
  
Figure 5. A: Image of the isolated fixed conduit with tissue inside. B: Diagram of the cut 
conduit.    
Each segment was sectioned on a microtome at 5 µm transverse sections and placed on glass 
slides. Currently, we finished sectioning all MP and MD pieces from all 15 conduits and 
continue sectioning of P and D pieces.  
After visual evaluation of the conduits possible regenerated nerve tissue was observed inside 
every conduit along its entire length (Fig.5, A).  
A B 
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As the first step in tissue characterization, the comparison of the most distal sections of MP piece 
and most proximal pieces of MD piece was performed. The corresponding 20 consecutive 
sections of MP and MD pieces of conduit and control nerve were imaged using dark field 
microscopy. Figure 6 shows representative images of the dark field imaging of MP section and 
MD section of the conduit. The presence of regenerated tissue was observed inside all MP as 
well as MD sections.  
Figure 6. Dark field microscopy images of most proximal (MP) and most distal (MD) cross 
sections of the conduit. Outlined area was used for the area quantification. The errors point to the 
placement of the conduit layers.  
The regenerated area inside of the conduit was outlined and quantified in mm2. Group results are 
presented in Figure 7.  
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Figure 7. Area of regenerated neuronal tissue in mm² within most proximal and most distal 
conduit pieces and for contralateral control sciatic nerve. N=3 
On average there was no significant difference between the area of regenerated tissue inside MP 
piece and inside MD piece (p=0.1562). Also, no significant difference was observed between MP 
and MD control sections (p=0.9478). On average the area of regenerated tissue inside of the 
conduit was two and half times smaller than cross-section area of control sciatic nerve.  
7.1.5. Immunohistochemical analysis of regenerated tissue inside of conduits. 
As the next step the standard immunohistochemical procedure was applied to regenerated tissue 
inside of the conduits using the antibodies listed in Table 1:  
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Table 1. Antibodies used for immunohistochemistry to examine nerve regeneration in the 
conduit. 
Primary 
Antibody 
Antibody target Antigen-binding site 
TUJ1 Neuronal marker Β-Tubulin microtubule  
NF-68 Light neurofilaments Cytoskeletal components of neurons 
NF-200 Heavier neurofilaments  Cytoskeletal components of mature 
neurons 
S100 Astroglial and Schwann cells Calcium binding protein, mark Nucleus 
and cytoplasm 
IBA1 Microglia marker- macrophages Ionized calcium binder in cytoplasm 
ED-1 Microglia marker- macrophages Single chain glycoprotein of 110 kD 
GAP43 Axonal growth cones in 
developing or regenerating 
neurons  
Growth-associated protein  
GFP GFP-expressing cells Green fluorescent protein 
  
Cell nuclei were marked with 4',6-diamidino-2-phenylindole (DAPI), a fluorescent stain that 
binds strongly to A-T rich regions in DNA.  
Images were captured using a compound fluorescence microscope with 40x and 100x 
magnification. Also, double staining was performed to immunolabel the same regenerated area 
inside of the conduit with neuronal markers (TUJ1, NF200) and glial cell marker (s100). Figures 
8 and 9 show representative images of TUJ1-s100 double staining of regenerate tissue inside MP 
and MD pieces of the conduit and control sciatic nerve correspondingly. TuJ1 antibody staining 
was highly effective in conduit sections as well as control sciatic nerve sections. 
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Figure 8. Regenerated tissue inside of the MP and MD pieces of the conduit double-labeled for 
TUJ1 Class III β-Tubulin (red) and SC-marker proteins s100 (green). DAPI (nuclei) staining is 
shown in blue. DIC images reflect the morphology of the neuronal tissue. 
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Figure 9. Regenerated tissue inside of the MP and MD pieces of the control sciatic nerve double-
labeled for TUJ1 Class III β-Tubulin (red) and SC-marker proteins s100 (green). DAPI (nuclei) 
staining is shown in blue. DIC images reflect the morphology of the neuronal tissue. 
TUJ1 staining was present in MP sections as well as MD sections revealing presence of the 
neuronal fibers along the entire length of the conduit (Fig.8). Comparison between DAPI 
staining of conduit sections and control sections illustrate that the number of cells inside the 
conduit is considerably higher compared to the intact sciatic nerve. Colocalization of s100 
staining around TUJ1 staining on control sections corresponds to Schwann cells wrapping 
around bundles of neuronal fibers (Fig. 9) Some s100 staining was present in conduit tissue but 
with the much smaller extent and was less organized (Fig. 8). DIC images reflected the 
morphology of the neuronal tissue inside of the conduit and in the sciatic nerve. Inside of the 
conduit, there was a higher number of fiber bundles smaller in diameter compared to the control.  
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Similar results were observed when tissue was double stained with neurofilament marker NF-200 
and Schwann cell marker s100. Figures 10 and 11 show representative images of this staining on 
regenerated tissue inside MP and MD pieces of the conduit and control sciatic nerve 
correspondently.  
 
Figure 10. Regenerated tissue inside of the MP and MD pieces of the conduit double-labeled for 
neurofilament NF200 (red) and SC-marker proteins s100 (green). DAPI (nuclei) staining is 
shown in blue. DIC images reflect the morphology of the neuronal tissue. 
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Figure 11. Regenerated tissue inside of the MP and MD pieces of the control sciatic nerve 
double-labeled for TUJ1 Class III β-Tubulin (red) and SC-marker proteins s100 (green). DAPI 
(nuclei) staining is shown in blue. DIC images reflect the morphology of the neuronal tissue. 
Thus far, MP and MD immunolabeled sections of three animals imaged with 100x magnification 
and were quantified using MetaXpress software. All averages presented further were calculated 
based on quantification of 10 images per condition per animal; a total number of animals 
included in group analysis equals three. First, the number of cell nuclei was counted based on the 
DAPI staining (Fig.12).  
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Figure 12. Averaged number of cell nuclei per 0.1 mm2 of regenerated tissue in the MP, MD 
pieces of the conduit and MP, MD pieces of control sciatic nerve.  
 
Group DAPI quantification support the individual examples on Figures 8-11, and  a higher 
number of DAPI staining was observed in the conduit tissue than in the control sciatic nerve.  
Also using the same software number of TUJ1 and NF200 immunolabeled neuronal bundles 
were quantified (Fig. 13) 
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Figure 13. Averaged number of neuronal fibers per 0.1 mm2 of regenerated tissue in the MP, MD 
pieces of the conduit and MP, MD pieces of control sciatic nerve immunolabeled with A: 
neuronal marker TUJ1; B: neurofilament marker NF200.  
 
Figure 14. Neuronal area immunolabeled with neuronal markers presented as a percentage of 
total area of regenerated tissue in the MP, MD pieces of the conduit and MP, MD pieces of 
control sciatic nerve A: neuronal marker TUJ1; B: neurofilament marker NF200. 
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Group results of TUJ1 and NF200 immunolabeling revealed that some neuronal bundles in the 
conduit were higher than in the control sciatic nerve (Fig.13). Also, the total area of 
immunostaining for TUJ1 and NF200 was quantified as a percentage of total area of regenerated 
tissue inside of the conduit or total area of control sciatic nerve (Fig.14). On average the stained 
area inside the conduit was larger than in sciatic nerve.  
Besides neuronal markers TUJ1 and NF200 and SCs-marker s100, tissue was immunostained 
with IBA1 and ED1 antibodies for the presence of macrophages. Almost no staining was 
observed inside of the regenerated tissue as well as in control sciatic nerve.  
Conduits preseeded with GFP-expressing cells sections were immunolabeled with anti-GFP 
antibodies to amplify GFP fluorescents. No GFP-expressing cells were observed inside of the 
conduit 12 weeks after surgery. This could be due to several reasons: cells might migrate out of 
conduit, they could lose their GFP expression, or they might not survive during the recovery 
period. To improve the survival of MSCs in conduits, we planned to improve the design of 
conduit by introducing the pores in the conduit wall to improve the transfer of nutrients and 
waste across conduit wall. 
7.1.6. Characterization of tMSCs growth on porous micropatterned PLA films fabricated with 
10% Salt. 
To characterize cell adhesion, growth and proliferation on porous films GFP-expressing tMSCs 
were plated and cultured on films produced with 10% Salt. Before cell placement, films were 
exposed to rat laminin-5 for 12 hours to provide an extracellular matrix coating for cells. The 
initial cell seeding density was 6,000 cells per cm2.  Cells on films were cultured in TDM3 
Schwann-like cells transdifferentiated media. To detect the changes in cell adhesion and 
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alignment two films with cells were fixed and stained after 1, 3 and 6 days culturing in vitro. 
Rhodamine phalloidin and DAPI fluorescent stains were used to visualize the cell’s cytoplasm 
and nuclei respectively (Fig.15). tMSCs adhered, aligned, and survived on 10% Salt porous 
micropatterned PLA films and no major decrease in the number of tMSCs was observed one 
week after plating. This experiment was repeated three times. The results were consistent 
between three experiments.   
 
Figure 15. tMSCs adhered, aligned, and survived on a 10% Salt micropatterned porous PLA film 
after 3 and 6 days culturing in vitro (DIV). Cells were fixed and stained with Rhodamine 
Phalloidin (RhPh) (red) and DAPI (blue) after 3 days in vitro (A-D) and after 6 days in vitro (E-
H). 
 
7.1.7. PLA porous micropatterned conduits manufacturing.  
To manufacture conduits for in vivo and in vitro tests, PLA porous micropatterned films were 
rolled about 2.5 times around carbon fiber rod and sealed with chloroform. On average the 
internal diameter of a conduit was equal 1.8 mm, the external diameter was 2.2 mm and the 
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length of each conduit was about 12.5 mm (Fig. 16). Conduits were produced using 10% 
Pluronic porous micropatterned PLA films as well as 10% salt porous micropatterned PLA films. 
 
Figure 16. Image of 10% Salt porous micropatterned PLA conduit (conduit dimensions: L=12 
mm, ID= 1.8 mm, ED=2.2 mm). 
7.1.8. Characterization of tMSCs growth inside porous micropatterned PLA conduits fabricated 
with 10% salt. 
To characterize cell adhesion, growth and proliferation on porous films, GFP-expressing tMSCs 
were plated and cultured inside of the conduits produced with 10% Salt. Before cell placement, 
conduits were exposed to rat laminin-5 for 12 hours to provide an extracellular matrix for cells. 
The initial cell seeding density was 60,000 cells per conduit. To achieve an even cell distribution 
inside of the conduit lumen during the seeding procedure, conduits were rotated ten times per 
minute for two hours right after cell suspension was injected into the conduit. Cells inside of the 
conduit were cultured in TDM3 Schwann-like cells transdifferentiated media. To detect the 
changes in cell adhesion and alignment two conduits with cells were fixed and stained after 1, 3, 
7 and 20 days culturing in vitro. Rhodamine phalloidin and DAPI fluorescent stains were used to 
visualize the cell’s cytoplasm and nuclei respectively (Fig. 17). tMSCs adhered, aligned, and 
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survived inside 10% Salt porous micropatterned PLA conduits over 20 days culturing in vitro. 
This experiment was repeated three times. The results were consistent between three 
experiments.   
 
Figure 17. tMSCs adhered, aligned, and survived inside a 10% Salt micropatterned porous PLA 
conduit after 3, 7 and 20 days culturing in vitro. Cells were fixed and stained with Rhodamine 
Phalloidin (RhPh) (red) and DAPI (blue) after 3 days (A-D), after 7 days (E-H) and after 20 days 
in vitro (I-L). 
Because the results from the multiple experiments where tMSCs were cultured on 10% Salt 
porous micropatterned PLA films or inside of the 10% Salt porous micropatterned PLA conduits 
were consistent and positive it was proposed to test the cell survival inside of these conduits in 
vivo. 
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7.1.9. Implantation of 10% Salt porous micropatterned PLA conduit preseeded with tMSCs in 
Brown Norway rats.  
To test the tMSCs survival inside of the 10% Salt porous micropatterned PLA conduits 
implanted in the animals a pilot in vivo experiment was recently initiated. Four young adult 
Brown Norway rats (150-250g) were used for these experiments. Two days before surgery 
prior to cell placement 10% salt porous micropatterned PLA conduits were exposed to rat 
laminin-5 for 12 hours to provide an extracellular matrix for cells. Then one day before surgery 
tMSCs were seeded inside of the conduits with a seeding density of 50,000 cells per conduit. 
Aseptic techniques were used during surgeries to ensure sterility. First, animals were 
anesthetized with isoflurane. Then, the sciatic nerve was exposed along the femur bone and 
transected at the mid-thigh (Fig. 18, A). A conduit was placed in the gap. Proximal and distal 
ends of the transected nerve were inserted and sutured to the lumen of the conduit using 18" 
micro nylon suture (Fig. 18, B). Then the wound was closed by muscles and skin suturing. The 
antibiotic ointment was applied on top of the sutured skin to prevent bacterial infections. To 
prevent autotomy, rat e-collars were placed on the animals’ necks.    
 
 
Figure 18. A) the sciatic nerve exposed along the femur bone; B) the 10% Salt porous 
micropatterned PLA conduits bridging 10 mm gap in sciatic nerve. 
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7.1.10. Isolation of 10% Salt porous micropatterned PLA conduits from rats.  
To test the tMSCs survival inside of the 10% Salt porous micropatterned PLA conduits in vivo 
implanted animals were euthanized 3, 8, 15 and 29 days after surgery. To recover the implanted 
conduits, rats were deeply anesthetized with isoflurane, sutures were removed, the previously 
implanted conduit was cleared of connective tissue and then cut proximally and distally with 
extra sciatic nerve tissue at the both ends (Fig 19, A). The conduit was immediately placed in 4% 
paraformaldehyde solution for 30 minutes to fix the tissue (Fig. 19, B). Then proximal nerve 
tissue with 2 mm of the proximal part of the conduit and distal nerve tissue with 2 mm of the 
distal part of the conduit were cut and paraffin embedded for the immunohistochemical analysis. 
Morphological analysis of the conduit inside revealed the presence of the tissue within all 
conduit lumen.  The middle part of the conduit was cut longitudinally into eight pieces, and the 
standard immunocytochemical procedure was applied to them to reveal the presence of the 
implanted tMSCs.  
 
Figure 19. 10% Salt porous micropatterned PLA conduit bridging 10 mm gap in sciatic nerve 
three days after in vivo implantation. A) Before conduit was removed from the animal, B), 
Isolated fixed conduit before the cut on proximal, middle and distal parts.    
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7.1.11. Immunocytochemical analysis of isolated 10% Salt porous micropatterned PLA conduits 
after 3, 8, 15 and 29 days in vivo. 
As the next step, the standard immunocytochemical procedure was applied to the middle part of 
the 10% Salt porous micropatterned PLA conduits which were implanted for 3, 8, 15 and 29 days 
in vivo. After conduits had been removed from animals, they were cut into three pieces. Then the 
middle part was cut longitudinally into four pieces, and each piece was immunolabeled for the 
presence of GFP-expressing cells and macrophages.  After 3 and 8 days in vivo conduits did not 
have much regenerated tissue formed inside but after 15 and 29 days formed tissue was 
observed, removed, sectioned and immunolabeled.  To amplify GFP expression of tMSCs, the 
anti-GFP antibody was applied. Also, Rhodamine phalloidin and DAPI were used to visualize 
cell cytoplasm and cell nuclei. Immunocytochemical analysis revealed that GFP-expressing 
tMSCs survived inside of the 10% Salt porous micropatterned PLA conduits after 3, 8, 15 and 29 
days in vivo (Fig. 20). After four weeks in vivo, the number of GFP-tMSCs decreased, and these 
cells were obscured by regenerated tissue overgrown on the internal surface of the conduit. (Fig. 
21).    Regenerated tissue inside of the conduit lumen showed the presence of many macrophages 
/microglia which were immunolabeled with the anti-IBA1 antibody (Fig.22).  
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Figure 20.  (A-E) tMSCs shown on 10% Salt micropatterned PLA conduit which was implanted 
in Brown Norway rat to bridge 10 mm gap in sciatic nerve for eight days. (F-J) tMSCs shown on 
10% Salt Micropatterned PLA conduit cultured in TDM3 for nine days in vitro. 
 
Figure 21.  (A-E) tMSCs shown on 10% Salt micropatterned PLA conduit which was implanted 
in Brown Norway rat to bridge 10 mm gap in sciatic nerve for 29 days. (F-J) tMSCs shown on 
10% Salt Micropatterned PLA conduit cultured in TDM3 for 30 days in vitro. 
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Figure 22.  (A-E) Macrophages /microglia immunolabeling in the regenerated tissue inside of the 
10% Salt micropatterned PLA conduit which was implanted in a rat to bridge 10 mm gap in 
sciatic nerve for eight days. (F-J) tMSCs shown on 10% Salt micropatterned PLA conduit that 
was implanted in Brown Norway rat to bridge 10 mm gap in sciatic nerve for eight days. 
7.1.12. Immunocytochemical analysis of regenerated tissue inside of isolated 10% Salt porous 
micropatterned PLA conduits after 3, 8, 15 and 29 days in vivo. 
After 15 and 29 days in vivo, regenerated tissue was observed inside of the conduit.  That tissue 
was removed, sectioned and immunolabeled for the presence of GFP-tMSCs, Neuronal tissue, 
glial cells, and macrophages. To amplify GFP expression of tMSCs, the anti-GFP antibody was 
applied. TUJ1 and NF200 antibodies were used to mark neuronal tissue. S100 and IBA1 
antibodies were used to immunolabel glial cells and macrophages correspondently. Results of the 
immunocytochemical analysis revealed that after 15 days in vivo the tissue inside of the conduit 
mostly consists of glial cells and macrophages. No presences of neuronal marker or GFP tMSCs 
were observed (Fig. 23). After 29 days in vivo the immunocytochemical analysis of regenerated 
tissue inside of the conduit showed that some appearance of the neuronal tissue, glial cells and 
macrophages (Fig. 24) No GFP-tMSCs were observed four weeks after implantation.  
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Figure 23. Immunolabeling of regenerated tissue inside of the conduit at 15 days in vivo at 10x 
magnification. Immunolabeling of TUJ1 and GFP, DAPI staining, merged image of 
TUJ1/GFP/DAPI (Top row). (Immunolabeling of TUJ1 and IBA1, DAPI staining, merged image 
of TUJ1/IBA1/DAPI (Middle row) Immunolabeling of TUJ1 and S100, DAPI staining, merged 
image of TUJ1/S100/DAPI image (Bottom row) 
 
Figure 24. Immunolabeling of regenerated tissue inside of the conduit at 29 days in vivo at 10x 
magnification. Immunolabeling of NF200 and s100, DAPI staining, merged image of 
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TUJ1/GFP/DAPI (Top row). Immunolabeling of TUJ1 and IBA1, DAPI staining, merged image 
of TUJ1/IBA1/DAPI (Bottom row) 
This pilot in vivo experiment showed that implanted GFP-tMSCs could survive inside of the 
PLA 10%Salt porous conduits, at least, one month after implantation although the number of 
implanted cells decreased during the recovery period. Since GFP-tMSCs were observed only on 
the internal surface of the conduit and not inside of the regeneration tissue it is suggesting that 
not much migration of these cells occur in vivo. The regenerated tissue started to form about two 
weeks after conduit implantation. These results have to be repeated on a higher number of 
animals for the longer recovery period. Future experiments will involve behavioral testing of 
motor and sensory recovery after implantation of 10% salt porous micropatterned PLA conduit 
preseeded with tMSCs in the new set of Brown Norway rats for long-term peripheral nerve 
recovery. Also, a large number of IBA1 positive macrophages in the conduit shows that immune 
cells play a very important role during the process of peripheral nerve regeneration. However, it 
has been shown in the literature that modulating the macrophage phenotype to a pro-healing one 
(M2 macrophages) helps with the regenerative outcome. So, in parallel to our in vivo work, we 
started working on fabrication of interleukin-4 (IL4) releasing micro/nanoparticles as it has been 
known that IL4 is capable of reprogramming macrophages into M2 phenotypic macrophages [1] 
and thus improves peripheral nerve regeneration. 
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7.2. Interleukin-4 (IL4) releasing nano/microparticles for modulating macrophage phenotype to 
enhance peripheral nerve regeneration 
As an additional strategy to facilitate nerve regeneration, we are encapsulating therapeutic 
proteins and cytokines in nano/microparticles. Polyanhydride nanoparticles have been 
successfully used for encapsulating various proteins and also for providing a sustained release of 
protein during the time of biodegradation. There are certain advantages of using polyanhydrides 
for making this protein releasing nanoparticles as they degrade by a mechanism of surface 
erosion unlike polyesters (PLA) that degrade by acid hydrolysis. Also, the degradation products 
cause less acidity in the immediate microenvironment as compared to the polyesters. Here we are 
planning to use copolymers of 1, 6-bis (p-carboxyphenoxy) hexane (CPH), 1, 8-bis (p-
carboxyphenoxy)-3, 6-dioxaoctane (CPTEG) and sebacic acid (SA) to fabricate 
micro/nanoparticles for controlled release of NGF and Interleukin-4 (IL4). NGF is known for 
stimulating the growth of regenerating axons while IL4 has been used to reprogram naïve 
macrophages (M0) into pro-healing phenotypes (M2) as opposed to pro-inflammatory 
phenotypes (M1). Our initial pilot in vivo experiments showed a massive infiltration of 
macrophages inside the conduit and in the literature it has been demonstrated that M2 phenotypic 
macrophages can have a significant effect on nerve regeneration. To reprogram the macrophages 
into M2 phenotype, we need only a short-term supply of IL4 to the macrophages that infiltrate 
the conduit at the start. Once reprogrammed, M2 phenotypic macrophages themselves release a 
higher amount of IL4 creating a loop for further conversion of M0 macrophages to M2 
phenotype. For achieving a short-term release of IL4 we have decided to coat the particles with 
IL4, but for NGF, we chose to encapsulate the NGF inside the particles so that we have a long-
term sustained release of NGF to stimulate the regenerating axons throughout the regeneration 
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period (See chapter 5). Our strategy is that these NGF encapsulated and IL4 coated 
nano/microparticles will be co-administered inside the conduit along with MSCs and will release 
NGF and IL4 as they degrade and stimulate the regenerating axons and reprogram the infiltrating 
macrophages into M2 phenotype. So far we have finished optimizing the properties of NGF 
loaded particles (chapter 4), and recently we started working on characterizing reprogramming of 
macrophages using IL4. 
7.2.1. IL4 release kinetics from IL4 coated 20:80 CPTEG: CPH and 50:50 CPTEG: CPH 
nano/microparticles in 0.5% BSA-PBS buffer. 
Previously we have shown that NGFβ encapsulated 50:50 and 20:80 CPTEG: CPH particles in 
0.5% BSA-PBS buffer, released NGFβ up to 8 weeks. To coat IL4 on the surface of particles, we 
used similar but blank, spray dried CPTEG:CPH particles. We dissolved 20 µg recombinant rat 
IL4 in 400 µl PBS and then incubated 5mg particles with this solution for a duration of 30 mins. 
After 30 mins, we centrifuged particles at the speed of 15,000 RPM for 10mins and followed by 
careful removal of supernatant without disturbing the pellet of particles. Another 200 µl of PBS 
was added to IL4 coated particles to wash out the excess IL4 before starting the release. Finally, 
release study was initiated by adding 200 µl of 0.5% BSA-PBS buffer, and samples were 
collected at 1, 4, 11, 24, 48, 72, 96, 120 and 144 hours after initial time point. Multiple ELISA’s 
were performed to optimize the dilution of the samples to bring the absorbance reading in the 
range of the ELISA assay. Figure 25 shows release kinetics data from IL4 adsorbed particles. 
Blank particles did not show any release. 
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Figure 25. Cumulative release curves for IL4 coated particles fabricated by adsorbing IL4 on the 
surface of 50:50 and 20:80 CPTEG: CPH particles. Blank 50:50 and 20:80 particles were used as 
a negative control. Both 50:50 and 20:80 NGFβ CPTEG: CPH microparticles showed a sustained 
release of IL4 for up to six days in 0.5% BSA-PBS buffer. Different release kinetics was 
observed for different copolymer chemistry. N=2 and error bars represent standard deviation. 
7.2.2. Characterization of RWS 264.7 (Mouse Macrophages) cells reprogramming using soluble 
IL4 
Different concentration of lipopolysaccharides (LPS) and IL4 was tested out to check conversion 
of RWS 264.7 macrophages into M1 and M2 phenotype respectively. Cells were plated in a 96 
well plate at an initial concentration of 2000 cells/well and were left for growing in the plate for 
24 hrs before adding LPS and IL4 at the desired levels. LPS was used at four different 
concentrations of 125, 250, 500 and 1000 ng/ml while IL4 was used at eight different 
concentrations of 1.56, 3.12, 6.25, 12.5, 25, 50, 100, 200 ng/ml. Positive M2 phenotypic markers 
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used were CD206 and CD163 while CCR7 was used for immunostaining M1 phenotypic 
macrophages. Additionally, double labeling was performed along with CD68 to immunostain all 
kinds of macrophages including M1, M2 and naïve (M0). Figure 26 shows immunostaining data 
for CCR7, figure 27 for CD163, figure 28 for CD206 and Figure 29 shows an average number of 
nuclei counted for each treatment condition. 
 
Figure 26. Percent CCR7 (M1 phenotypic marker) immunostaining of RWS 264.7 macrophages 
treated with various concentrations of LPS and IL4. NT stands for non-treated control. Percent 
CD68 immunostaining was also quantified for all the conditions. LPS treated cells showed more 
CCR7 immunostaining as compared to IL4 treated cells. 
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Figure 27. Percent CD163 (M2 phenotypic marker) immunostaining of RWS 264.7 macrophages 
treated with various concentrations of LPS and IL4. NT stands for non-treated control. Percent 
CD68 immunostaining was also quantified for all the conditions. IL4 treated cells showed little 
to no staining as compared to LPS treated cell. 
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Figure 28. Percent CD206 (M2 phenotypic marker) immunostaining of RWS 264.7 macrophages 
treated with various concentrations of LPS and IL4. NT stands for non-treated control. Percent 
CD68 immunostaining was also quantified for all the conditions. IL4 treated cells showed little 
to no staining as compared to LPS treated cell. 
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Figure 29. Comparison of an average number of nuclei across various conditions. LPS was found 
to be cytotoxic in nature, and some cells after LPS treatment was found to be significantly lower 
as compared to IL4 or non-treated cells. 
 
From our initial characterization experiments, we found that the IL4 that we used for treating the 
macrophages was not useful in reprogramming the cells. We repeated the experiment, and we 
still did not see any increase in expression of M2 phenotypic marker proteins (CD206 and 
CD163) in IL4 treated cells as compared to non-treated cells. Going further, we used other 
antibodies (CD206 from a different company) and CD11C (M1 marker) which we borrowed 
from Dr. Bratlie’s group and found that RWS 264.7 macrophages still did not show any 
expression of these M1 and M2 marker proteins. Previously, Dr. Bratlie’s group has shown that 
these macrophages reprogram themselves in the presence of IL4. Finally, we decided to try 
Mouse IL4 that Dr. Bratlie’s group used for reprogramming and planned to compare with the 
recombinant Rat IL4 (cross-reactive with Rat, Mouse, and Human) we were using for our 
experiments. When we used Mouse IL4 for reprogramming, we immediately saw evidence of 
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morphological changes in macrophages, and a fraction of macrophages acquired a bipolar 
morphology as compared to a round shaped naïve macrophages. We also stained the cells with 
CD206, CD163, and CCR7 and saw an increase in M2 phenotypic marker with Mo IL4 treated 
cells as compared to Rat IL4 and control cells (Figure 30). Also, in the presence of Mo IL4, we 
saw an increase in cellular proliferation and a higher number of macrophages were found in the 
wells treated with Mo IL4 as compared to Rat IL4 and non-treated macrophages (Figure 31).       
 
Figure 30. Percent CD206, CD163 and CCR7 immunostaining of RWS 264.7 macrophages 
treated with 25ngs/ml of IL4. Macrophages treated with Mo IL4 showed the highest expression 
of M2 marker antibodies. 
 
 
207 
 
 
 
Figure 31. An average number of cells per site and mean cellular area for macrophages treated 
with Rat and Mouse IL4. Macrophages treated with Mouse IL4 proliferated a lot more as 
compared to Rat IL4 and non- treated cells pointing out that Mo IL4 is effective as compared to 
Rat IL4. 
Because we plan to do our in vivo studies in rats, and recombinant rat IL4 was not found to 
useful in the reprogramming of RWS 264.7 mouse macrophages, we purchased a rat specific 
macrophage cell line (NR8383) and test Rat IL4 to reprogram the new cell line. 
7.2.3. Characterization of NR8383 (Rat alveolar macrophages) cells reprogramming using 
soluble IL4 
Semi-adherent rat alveolar macrophage cell line (NR8383) was bought from ATCC and cultured 
for a week to freeze down stock vials of cells. For reprogramming of this cell line, Rat IL4 was 
used at a concentration 50ng/ml. In literature, it is shown that pro-healing phenotypic 
macrophages (M2) decreases the production of nitric oxide and increase the proliferation and 
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migration of Schwann cells, which in turn helps with nerve regeneration. So, we also wanted to 
test out such behavior of M2 macrophages, and we chose the following four assays. 
 Production of nitric oxide (Griess assay) 
 Proliferation of RT4-D6P2T (Schwannoma) cells (Ki67 immunostaining) 
 Proliferation of RT4-D6P2T (Schwannoma) cells (CCK8 assay) 
 Migration of RT4-D6P2T cells (Boyden chambers) 
7.2.3.1. Production of Nitric Oxide 
NR8383 cells were plated in wells of a 24 well plate at an initial seeding density of 40,000 cells 
per well in 300ul media. Cells were allowed to grow for a day and then IL4 was added to the 
cells at a concentration of 50ng/ml. IL4 treatment was done for a day to let the cells reprogram 
and after a day IL4 containing media was removed and fresh warm maintenance media was 
added to cells. After another 24 hrs, conditioned medium from the reprogrammed macrophages 
was collected and used for testing out nitric oxide production. 50 µl and 100 µl conditioned 
media was added to equal volume of modified Griess reagent in a 96 well plate, and the 
absorbance of the solution was read out after 15 mins using a spectrophotometer at a wavelength 
of 540 nm. M2 phenotypic macrophages released a lower amount of nitric oxide as compared to 
M0 macrophages, and Mo IL4 treated macrophages (Figure 32), showing that macrophages got 
converted to M2 phenotype after treatment with rat IL4. 
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Figure 32. Griess assay to quantify the release of nitric oxide from reprogrammed macrophages 
vs. naïve macrophages. Macrophages treated with Rat IL4 released a lower amount of nitric 
oxide as compared to naïve macrophages and mouse IL4 treated macrophages. 
7.2.3.2. Proliferation of RT4-D6P2T (Schwannoma) cells (Ki67 immunostaining or CCK8 assay) 
RT4 cells were plated at an initial seeding density of 2000 cells per well in a 96 well plate in 
50:50 RT4 medium and macrophages conditioned medium. Cells were grown for two days 
before fixation and then immunostained with Ki67 (proliferation marker) to compare the RT4 
proliferation rate in various conditioned and control medium. RT4 cells treated with M2 
macrophages (rat Il4 treated) conditioned medium was found to have higher Ki67 antibody 
staining as compared to naïve, or M0 IL4 treated macrophages conditioned medium. However, 
the staining was still found to be lower than control RT4 cells (100% RT4 cells medium) and 
RT4 cells growing in 50:50 Fresh RT4: fresh Macrophages medium (Figure 33). These results 
showed that FBS in the fresh medium affects the proliferation (Figure 34) and needs to be 
removed to make proper comparisons of conditioned mediums. We also conducted CCK8 assay 
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where we added 10% CCK8 dye to the RT4 cells after two days of growth and then after an 
hour, read the absorbance of different wells using a spectrophotometer at a wavelength of 
450nms. CCK8 assay also showed a similar pattern of results compared to Ki67 immunostaining 
(Figure 35). 
 
Figure 33. Percent Ki67 immunostaining of RT4 cells treated with different macrophages 
conditioned medium. Rat IL4 treated macrophages’ conditioned medium caused a higher 
proliferation as compared to Naïve and Mo IL4 treated macrophages’ conditioned medium. 
Control cells growing in the fresh medium had the greatest increase in cell number pointing out 
that, the FBS removal is required to test out the real effect of macrophage conditioned medium. 
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Figure 34. Average number of RT4 cells per site. Fresh macrophage medium caused a high 
proliferation of RT4 cells as compared to fresh RT4 medium and macrophages conditioned 
medium. 
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Figure 35. CCK8 assay. Rat IL4 treated macrophages’ conditioned medium caused a higher 
proliferation of RT4 cells than naïve, and Mo IL4 treated macrophages’ conditioned medium, but 
proliferation was still found to be lower than control cells growing in the fresh medium. 
7.2.3.3. Migration of RT4-D6P2T (Schwannoma) cells (Boyden chambers) 
Boyden chambers were used to study the effect of migration of RT4 cells in the presence of M2 
phenotypic macrophages as compared to M0 phenotypic macrophages. After reprogramming, 
50,000 RT4 cells were plated on top of Boyden chambers in a 24 well plate where different kinds 
of macrophages were growing in different wells. Soluble factors secreted by macrophages 
caused the RT4 cells to migrate from the top of the membrane to the bottom. After two days of 
migration, Boyden chambers were stained with sytox green (1:1000) and then ImageXpress 
Micro high content screening system was used to take images of the cells growing at the bottom 
of chambers using a 10X objective. Our initial data from these experiments shows that M2 
macrophages (Rat IL4 treated) caused a higher migration of RT4 cells as compared to M0 
macrophages and control RT4 cells (Figure 36). 
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Figure 36. Boyden chambers migration assay. M2 macrophages caused a higher migration as 
compared to M0 and control RT4 cells.  
7.2.4. Future direction for IL4 releasing nano/microparticles study 
7.2.4.1 Third replicate for IL4 release kinetics  
So far, we have finished two replicates for IL4 release kinetics data. We will soon be conducting 
the third replicate for the same to get our replicate count to three. 
7.2.4.2 Macrophage reprogramming using IL4 in serum free medium 
Our initial experiments have showed that NR8383 cells are getting reprogrammed to M2 
phenotype, but their effect on proliferation of RT4 cells is not clear because of the presence of 
FBS in the medium. In our future experiments, we will use the serum free medium to make sure 
proliferation is only affected by soluble factors released from reprogrammed macrophages. 
7.2.4.3. Effect of M2 phenotypic macrophages on transdifferentiated MSCs (tMSCs) 
Because of Schwann cell-like characteristics of tMSCs, we will also test out proliferation and 
migration of tMSCs in the presence of M2 and M0 phenotypic macrophages in vitro.  
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CHAPTER 8: SUMMARY AND CONCLUSIONS 
 
We have successfully fabricated micropatterned poly (lactic acid) (PLA) films and polystyrene 
(PS) films and shown that these patterned films supported the growth of undifferentiated 
mesenchymal stem cells (uMSCs). We found that uMSCs proliferate at about the same rate 
across all four types of substrates (PLA patterned (PLA Pa), PLA smooth (PLA Sm), PS 
patterned (PS pa), PS smooth (PS sm)) and thus, micropatterns did not affect the proliferation of 
uMSCs. Further, by transdifferentiating MSCs to a Schwann cell-like phenotypic cells on these 
micropatterned films, we found that micropatterns do not cause any deleterious effect on the 
differentiation potential of MSCs. Percentages of S100β and p75NTR (markers of Schwann cells) 
immunostaining revealed that transdifferentiation of MSCs on these films resulted in a higher 
degree of differentiation (~80%) as compared to glass substrates (~40%). Percentage 
transdifferentiation was found to be similar on the patterned vs. smooth parts of both PS and 
PLA films. However, transdifferentiated MSCs (tMSCs) on the patterned part of the films were 
found to be highly elongated, spindly and the majority (~80%) were found to be oriented in 
directions of the patterns, while the tMSCs growing on the smooth substrate were considerably 
short and fibroblastic in nature. Aspect ratio, the ratio of cellular width to its height, was found to 
be 4-5 times greater for the tMSCs growing on patterned films vs. the tMSCs growing on smooth 
films. With this study, we found that micropatterned film is a suitable substrate for oriented 
growth of MSCs, and these films do not affect MSCs’ transdifferentiation capability and thus, 
can be used for fabricating an implantable conduit having micropatterned inner lumen. We were 
able to roll these films into conduits consistently, which were used for the in vivo studies.  
Furthermore, before in vivo transplantation studies, we genetically modified MSCs for 
expression of the green fluorescent protein (GFP) and tested transdifferentiation of GFP-
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expressing MSCs. GFP-expressing tMSCs exhibited a higher percentage of S100, S100β, p75NTR 
(Schwann cell marker protein) and βIII-tubulin (neuronal marker) immunostaining as compared 
to GFP-uMSCs showing that tMSCs behave like hybrid neuronal-glial like cells. Also, GFP-
tMSCs released a significantly higher amount of nerve growth factor-β (NGFβ) and brain-
derived neurotrophic factor (BDNF) as compared to GFP-uMSCs. These GFP-tMSCs were 
found to benefit functionally as well and caused a significantly longer neurite outgrowth in 
PC12-TrkB cells compared to the control GFP-uMSCs. 
 
Long-term continuous supply of neurotrophic factors such as brain-derived neurotrophic factor 
(BDNF) and glial cell line-derived neurotrophic factor (GDNF) has been found to 
neuroprotective in the case of many neurodegenerative disorders and has been shown to help 
even with nerve regeneration. We genetically modified mouse mesenchymal stem cells to secrete 
BDNF, GDNF, and BDNF/GDNF. We characterized the neurotrophic factor (BDNF, GDNF, 
BDNF/GDNF) secreting mouse MSCs on various extracellular matrix proteins to ensure that 
genetic modification does not affect the proliferation and migration capabilities of these cells 
negatively compared to control wild type and GFP-MSCs. We successfully achieved this by 
taking advantage of ImageXpress Micro high content screening (HCS) system that can be used 
for automated imaging and analysis of the samples in a multi-well plate format and showed that 
the cells were behaving normally via proliferation (Ki67 immunostaining), migration (time-lapse 
imaging) and cell survival assays (propidium iodide staining). We found that BDNF, GDNF, and 
BDNF/GDNF MSC subtypes secreted a significantly higher amount of respective therapeutic 
proteins as compared to control wild type and GFP-expressing MSCs. Conditioned media 
collected from these BDNF and GDNF MSCs caused a significant higher neurite extension in 
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PC12-TrkB and PC12 cells respectively showing the potential functional benefit associated with 
using these MSCs in vivo. Therefore, transplantation of genetically modified cells can be used as 
an alternative strategy for replacing native SCs during nerve injuries. 
 
Using amphiphilic polyanhydride copolymers, we successfully fabricated NGFβ releasing 
micro/nanoparticles. Particles released protein for a period of two months, and different polymer 
chemistries resulted in different release profile. When these particles were used at a 
concentration of 125µgs/ml or lower, they did not show any cytotoxicity on mesenchymal stem 
cells. Finally, using noncontact coculture assays, we tested the therapeutic benefit of the released 
NGFβ from particles on the differentiation of PC12 cells and found significant higher neurite 
extension in PC12 cells as compared to control PC12 cells.  
 
We have also successfully transplanted GFP-expressing transdifferentiated MSCs along with 
biodegradable porous micropatterned conduits in vivo and showed that transplanted cells 
survived for up to a month. After a one-month period, we also saw a huge infiltration of 
macrophages inside the conduit. Macrophages reprogrammed to M2 phenotype are known to 
enhance nerve regeneration. So, in vivo transplantation work and NGFβ releasing polymeric 
particle work, lead up to the work where we are fabricating cytokine (interleukin-4) releasing 
micro/nanoparticles.  
In the future, in vivo transplantation studies will be conducted using a multifunctional nerve 
regeneration conduit incorporating various regenerative cues that we have characterized and 
developed during this dissertation. This multifunctional conduit will have following properties 
 Biodegradability to avoid possibility of a second surgery 
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 Porosity to improve the flow of nutrients and waste from conduit microenvironment 
 Longitudinal micropatterns to guide regenerating axons 
 Patient-specific transdifferentiated mesenchymal stem cells as an alternative to Schwann 
cells 
 Nerve growth factor-releasing microparticles to stimulate further the regenerating axons 
 Interleukin-4 releasing microparticles to reprogram the macrophages infiltrating the 
conduit to wound healing M2 phenotype 
 
From the work done during this dissertation, we have hypothesized that we can fabricate a 
multifunctional nerve regeneration conduit capable of providing effective mechanical, biological 
and trophic support to the regenerating nerves by combining strategies such as polymer 
scaffolding, nanoparticle delivery system, and stem cell engineering.   
 
 
